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ABSTRACT 
In recent years, the field of host-guest chemistry has become a large and rapidly 
advancing area of research with a vast number of new host molecules being reported. Many 
of these developments are outlined in Chapter 1. The aim of this project was to achieve the 
synthesis and isolation of seven host molecules based upon a cyclic hexapeptide structure. 
Within this cyclic peptide, two glycine residues were incorporated to encourage the 
stabilization of the structure via the formation of ß-toms. Four lysine residues made up the 
complement of six amino acid residues in each target molecule. In three of the synthetic 
targets, these lysines were to be crosslinked with different units to form polycyclic peptides 
with a cavity. In the other four synthetic targets, the lysines were to be used to allow the 
capping of a porphyrin unit onto the cyclic hexapeptide. 
With the aim of synthesising the three polycyclic peptides, it was necessary to prepare 
and isolate a tripeptide crosslinked with an appropriate crosslinker. As described in 
Chapter 2, successful crosslinking was achieved when an NE-tosyl protected tripeptide was 
reacted with 1,2-bis(2-tosylethoxy)ethane, 1,6-dibromohexane and 1,4-a, a'-dibromo p- 
xylene. 
In Chapter 3, the final stages in the attempted synthesis of two of these polycyclic 
peptides are described via the successful cyclodimerisation of a crosslinked tripeptide and 
its resultant detosylation. Evidence from FAB mass spectrometry indicated that following 
a crosslinlcing reaction with 1,4-a, a'-dibromo p-xylene, a polycyclic peptide was 
successfully formed. However, whereas the 1H NMR spectra were consistent with the 
desired molecule, they could not be used to conclusively prove its synthesis. 
The attempts made to synthesise a porphyrin capped cyclic peptide are described in 
Chapter 4. However, none of these attempts were successful, either due to problems 
encountered in the purification of advanced intermediates or unsuccessful capping of the 
cyclic peptide by the appropriate porphyrin. 
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CHAPTER 1: 
INTRODUCTION 
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1.1 Host-guest chemistry 
Few scientists who have studied the biochemistry of biological systems at the 
molecular level could fail to be inspired. The specificity of binding in enzymes and 
antibodies has led many chemists to speculate as to the feasibility of mimicking such systems 
using synthetic organic species'. The Athenian Poet-Dramatist, Aeschylus wrote 2500 
years ago, "Pleasantest of all ties is the tie of host and guest2. " It has been the aim of many 
chemists for 30 years, to study this tie between host and guest at the molecular level. 
The area of host-guest (or supramolecular) chemistry is concerned with the chemistry 
of the intermolecular bond and, in particular, the chemistry of entities formed by the 
association of two or more species. This new field is a rapidly expanding area of research 
and one of its particular attractions is that it draws together chemists from many disciplines - 
from organic synthesis through to inorganic, physical and biochemistry 3. It was in 
recognition of the significance of host-guest chemistry that the 1987 Nobel Prize for 
Chemistry was awarded to three of its pioneers, Charles Pedersen4, Donald Cram' and Jean- 
Marie Lehn3. Pedersen's discovery in 1967 of dibenzo-18-crown-6 and its ability to form 
stable complexes with alkali and alkaline-earth metals, can be considered to mark the 
beginning of synthetic supramolecular chemistry5'6. Cram and Lehn have done much to 
develop this work by the design, synthesis and study of cryptands, podands, carcerands and 
many other kinds of novel host molecules. 
Such is the size of the area of host-guest chemistry5 7, that it is clearly not feasible to 
give a comprehensive review within the confines of this chapter: many reviews have already 
been published in this field5a"u. Instead, it is the aim of this chapter to describe some of the 
fundamental principles, to show the development and to highlight some of the key recent 
successes in host-guest chemistry. Particular reference will be made to those host 
molecules containing amide bonds and porphyrins as key units in their construction. 
1.1.1 Basic concepts of host-guest chemistry 
A prerequisite to the understanding of the area of host-guest chemistry is a familiarity 
with the basic terminology and definitions. The partners of a supramolecular species have 
been named the molecular receptor and substrate 3,13,14. Alternatively, many articles refer 
to them as the host and guest'5"16. The latter terminology will be used in this thesis. The 
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association of the host and guest are said to form a superntolecule3 or complex. Such 
complexes often possess features as well defined as molecules in that they are distinct and 
frequently reasonably stable entities. 
The host molecule is often defined as being the larger of the two species in the 
complex. In addition, one can say that the host molecule presents a more concave binding 
site whereas the guest binds over a more convex surface", " It is often the precise shape 
or electronic structure of these two surfaces that determines the specificity of the binding 
interaction'. 
Selective molecular interactions are crucial to many processes that occur in 
biochemistry. Vital processes such as substrate binding to a receptor protein, enzymatic 
reactions, translocation and transcription of DNA and immunological antigen-antibody 
association all depend upon selective molecular recognition processes in which key 
interactions mostly take the form of intermolecular bonds. It is the aim of many 
supramolecular chemists to mimic the selectivity of such natural recognition events by the 
design, synthesis and study of synthetic host molecules'. 
Molecular recognition, translocation and transformation represent the basic functions 
of host-guest complexes3. The binding of a guest to a host involves a molecular 
recognition process. A situation where this occurs in nature is in the irreversible inhibition 
of an enzyme'. In many enzymes, the binding is mostly permanent but in other systems, 
if the host-guest complex is transported to another environment, the guest can be released. 
A particularly famous example is the uptake of 02 by hemoglobin in the oxygen-rich 
environment of the lungs and its release in the more oxygen-deficient muscles". Thus the 
translocation of a guest has occurred. Finally, if the host contains not only binding sites 
but also reactive functional groups, chemical transformation of the bound substrate may 
occur. An example is the specific hydrolysis of peptide bonds on the carboxyl side of 
aromatic residues by the enzyme chymotrypsin'$. The relationship of these functions to 
complexation is illustrated in the diagram in Fig 1.1. 
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Fig 1.1 : Relationship between host, guest and complex and the basic functions of host-guest 
complexes 
Host Recognition 
Complexation 
Complex > Translocation 
Intermolecular 
bonds 
Guest Transformation 
1.1.2 Lock and keyp principle 
One of the earliest and most enduring contributions to the study of the selective 
binding of guests by hosts was made in 1894 by Emil Fischer19. In describing the 
interaction of enzymes with glucosides, he stated that host and guest fit together like a "lock 
and key"20. He extended the applicability of this so called "Schlussel-Schloss-Prinzip, " to 
the action of enzymes in genera12' and explained that the selectivity of binding of a guest and 
a host is dependent upon the complementarity of the "geometrical structure" of the guest 
(key) with the host (lock). Thus, if the guest and host have complementary shapes, they 
will bind. 
Related to this idea of the lock and key is Cram's principle of complementarity 1. 
Cram argues that if a host and guest are to bind, then not only must the two have 
complementary shapes but they must also possess complementary functional groups. 
Complexes are produced by the formation of such intermolecular bonds as van der 
Waals forces, hydrophobic interactions and also hydrogen bonds. If this intermolecular 
bonding, particularly hydrogen bonding is to be effective, it is vital that within the complex, 
groups capable of forming such forces are in complementary positions. Thus Cram states 
that "to complex, hosts must have binding sites which co-operatively contact and attract 
binding sites of guests without generating strong non-bonded repulsions"". 
Both Fischer's lock and key principle and Cram's principle of complementarity are 
summarised in the diagram in Fig 1.2. 
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Fig 1.2 : Schematic diagram showing the binding of a complementary host and guest 
H ý' 
D HA HD 
HA = Hydrogen bond acceptor 
HD = Hydrogen bond donor 
1.1.3 Induced-fit theory 
HD HA 
HD D HA 
As knowledge of the functions and properties of enzymes increased, it became clear 
that the basic lock and key principle as described by Fischer could not account for every 
enzymatic action23. A classic example is non-competitive inhibition of an enzyme. This 
phenomenon has been explained by saying that an inhibitor prevents enzyme action but does 
not affect the binding of the substrate". This result cannot, however, be explained by the 
classical lock and key principle, since if the inhibitor does not block the binding site, the 
binding site or lock should still remain open to and complementary to the guest or key. 
This anomalous result neccessitated the modification of the lock and key principle. 
Thus in 1958, Koshland introduced his induced-fit theory24. Using the example of enzymes, 
Koshland explained his theory in the following terms; 
"a) the precise orientation of catalytic groups is required for enzyme action, 
b) the substrate causes an appropriate change in the three-dimensional relationship of the 
amino acids at the active site and 
c) the changes in the protein structure caused by the substrate will bring the catalytic groups 
into the proper alignment whereas a non-substrate will not. " 
Thus, whilst a host may not initially possess a complementary binding surface to a guest, its 
conformation can change on binding in such a way as to become complementary to the guest 
to which it evolved to bind. This has been likened to the image of a "hand-in-glove, " thus 
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combining the idea of a selective fit together with the concept of flexibility-'. A schematic 
model illustrating the induced-fit mechanism is illustrated in Fig 1.3. 
Fig 1.3 : Schematic diagram illustrating the binding of a substrate by an enzyme following 
the induced-fit mechanism 
0= Reactive group 
Many experiments were performed in order to test this theory, a classic example of 
which is illustrated in Fig 1.4. The enzyme phosphoglucomutase was chosen and the 
reactivity of its SH group used as a test. Ligand binding induced the exposure of the SH 
groups, an observation which is inexplicable using the basic lock and key theory25 
Fig 1.4 : Binding of a substrate by phosphoglucomutase showing the exposure of an SH 
group upon binding, as explained by the induced-fit mechanism 
-- __º 
20 
Enzyme 
4 
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1.1.4 Principle of preorganisation 
An additional theory describing binding between host and guest can be seen by making 
comparisons between the crystal structures of uncomplexed 18-crown-6 and 2,2,2-cryptand 
with their respective KK complexes. In both cases considerable host reorganisation and 
desolvation needs to occur upon complexation. As illustrated in Fig 1.5, prior to 
complexation, the hosts contain neither cavities nor convergently arranged binding sites, 
both of which are present in the complexed form'. 
Such binding site organisation as occurs upon complexation is not uncommon. Fig 
1.6 shows the ligands which Cram synthesised in order to study what effect preorganisation 
has upon the strength of binding. He designed ligand (1), called a "Spherand, " in which the 
oxygens are predisposed to an octahedral arrangement around an enforced spherical cavity, 
complementary to Liiand Na+ions26'27. The oxygens are deeply buried in the hydrocarbon 
shell and when not bound to a guest are unsolvated. This ligand is thus preorganised for 
binding - there are negligible free energy costs for organising the ion binding conformation 
and for desolvating the binding cavity. 
Fig 1.5 : Binding of a potassium ion by 18-crown-6 and 2,2,2-cryptand 
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The spherand's open chain counterpart, podand (2), is by contrast, not preorganised. 
It differs constitutionally from spherand (1) solely in that it contains two Ar-H bonds as 
opposed to an Ar-Ar bond. It can exist in over 1000 conformations, only two of which can 
bind metal ions octahedrally. In addition, upon binding, free energy is required to desolvate 
the oxygens'. 
The difference in the relative strengths of binding of metal ions between the 
preorganised and unpreorganised ligands can be seen in the -A G° values for the two 
complexes. Guest salts of lithium and sodium picrate were distributed between CDC13 and 
D20 at 25°C in the presence and absence of host. Spherand (1) binds Li' with 96.3 kJ mol-' 
and Na+ with 80.8 kJ mol"' 22. Podand (2) binds Li' and Na+ with -0 G° < 25.1 kJ mol". 
From these and other results, Cram has formulated his "Principle of 
Preorganisation, " emphasising it as a central factor in the strength of binding. He states 
that, "the more highly hosts and guests are organised for binding and the lower their 
solvation prior to their complexation, the more stable will be their complexes'. " 
Fig 1.6: Diagrams showing the relative rigidity of spherand (1) compared to the flexibility 
of podand (2) Me 
Me 
QJMeT? T9 
oM 
Me0 MeO -Me 
Me 
(1) 
OMe OMe OMe OMe OMe OMe 
HH 
OOOOOO 
Me Me Me Me Me Me 
(2) 
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1.1.5 RecenLdevelopments in host-guest chemistry 
In the preceding pages, some of the key principles governing the binding of guests by 
hosts have been outlined. In the following pages of this chapter, recent progress in the field 
of host-guest chemistry will be described. Many of the simple functions of host molecules 
can be classified into the areas of recognition, transport and catalysis3. Each of these areas 
will be summarised in turn, comparing examples of natural hosts with some of the myriad 
of synthetic host molecules that have been synthesied over the past few years. Particular 
emphasis will be given to examples of hosts containing amide bonds, peptides and porphyrin 
structures. A brief mention will then be made concerning the general synthetic methods 
available for forming a variety of host molecules before the practical aims of my research 
are described. 
1.2 Molecular recognition 
1.2.1 Natural host molecules 
One of the guiding inspirations behind much of the work carried out in the area of 
synthetic host-guest chemistry has been the desire to mimic the degree of guest binding 
specificity achieved by a large number of natural binding systems. Two examples of such 
natural hosts will be described, illustrating the guest binding principles outlined in Section 
1.1, before a brief survey is made of the kinds of synthetic hosts that have been prepared. 
1.2.1.1 Vancomycin 
The vancomycin group of antibiotics offer excellent systems for the study of host- 
guest interactions29. These natural antibiotics, all based upon a structure containing seven 
amino acids, exert their antibacterial activity by preferentially binding to peptide 
intermediates involved in cell-wall synthesis. They selectively bind to peptides terminating 
in D-Ala-D-Ala, their binding constants having values up to 106 M'13a33 
The binding of vancomycin to the dipeptide Ac-D-Ala-D-Ala and to the tripeptide 
Ac j-L-Lys-D-Ala-D-Ala has been studied principally by the use of high-field 'H NMR31. By 
the use of NOE studies, it has been found that the above mentioned principle of 
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complementarity of size, shape and charge distribution operates efficiently. Fig 1.7 
describes the vancomycin-tripeptide complex and reveals the complexity of the interactions 
required for strong, selective binding. Not only does the host cavity have the correct size 
and shape but it also contains hydrogen bonding acceptor and donor sites in complementary 
positions to those of the guest. Recent research has also indicated that the formation of 
vancomycin dimers contributes to the formation of the correctly shaped binding site and thus 
strengthens the complex"-" Such a dimer-guest complex is of necessity formed within a 
dilute aqueous solution so as to correspond to physiological conditions. 
Fig 1.7 : Binding of a tripeptide substrate by the antibiotic vancomycin 
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1.2.1.2 Car oxvnentidase Air 
Some of the most impressive binding selectivities achieved in natural systems are those 
of enzymes. An example is carboxypeptidase A, a digestive enzyme that hydrolyses the 
carboxyl-terminal peptide bond in polypeptide chains. Hydrolysis is particularly efficient 
if the carboxyl-terminal residue has an aromatic or bulky aliphatic side chain as the enzyme 
has binding selectivity for these guests or substrates. 
24 
The structure of carboxypeptidase A is based upon a single polypeptide chain of 307 
amino acid residues. This folds to present a binding site containing tyrosine, arginine and 
glutamic acid residues, together with a co-ordinated zinc ion. A schematic diagram of the 
binding of a guest such as glycyl tyrosine is given in Fig 1.8. Before the binding of such a 
guest, these residues are widely spaced. However, upon binding, considerable structural 
rearrangement occurs, with the binding groups being brought together to surround the 
guest. Indeed, the largest such movement is that of the phenolic hydroxyl group of the 
tyrosine, which moves 12 A, a distance equal to about a quarter of the diameter of the 
protein. Consequently, this enzyme provides an example of the induced-fit model of 
binding described in Section 1.1.3. Following this conformational change, the enzyme has 
formed a binding site of the appropriate shape for binding. Again, the importance can be 
seen of complementarity of size, shape and binding interactions between host enzyme and 
guest peptide. 
Fig 1.8 : Schematic diagram of the binding of glycyltyrosine to the active site of 
carboxypeptidase 
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1.2.2 Synthetic host molecules 
1.2.2.1 Early host molecules 
One of the earliest synthetic host molecules to be developed was dibenzo-18-crown-6 
(3). It was synthesised by Pederson in 1967 and was found to be the first neutral compound 
to complex alkali metal ions6 (Fig 1.9). Moreover, it was found to have partial selectivity 
for K* over other alkali metals. Smaller and larger crown ethers were found to have partial 
selectivity for alkali metal ions higher up or lower down the periodic table, respectively'. 
In synthesising cryptands, Lehn enhanced the relative selectivities achievable for alkali 
metal ions3. Cryptands, eg. (4), contain a three dimensional, spheroidal cavity which 
entirely surrounds the bound ion. Consequently, the higher selectivity for a given guest of 
cryptand over crown ether is explained by the former's greater rigidity and preorganisation 
(Fig 1.9). 
An efficient host for binding tetrahedral guests such as ammonium ions has also been 
developed (5). It contains a tetrahedral recognition site and is able to bind NH4* rigidly by 
the formation of hydrogen bonds3a"35. Further developments related to crown ethers have 
resulted in the formation of receptors that bind guests with two appropriate functional 
groups. Such hosts are given the name "ditopic hosts. " Thus diammonium cations have 
been bound by cylindrical molecules - for example (6)36. One of the most unusual 
molecules of this type is (7), in which a porphyrin moiety is incorporated within the host 
molecule37. 
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Fig 1.9: A selection of host molecules based upon the crown ether and cryptand structures 
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1.2.2.2 The binding of barbiturates 
(4) 
(6) 
The use of hydrogen bonds to bind ammonium derivatives is just one example of their 
widespread use in host-guest chemistry. In another case, Hamilton has synthesised hosts 
capable of binding barbiturates38'39. Barbiturates are widely used as sedatives and 
anticonvulsants and a possible application for artifical hosts is to facilitate their removal from 
biological systems. Hosts (8) and (9) contain two 2,6-diaminopyridine units which 
complement and complex the imide NH's and carbonyls of the barbiturate. The pyridine 
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units are themselves linked together by suitable spacer groups to form the structures shown. 
'H NMR binding studies of (9) in CDC13, in which host was titrated against guest, 
indicates 1: 1 binding and provides evidence for the hydrogen bonding. Thus, for example, 
large downfield shifts of the host amide (1.65 and 1.63 ppm) and guest imide (4.38 ppm) 
resonances are revealed. Further evidence for this binding comes from X-ray 
crystallography of the bound and unbound host. This technique also reveals the 
conformational change which occurs in the host on binding, placing all 6 hydrogen bonding 
groups into one plane. Thus, the host illustrates, for a synthetic system, the induced-fit 
theory described in Section 1.1.3. Overall, the binding is very strong (Ka = (6.0 ± 1.4) x 105 
M-t), due principally to the complementarity of host and guest39 
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Rebek has also synthesised hosts which are complementary to barbiturates. He has 
designed an acyclic host molecule in which two derivatised cyclohexane moieties are linked 
by a disubstituted naphthalene spacer (10). A barbiturate derivative has been bound in 
CDC1340. The importance of the complementarity of the host to the guest is shown by the 
fact that whereas the 2,7-disubstituted naphthalene derivative bound the guest strongly (Ka 
= 32400 M''), the 2,6-derivative did so 36 times less strongly, Ka= 890 M'1. 
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1.2.2.3 The binding of nucleic acid bases 
Amongst the many species that Rebek has been able to bind using his cleft like hosts, 
nucleic acid bases such as ethyl adenine have figured prominently40,41 Hydrogen bonding 
again plays a key role in the intermolecular binding, but n-it interactions are also significant. 
With hosts (11) to (13), such it-it' interactions increase the more polar the solvent used. 
Conversely, 'H NMR evidence shows that hydrogen bonding between host and guest 
decreases to negligible as more hydrogen bonding solvents are used. Thus, from CDC13 to 
acetone-d6 to D20, binding decreases from 1.5 x 10' M'' to 1.3 x 103 M'1 to 85 M-' 
respectively. 
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The importance of 7t-stacking in the binding of ethyl adenine is illustrated by a study 
in which Rebek synthesised related host molecules42. Scheme 1.1 shows the results of this 
analysis, in which a difference of 5 kJ mol-', separates the binding of ethyl adenine to 
anthracyl versus a methyl derivative. 
Scheme 1.1 : Binding of ethyl adenine by the related host molecules of Rebek 
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Schmidtchen has synthesised host molecule (14), capable of binding nucleotides as a 
whole43. It contains two guanidines linked by an aromatic urethane unit and binds 
specifically to the phosphate group on the nucleotide. In his report on this host, the author 
calculates an association constant of 10.6 M'1 in water and claims that it is the first example 
of the binding of a mononucleotide to an artificial host in water. 
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However, Rebek and de Mendoza have synthesised cleft host molecules (15) and (16) 
capable of binding mononucleotides by forming intermolecular bonds with the phosphate 
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group as well as the basea..... Both use the guanidine unit of Schmidtchen, to bind the 
phosphate and use imide groups to bind the base. However, whereas Rebek uses two 
imides from the two Kemp triacid derivatives in his host, de Mendoza only uses one imide. 
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Finally, Rebek has designed host (17) for binding dinucleotides46. This host molecule 
contains the usual Kemp triacid derivative functionality as well as the guanidine unit. 
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1.2.2.4 The binding of amino acids and peptides 
Peptides and amino acids are amongst the most common kinds of guests to be 
complexed in biological systems. Enzymes, antibodies and antibiotics are examples of host 
species capable of binding peptides with high selectivity. Thus a great deal of work has 
been undertaken in recent years to try to mimic these binding interactions47. 
An early example of such a host was synthesised by Ogoshi48. This host (18) was 
based upon bifunctional rhodium porphyrins and was capable of binding amino acids at the 
amino and carboxyl functions, with binding constants in'CHC13 of up to 5x 106 M"1. The 
lack of enantioselectivity, however, was a problem. 
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The enantioselective complexation of phenylalanine and tryptophan was achieved, 
however, by de Mendoza49. The S, S diastereoisomer of his host (19), is capable of 
selectively complexing L-tryptophan. As can be seen, the amino acid is bound in 3 places 
with 3 different kinds of interaction - electrostatic, hydrogen bonding and n -lt interactions. 
In the above interaction, only 0.5% of the D-Trp was detected, whilst for D-Phe, the figure 
was 2%. 
Chamberlin has synthesised a receptor (20), which as shown is capable of binding 
cyclic dipeptides or diketopiperazines50. This enantioselective host binds cyclo-L-Leu-L- 
Leu with a binding constant of K= 606 M'1 compared to K= 74 M'' for cyclo-D-Leu-D- 
Leu, this giving an enantioselectivity of 0AG=5.15 kJ mol-1. Chamberlin's host 
complexes cyclo-Gly-L-Leu most strongly with K= 2260 M'1 and an enantioselectivity of 
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a similar order of magnitude to the previous cyclic dipeptide (A AG = 4.06 kJ mol"1): Such 
enantioselectivity is remarkable for such a flexible host molecule and as shown, binding 
occurs via hydrogen bonding. 
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Much greater enantioselectivity, combined with considerably stronger binding for the 
favoured enantiomer has been achieved by Rebek using his cleft molecule (21)51. In this 
case, the binding achieved was K= 82000 M'1, whereas for the enantiomer of the host, the 
binding was K= 840 M' (A 0G= 10.5 kJ moll). Again, binding is via hydrogen bonding, 
with the enantioselectivity explained as being due to adverse steric interactions towards the 
unfavoured enantiomer. 
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A selection of linear dipeptides have also been bound within related molecules, 
although this time with reduced enantioselectivity52. One enantiomer of the host (22), binds 
N-Z-L -L. eu-Gly-NHBn with a binding constant of K= 4736 M''. However, in the case of 
the opposite enantiomer, the binding is only halved, at K= 2340 M'' This comparatively 
poor enantioselectivity is explained as being due to the flexibility inherent in both host and 
guest. When more rigid guests such as the cyclic dipeptide piperazines are bound, 
enantioselectivity is correspondingly greater. 
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Particularly impressive enantioselective binding has been achieved by Kilburn. He has 
synthesised a selection of host molecules capable of binding amino acids and peptidesss, sa 
Host (23) is a recent example and has been used to achieve a binding enantioselectivity of 
80: 20 or AAG=3.2 kJ mol' using N-benzyloxycarbonyl- ß -alanyl-L-alanine as guest's 
As with Rebek's host molecules (21) and (22), Kilbum's macrocycle was synthesised in 
racemic form - the racemate being bound to a homochiral guest. The solvent was CDC13, 
with binding constants of -0 G.. c = 
19.4 and 16.2 kJ mol'1, being calculated using a 'H 
NMR titration experiment. 
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Some of the best enantioselective binding, however, has been achieved by Still"'. 
One of his earliest peptidic host molecules (24) contains an amide binding site and additional 
functionality designed to distinguish between different guest enantiomers via steric and 
hydrogen bonding interactions. Enantioselectivities of 70 % have been achieved as in the 
case of the strong binding in CDC13 of Ac-L-Ala-NH-tert-butyl (-0 G=9.84 U mol-1) over 
the weaker binding of its enantiomer Ac-D-Ala-NH-tert-butyl (-0 G=4.35 kJ mol-'). In 
this case, the difference of 5.49 kJ mol'1 is quite large. A difference of 3.8 kJ mol'' was 
recorded for Ac-L-Ala-L-Ala-OBn against Ac-D-Ala-L-Ala-OBn, also in CDC13. 
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More recently a selection of novel C3-symmetric host molecules ((25) - (28)) have 
been synthesiseds"' . Each of these molecules possesses a 
deep apolar binding cavity with 
alternate hydrogen bond donor (D) and acceptor (A) sites and conformational stability. 
These features enable hosts to bind amino acids and also octyl glycosides with high 
selectivity. 
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Host (26) is particularly appropriate for the binding, with high selectivity, of Boc 
protected N-methylamides of a-amino acids such as Boc-Val-NHMe61. In chloroform, the 
highest enantioselectivities were found when derivatives of alanine, valine, leucine, serine 
and threonine were used as guests. In these cases, enantioselectivity corresponded to 8-12 
kJ mol' or 90-99% ee, in favour of the L-enantiomer. It was also found that such 
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derivatives of serine and threonine with their hydroxylated side chains bind z8 kJ mol'' more 
tightly than equivalent amino acids with simple alkyl side chains such as alanine, valine and 
leucine. Those amino acids with an N-terminal methoxycarbonyl group generally bind more 
strongly. For example, L-McO2C-Ala-O'Bu binds 3.8 kJ mol-' more strongly than L-Boc- 
Ala-NHMe. However, enantioselectivities are similarly high in the range of 90-99%. The 
manner in which many of these guest amino acids bind is illustrated in Fig 1.10. 
Fig 1.10: Schematic diagram of the binding of amino acid derivatives by host molecule (26) 
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Practical applications for this host molecule have been devised whereby it is covalently 
bound to a solid phase support in order to effect the resolution of amino acid derivatives. 
Thus (27), which has the same enantioselective binding characteristics as (26), has been 
designed to bind to such a support62. 
Similarly, host (28) can be synthesised by binding the host to a dye such as Disperse 
Red. Using Combinatorial Chemistry to synthesise the guests, up to 50000 different 
potential peptide guests can be screened for binding6 , ". A Combinatorial Library of 
different substrates is attached to Merrifield beads such that there is only one substrate per 
bead. Different chemical tags are also attached which following the binding experiment can 
be readily removed by photolysis and analysed by gas chromatography so as to rapidly 
distinguish the structure of each bound guest. It is clear from the experiment, which beads 
one needs to analyse in order to determine the most strongly bound dyed host molecule 
since they are the ones with the most intense red colour. By this method, one of the highest 
artifical enantioselectivities known was identified. Following large scale synthesis of the 
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guest, cyclopropanoyl-L -Ala-L-Pro-L-Ala-NHC12Hu was found to bind with 0G= 23.9 kJ 
mov, whereas its diastereomer cyclopropanoyl -D-Ala-L-Pro-L-Ala-NHC12H25 was not 
observed to bind at a1163. 
A final example of a host molecule designed by Still (29) likewise binds peptides with 
high enantioselectivity65. However, its major advantage is its ease of synthesis. A 13% 
yield has been achieved simply by mixing the acid chloride of A with B at 3 mM 
concentration with Honig's base in dry THE 
As before, when a dye is attached to the substrate (30), Combinatorial Library binding 
is possible, with the result that 50000 acylated tripeptides have been analysed for their 
binding potential66. ' 
Bý ýg 
g/ 1 
Ate/ 
gý 
Aýg (29) 
CO 
HN2 
OC CO HN 
/ 
A 
B/I\B' 
B' A 
\B 
B/ B 
(30) 
HN,, 
ýý 
B' = 
HN 
).. 
N-COCH22CO-DYe 
38 
1.3 Transport 
1.3.1 Natural transport systems 
In addition to the binding of guests within a particular solvent environment a variety 
of host molecules are able to transport them and then release their guests into a different 
medium. A well known example of a natural host molecule which transports guests across 
a membrane in biological systems is valinomycin This molecule has been a model for many 
synthetic host molecules. In the following pages its structure and mode of action will be 
described followed by examples of two synthetic transport systems. 
1.3.1.1 Valinomycin68 
Valinomycin is a cyclic dodecadepsipeptide, an unusual peptide having alternate amino 
and hydroxycarboxylic acids linked by amide and ester bonds; [IValine-D-hydroxyisovaleric 
acid-D-valine-L-lactic acidl3(31). Its physiological function is the selective transport of K* 
ions across cell membranes from the outside to the inside of cells. 
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Valinomycin was isolated from streptomycesfulvissimus by Brockmann and Schmidt- 
Kastner in 195569 and synthesised in 1963 by Shemyalcin70. As such it played an important 
part in., the birth of the chemistry of molecular recognition. Its conformation in solution 
depends upon the solvent polarity (Fig 1.11)71. 
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Fig 1.11: The different hydrogen bonds present in valinomycin depending upon the nature 
of the solvent. 
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In non-polar solvents such as heptane or CCl4, the bracelet-like structure A is mainly 
present. In this structure, all the NH groups participate in hydrogen bonding. In solvents 
of medium polarity, hydrogen bonding breaks down such that only D-valyl NHs are involved 
- as represented by structure B. At elevated temperatures and in highly polar solvents, the 
NH groups are hydrogen bonded to the solvent - structure C. 
On complexation with KK a structure having three-fold symmetry is formed, with the 
cation located at the centre of a 36 membered macrocycle and octahedrally co-ordinated to 
six ester carbonyl groups"'. All the carbonyl oxygen atoms of the amide atoms of the 
amide groups take part in hydrogen bonding thus establishing a ring of limited flexibility. 
The diameter of the cavity corresponds to the size of KK or Rb* and thus valinomycin is 
specific for KK over Na+. 
The presence of the lipophilic side chains pointing towards the exterior of the 
molecule contribute to the solubility of the complex in solvents and media of low polarity, 
such as membranes. Thus the complex is able to travel through lipid membranes such as 
cell walls. A complex involving Na+, in which the ion is bound weakly to the outside of 
valinomycin7 would be unable to do this. A schematic diagram of the mode of binding of 
K+ is given in Fig 1.12. 
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Fig 1.12: Schematic diagram of the binding of K' by valinomycin 
1.3.2 Synthetic transport systems 
In designing a host for membrane transport, such a molecule should ideally possess 
different properties in each of three, chemically different media - the source phase, lipid 
membrane interior and the receiving phase. In the source phase, binding should be fast and 
strong76. In the hydrophobic membrane the cation should be strongly bound. In the 
receiving or exit side of the membrane, binding should be weak and release of the guest fast. 
Just some of the ways in which this is achieved synthetically are described in the next few 
pages. 
1.3.2.1 Transport of amino acid anions 
Tsukube has studied the transport of amino acid anions across a chloroform 
membrane". His apparatus consisted of aU tube in which was placed a solution of the host 
in chloroform. Buffered aqueous solutions of equal concentrations of the amino acid anion 
at the same pH were placed in the arms of the U tube. These aqueous solutions floated on 
the chloroform membrane. The concentrations of the amino acid anions in both aqueous 
phases were recorded at steady state, usually after 24 h. 
41 
o 
io 
co 
o 
ý, O,, ) 
(32) 
IN" C"N 
O 0000 
(34) 
<r-o 
0-) 
H21CIG, N-C10H21 
O O-/ 
(33) 
Q 
N 0%0. 
'\N 
(35) 
In the presence of an alkali-salt such as KCl in the aqueous source phase, the amino 
acid derivatives were successfully transported against their concentration gradients by the 
aid of artifical hosts (32) to (35). Each host proved to have differing abilities as a carrier 
of amino acids across the membrane. Thus crown ether (32) > diaza-crown ether (33) > 
non-cyclic crown ether (34) z cryptand (35). In addition, each host had its own guest 
specificity. Thus, for example, crown ether (32) transported Bz-Phe more readily than Bz- 
Gly. With Bz-Phe as the guest, the steady state concentrations suggested that the receiver 
aqueous phase contained 70 % of the available Bz-Phe. With Bz-Gly as the guest, 
however, the receiver phase contained only 50 %. 
However, such selectivities are small. Each of these hosts form complexes selectively 
with K+, the hosts recognizing this metal only. The Z-amino acid carboxylate anions are 
co-transported, owing to ion pairing with cationic host - KK complex. Thus the differing 
rates of amino acid transport are probably due to the differing guest lipophilicities rather 
than the specific recognition ability of each host78. 
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Gokel has used a similar system to that of Tsukube, again using a chloroform 
membrane79. The rates (mol li ) at which Z-protected amino acid anions were transported 
through the membrane were measured. (36) and (37), called lariat ethers, are examples of 
the kinds of host molecules used. Such hosts are derived from diaza-crown ethers and 
dipeptides. 
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(36) R= Z-PhgGly 
(37) R= McOPhgGly 
Z= PhCH2000- 
Phg = D-a-phenylglycine 
Chiral recognition of enantiomeric guests provides strong evidence of direct 
recognition of guests by the host's chiral pendant arms. Thus, for example, 0.15 mmol Z- 
L-Phe-OK was transported by 0.0372mmo1(37) across the 3 cm3 membrane at a rate of 
20.5 ymol If', compared to 14.9 jcmol h'' for Z-D-Phe-OK. The existence of hydrogen 
bonding interactions between the lariat pendant arms and bound Z-PheOK was shown by 
specific NH proton shifts in the 'H NMR spectra of 1: 1 mixtures of (37) and Z-PheOK in 
CDC13. 
1.3.2.2 Transport of nucleotides and nucleosides 
Nucleotide analogues have recently been the focus of considerable attention due to 
their potential antiviral activity. However, because of their charged nature, many 
nucleotides are poor at penetrating through the cell walls and into cells. Lipophilic host 
molecules, capable of masking this charged nature might have utility in aiding the passage 
of nucleotides through cell walls and delivering them to the point where they are required80. 
'- Sessler has used a host system to mediate the transport of guanosine 5'- 
monophosphate (GMP) through a lipophilic membrane80. The system used was a simple 
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three phase (H20 - CH ci 2- H 9) model membrane. The host was a 227z-electron 
pentapyrrolic "expanded porphyrin" called a sapphyrin (38)81. Such a molecule can exist 
as H3Sap, H4Sap+ and H5Sap2+ according to its degree of protonation. 
(38) 
Initial transport experiments were carried out at pH 2.5 with GMP2" diacid in the initial 
aqueous phase (Aq I) and HSSapz+ in the CHZC12 phase. A steady buildup of GMP in Aq 
II was observed, corresponding to an initial transport rate of 86.9 x 10-3 pmol Cm -2 h'1. By 
contrast, when sapphyrin is not present in the organic phase, no transport occurs, even after 
3 days. When the pH is increased to pH 4, initial transport rates decrease dramatically as 
the H4Sap+ form of Sapphyrin gains stability. Thus a 1: 1 complex between sapphyrin and 
GMP diacid is proposed, as illustrated in Fig 1.13. 
Fig 1.13 : The binding of a nucleotide by sapphyrin (38) 
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Nucleoside transport is also possible and by using triisopropyl (Tips) substituted 
nucleoside derivatives as the host molecules (39) to (42), other nucleoside analogues have 
enhanced transport in a simple (H20 - CHC13 - H20) liquid membrane system82. Amongst 
these nucleoside analogues is 3'-azido-2', 3'-dideoxythymidine (AZT) (43), an approved drug 
in the treatment of AIDS. AZT has high intrinsic lipophilicity but a small enhancement of 
AZT transport across the chloroform membrane was observed using (39), (40) and (42) as 
transport agents. It is thus possible that analogous transport agents might encourage the 
transport of AZT through a cell membrane. 
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Tips = triisopropyl 
(39) B= adenine 
(40) B= uracil 
(41) B= cytosine 
(42) B= guanine 
1.4 Catalysis 
1.4.1 Natural catalytic systems 
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One of the key aims in the synthesis of host molecules is to produce systems which 
not only bind guests specifically but also catalyse reactions between them. If this can be 
done efficiently with high turnover and with minimal degradation of the host molecule, then 
an enzyme mimic will have been produced83. In the pages which follow, the catalytic 
processes occurring in a digestive enzyme called chymotrypsin will be outlined, following 
which some examples of synthetic hosts involved in the catalysis of both bond fission and 
bond fusion reactions will be described. 
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1.4.1.1 Chymotrypsin'7 
This enzyme consists of three polypeptide chains connected by two interchain 
disulphide bonds folded to produce a compact ellipsoid shaped molecule. Produced in the 
pancreas, its biological function is to catalyse the cleavage of peptide bonds specifically at 
the carboxyl side of aromatic side chains tyrosine, tryptophan and phenylalanine and of large 
hydrophobic residues such as methionine. 
The mechanism of the reaction requires 3 key residues which act together as a 
"catalytic triad". The three residues which form this triad, Ser 195, His 57 and Asp 102, 
are positioned close together in space and the latter two amino acids activate Ser 195 to 
react with the amide bond to be cleaved. The mechanism, which is illustrated in Scheme 
1.2, involves attack by the Ser 195 hydroxyl group onto the amide bond to form a 
tetrahedral transition state and then an acyl enzyme intermediate. Acyl transfer thus occurs 
-a reaction which is mimicked in some of the synthetic systems described in Section 1.4.2.1. 
The acyl enzyme intermediate is then hydrolysed by water. 
As with many enzymes, the reaction it catalyses follows Michaelis-Menten kinetics. 
Thus the rate of catalysis V, varies with the substrate concentration [SI in a manner shown 
in Fig 1.14. V is defined as the number of moles of product formed per second. Thus at 
a fixed concentration of enzyme, V is almost proportional to [S] when (Sl is small. With a 
high value of [SI, V is nearly independent of [S]. 
Fig 1.14: Graph illustrating the Michaelis-Menten model of enzyme kinetics 
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Scheme 1.2: Mechanism of peptide bond cleavage by chymotrypsin 
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In 1913, Michaelis and Menten proposed a simple model to account for these kinetics. 
Crucial to this was a specific enzyme-substrate (ES) complex, which acted as an 
intermediate in the catalysis. Their model was as shown in Scheme 1.3. 
Scheme 1.3 : Equation of the Michaelis-Menten model of enzyme kinetics 
E+S 
kl 
k2 
k3 
ES E+P 
The Michaelis constant KM, found from the graph in Fig 1.14, is defined as the 
concentration of substrate at half the maximum reaction rate. Its significance is that it is 
related to the rate constants of the individual steps in an enzyme reaction. Thus if, for 
example, in Scheme 1.3, k2 is much greater than k3, a high K,, 1 would indicate weak binding. 
Conversely, a low K,,, indicates strong binding. 
1.4.2 Synthetic catalytic systems 
1.4.2.1 Acyl transfer catalysts 
In Section 1.2.2.2, a host molecule was described which was capable of binding 
barbiturate guests. Hamilton has taken this work a stage further by the synthesis of the host 
(44)84. Fig 1.15 shows how the host binds to a guest containing an ester functionality. 
Molecular modelling studies on (44) show a minimum energy conformation in which the 
thiol is directed into the cavity and positioned ca. 3.5 A from the ester carbonyl on the guest. A 
This system is thus ideally designed to allow thiolysis or an acyl-transfer reaction to occur. 
When compared to a standard uncatalysed reaction between the guest (45) and (46), 
the presence of the host catalyst in CHZC12, accelerates the reaction by a factor of more than 
104. This effect is due to the precise hexa-hydrogen bond complementarity between host 
and guest as evidenced by the 8-fold rate increase when the reaction is carried out in the 
presence of (47). In addition, the reaction follows Michaelis-Menten kinetics, showing 
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saturation behaviour as the host concentration is increased and a Michaelis-Menten constant 
Km = 6.89 ± 0.20 x 10 5 mol dm-3. However, a key drawback is the lack of turnover in the 
reaction, an effect caused by product inhibition. 
Fig 1.15 : Binding of a guest to host molecule (44) 
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Diederich has also designed molecules capable of catalysing acyl transfer". An 
example of such a host molecule (48) is illustrated in Fig 1.16 alongside a schematic diagram 
of the binding of the guest. 
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Fig 1.16 : Catalysis of acyl transfer by host molecule (48) 
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The guest in (48) is bound by hydrophobic forces when the solvent is an aqueous 
buffer solvent system. Due to the relative sizes of the cavity in the host and the size of the 
guest, binding occurs in the orientation shown, allowing supramolecular acyl transfer to 
occur. The rate of reaction was found to be fastest in phosphate buffer at pH8, being 472 
times faster than the hydrolysis in the buffer when the host molecule was not present. 
"Weak but significant turnover" is also claimed, however, a figure for the number of 
catalytic turnovers is not given. 
A final example of a system capable of catalyzing acyl transfer is (49)86. 
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Acyl transfer occurs as shown in Scheme 1.4. In the uncatalysed reaction in toluene 
at 70° C, the apparent second order rate constant is 3.4 x 10-5 dm-3 mol-t s'1. With 9x 10'3 
mol dni 3 concentrations of each substrate and 0.45 x10"3 mol dm '3 of host, the rate was 
increased 16-fold. 
Scheme 1.4: Acyl transfer catalysed by host molecule (49) 
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Amongst the evidence that this transformation occurs within the cavity is the fact that 
competitive inhibition is affected by the introduction of a molecule possessing a similar size 
and shape to the expected transition state. Such a molecule is (50). 
1.4.2.2 Catalysis of ATP and ADP hydrolysis" 
The hydrolysis of both adenosine triphosphate (ATP) and adenosine diphosphate 
(ADP) is catalysed by the macrocycle (51) designed by Lehn - Scheme 1.5 87. The. reaction 
rate is accelerated by factors of 3 for the hydrolysis of ADP and 9 in the case of ATP, the 
difference being due to the better fit of ATP for the macrocycle over ADP. The binding of 
ATP with (51) was studied by31P NMR Spectroscopy using a 1: 9 D20: H20 solvent system 
at pH 7. The addition of 1 mole equivalent of (51) to a 10-2 M solution of ATP caused a 
a slight downfield shift of the P. signal (-0.07 ppm) whereas both the central Pa signal and 
the terminal PY signal were shifted upfield by 1.32 ppm and 2.22 ppm respectively. The 
addition of 1 mole equivalent of ATP to a 10-3 M solution of (51) at pH 7 in D20 caused 
significant upfield shifts of aromatic protons of the acridine moiety of (51). These results 
have been interpreted as suggesting that ATP is bound by hydrogen bonding between the 
phosphate and the macrocycle and by 7r-7r hydrophobic interactions between adenosine and 
acridine groups. Such hydrogen bonding within water is extremely unusual due to the 
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competition for hydrogen bonds by the presence of the water, but it is probably facilitated 
by the opposite charges of the phosphate groups and the macrocycle. Scheme 1.5 gives a 
representation of the mechanism of the reaction. 
Scheme 1.5 : Catalysis of ATP hydrolysis by host molecule (51) 
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1.4.2.3 Catalysis of the benzoin condensation 88'89 
Ever since the work of Breslow in the 1950's 9091, it has been established that, in the 
absence of enzymes, the thiazolium ring acting as a thiazolium ion in such coenzymes as 
thiamin pyrophosphate (TPP) (52), catalyses many enzymatic reactions such as the acetoin 
condensation92"93. 
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Diederich has incorporated TPP into a macrobicycle, designed to catalyse the benzoin 
condensation. The macrocycle (53) and the mechanism of reaction are illustrated in 
Scheme 1.6. 
Scheme 1.6 : The mechanism of the benzoin condensation as catalysed by host molecule 
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As with reactions described earlier, the reaction follows Michaelis-Menten kinetics 
with catalysis of both forward and reverse reactions. 
In addition, rates of reaction increase with decreasing solvent polarity and with 
increasing concentration of triethylamine base. These solvent effects are perhaps contrary 
to expectation, since one would expect increasing solvent polarity to result in guests being 
bound by stronger hydrophobic forces, thus increasing the effective molarity of the reagents 
within the cavity. However, increasing base concentration agrees with the expected result 
in that it would readily encourage reaction. 
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1.4.2.4 Oxidation of aromatic aldehydes94 
Diederich has designed macrocycle (54) which is related to (53) and which is capable 
of catalysing the oxidation of aromatic aldehydes to carboxylic acids. The 'H NMR 
spectrum of the macrocycle in D20 compared with that of (55), reveals considerable upfield 
shifts of all the thiazolium protons (0.27 - 0.70 ppm), indicating that the thiazolium ring is 
located within the cavity. 
+ 
(54) 
CHzý + CH3 
CI 
S 
c 
(55) 
Oxidation of 2-naphthaldehyde is catalysed by (54), in the presence of potassium 
ferricyanide in 60: 40 (v/v) Me2SO : aqueous phosphate buffer (pH = 7.5) at 303K. 
Compared to its non-macrocyclic derivative (55), the rate of reaction is 6.2 times greater 
in the presence of macrocycle, due to the binding of the aldehyde in the cavity by 
hydrophobic forces. The mechanism of reaction is given in Scheme 1.7. 
Scheme 1.7 : Mechanism of the oxidation of aromatic aldehydes as catalysed by host 
molecule (54) 
RN 
R'-CO-COON 
RN RAN 
or OH oxidation O 
S R'-CHO S 
R' R' 
active 
aldehyde 
Nu /H20 
0 
RN 
+ 
R'jýOH S 
54 
1.4.2.5 Catalysis of the Diels-Alder reaction 95-97 
As well as catalysing an acyl transfer reaction, the cyclic porphyrin trimer of Sanders 
(56) has been shown to catalyse the Diels-Alder reaction between a furan derived diene and 
maleimide derived dienophile. In this reversible reaction, the guests were bound to the 
metallated porphyrins by the attachment of pyridine moieties. These pyridine units bind 
very strongly to the hosts and this, in addition to the fact that the reaction products bind at 
two locations to the host giving a strong chelate effect, causes product inhibition and thus 
a lack of reaction turnover. However, due to the reversible nature of the reaction97, its 
kinetics and transition state energies can be studied. Scheme 1.8 shows the nature of the 
Diels-Alder catalysis. 
Scheme 1.8 : Catalysis of the Diels-Alder reaction by host molecule (56) 
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In the absence of porphyrin trimer, the endo adduct obtained by kinetic control is a 
significant product at low temperature, whilst the exo adduct obtained by thermodynamic 
control is the only product detected at high temperatures. At 60° C, the exo/endo ratio is 
initially about 4, but due to the reversibility of the reaction, the endo adduct gradually 
disappears97. However, on addition of one equivalent of the trimer to the two reactants, 
the forward diels-alder reaction is accelerated 200 times at 60° C, yielding the exo adduct 
as the only detectable product. The stereochemistry of the product is drastically altered by 
the trimer, due to its increased stabilisation of the exo transition state with respect to the 
endo transition state. On addition of trimer, the energies of the bound transition states 
correspond to an increase in the activation energy of the forward endo reaction from 110 
to 114 kJ mor' and a decrease in activation energy for the exo reaction from 105 to 101 kJ 
mol'` 97. Thus, due to the reversibility of this reaction, the trimer effectively encourages 
conversion of the endo adduct to its exo isomer. Consequently, whilst a 0.9 X10-3 mol dm 3 
solution of endo adduct in the absence of trimer is quickly converted to an almost 
completely dissociated diene-dienophile pair, in the presence of trimer it is converted into 
about 55 % exo adduct in 100 h. 
1.5 Synthesis of host molecules 
In order to achieve the synthesis of many of the host molecules described above, a 
wide variety of strategies have been described in the literature98. Common to all these 
strategies is the "molecular building block principle" - the stepwise assembly of easily 
accessible structural subunits. Scheme 1.9 gives a schematic diagram of the kinds of 
strategies possible in the synthesis of triply bridged cyclophane hosts. Thus it is possible 
to form such a molecule by six-fold bond formation using five components, namely two 
spacers and three bridge units (path A). Whilst this method is simple, it often gives low 
yields with difficult purification problems. Alternatively, a longer synthesis would give only 
two molecules in the final cyclisation step (paths C and D) or a situation where the final ring 
closure occurs intramolecularly (paths E, F and G). Frequently, the choice of synthetic 
strategy is dictated by the nature of the molecule being synthesised. 
J 
56 
Scheme 1.9 : Schematic diagram showing possible strategies towards the synthesis of triply 
bridged cyclophane hosts 
SDae. SDaer sooe. 
sDacr s0ocr 50«r 
A BI C 
sD« . 
spec. 
HD 
D 
sDacr 
r Sc ZG 
Ft E 
So«r s. oe. 
spur sD«. 
j 
An example of a molecule synthesised according to the strategy outlined in path G is 
Still's C3 symmetric host (27)60. The final stages in its synthesis are given in Scheme 1.10. 
57 
Scheme 1.10 : Final steps in the synthesis of host (27) 
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The addition of (57) to a large volume of Honig's base in THE was carried out at 
room temperature over 40 h using a syringe pump so as to maintain a high dilution of the 
compound. As will be described shortly, a high dilution is necessary in order to ensure infra 
over intermolecular reaction. Consequently, the final cyclisation was achieved in 78 % yield 
after silica gel chromatography. 
Alternatively, a strategy analogous to that illustrated in Path E has been used to 
synthesise Kilbum's macrocycle (60) in Scheme 1.1154. 
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Scheme 1.11: Final step in the synthesis of host (60) 
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The cyclisation precursor (59), is synthesised in 6 steps before the ring closure step 
is achieved in 15 % yield by means of a palladium catalysed biaryl formation. For this 
reaction, the cyclisation precursor (59) is kept at a high dilution of 10 x 10"3 mol dm 3. 
The synthesis of both (27) and (60) illustrate the importance of maintaining a high 
dilution of reactants in the final cyclisation. These conditions can be obtained by use of 
large quantities of solvent and also as in the synthesis of (27), by controlling the rate of 
addition of the reactants. In designing such cyclisations, the aim is to introduce reactants 
at a rate equal to the rate of the cyclisation. 
The ratio k; ntm 
/ kinter has been established as important in determining the likelihood 
of a macrocyclisation occurring 1°'. This ratio is known as the "effective molarity " (EM) 
and has units of mol dn- 3. It represents the reactant concentration at which the cyclisation 
(k; ntm) and polymerisation (k; nter) of a given 
bifunctional monomer, occur at the same rate. 
Practically, it gives a guide as to the required rate of addition of reactants if cyclisation is 
to predominate over polymerisation. The reactants are infused continuously into the 
reaction mixture at such a rate as to prevent their accumulation. If the rate of feed of is less 
than EM x kintr,, then cyclisation predominates. 
In addition to the high dilution principles, templates have also been used to achieve 
efficient macrocyclisations1°2. The use of cyclisation promoting templates can increase the 
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proportion of the conformers of a monomer that are suitable for cyclisation. Thus the ki,,. 
value is enhanced relative to k;,,,,,, EM is increased and the concentration of monomer 
required to achieve a particular yield of macrocycle is increased. 
Template effects were used by Pedersen in the early days of host-guest chemistry in 
the synthesis of dibenzo-18-crown-6 (61)1. In the synthesis of this compound, outlined in 
Scheme 1.12, high dilution techniques were not required, due to the fact that the reactants 
became orientated correctly for synthesis, through ion-dipole interactions. 
Scheme 1.12: Pedersen's synthesis of dibenzo-18-crown-6 
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A more recent example of the use of the template effect in synthesis, is the 
construction of the porphyrin trimer (56) and also of porphyrin dimer (62)'0"05. As can be 
seen in Scheme 1.13, when the porphyrin (63) is reacted under Glaser coupling conditions, 
the outcome of the reaction can be directed down either of two very different pathways, 
depending upon the use of a particular template. 
60 
Scheme 1.13 : Template synthesis of porphyrin trimer (56) and porphyrin dimer (62) 
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Thus, when 4,4'-bipyridyl is used as the template, the cyclic porphyrin dimer is formed, 
whereas template directed synthesis using 5-tri(4-pyridyl)triazine results in the formation of 
the trimer. The reason for the effectiveness of these templates is suggested as being due 
to the ability of their pyridyl groups to coordinate to the metallated porphyrins and thus 
orientate them to the appropriate conformation for cyclisation. Evidence for this suggestion 
is the fact that such product selection only occurs in non-coordinating solvents such as 
CHZC12. The use of a solvent such as pyridine, capable of competitive binding to the 
metallated porphyrin, results in mixed products. 
The caesium effect has also been employed in many macrocyclisations, using Cs2CO3 
in DMF solution106''os Thus, for example, Kellogg has deprotonated a series of long-chain 
diamines as their bis-tosylated derivatives using Cs2CO3 in DMF106. The dicaesium salts 
were thus foamed and reacted with various dibromides or dimesylates to give tosyl derived 
cyclic diamines. These cyclisations, which were not carried out under high dilution 
conditions, gave yields of the cyclic product of between 25 % and 95 % depending upon the 
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lengths of the alkyl chains. 
There is much debate concerning the origin of this caesium effect. One idea is that 
the caesium ion collects the two ends of a monomer onto its surface thus encouraging a 
conformation which facilitates cyclisation over polymerisation. However, Gall! and 
Mandolini have argued that caesium carbonate, compared to other alkyl metal bases, has no 
special ability to promote cyclisation109. In their experiments, performing 
macrolactonisations with a variety of alkali metal carbonates in DMF, yields of cyclised 
product were higher using Cs2CO3. However, the differences with K* and Na* were small 
and easily attributable to the change in cation size. 
Amongst other methods used to encourage cyclisation is the use of the rigid-group 
principle' `a"'. This strategy has been used by Drewes to encourage the formation of cyclic 
esters in which the rigid group 1,4-a, a'-dibromo-o-xylene reacts to form the rings (64) to 
(75)1 12,113 . Highest yields were obtained either when both reactants possessed "rigid 
groups" ((73) - (75)), or where one reactant had a "rigid group" and the other was a short 
chain dicarboxylic acid ((64) and (66)). (65) had an anomolous low yield. 
O0 
OLCH2A oi GCOIJ_-ICH2)n 
O 
00 
o: 
xx 
(64) n=0 (69) n=5 
(65) n=1 (70) n=6 
(66) n=2 (71) n=7 
(67) n=3 (72) n=8 
(68) n=4 
0 
ýoý 
ýý o ýýý 
0 
(73) R=H 
(74) R =Me 
(75) 
It is suggested that rigid groups are effective in promoting cyclisation by limiting the 
conformational possibilities and orientating reactive groups of a linear precursor closer 
together. Thus, whilst the activation energies between conformers may not necessarily be 
decreased, the proportion of cyclic like conformations over linear ones are enhanced. 
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Finally, factors such as choice of solvents and temperature affect the rate of cyclisation 
of a macrocycle. The rate of cyclisation is increased if the two ends of a precursor are in 
close proximity to each other. This is encouraged or hindered depending upon how the 
solvent interacts with the solute and, as was seen with the synthesis of the porphyrin dimers 
and trimers above, how the solvent affects any templates. Increases in temperature can 
overcome activation energies involved in the interconversion of conformers although such 
an increase might make some cyclic-like conformers entropically disfavoured. 
1.6 Polycvclic peptide host molecules 
1.6.1 Early results 
The pages above have described some of the many types of cavity like hosts that have 
been synthesised, the types of guest that they have bound and the applications to which they 
have been put. 
Since 1988, work has been in progress within the group of P. D. Bailey to design and 
synthesise cyclic peptide based host molecules with significant 3-dimensional cavities. Two 
examples of such molecules, which have been successfully synthesised, are (76) and (77) h la' 
121 
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j 
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The common structural component of both these molecules is the cyclic hexapeptide 
cyclo-(Lys-Lys-Gly)2. The use of such a cyclic peptide provides a good platform on which 
to build the cavities. Glycine was chosen for the cyclic peptide due to its ability to promote 
(3-turns which stabilize cyclic peptide structures. ß-turns area form of secondary structure 
within the cyclic peptide which link those residues which are 1,4 to each other by hydrogen 
bonding (Fig 1.17). 
Fig 1.17 :A ß-turn in a cyclic peptide 
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The use of L-lysine provides e-nitrogens which are available for the crosslinking of 
groups between residues to form a cavity. In addition, the length of the side chain (4 
carbons) gives a relatively deep cavity, the size of which can be varied by alternatively using 
homolysine (5 carbons) or ornithine (3 carbons) as required. Finally, because both (76) and 
(77) are symmetrical, a convergent synthetic strategy is feasible. 
By using crosslinks between the lysine side chains, the conformations of the molecule 
can be further constrained. Varying the nature of the crosslinks, the size of the cavity 
produced can likewise be altered. 
Performing a Monte Carlo conformational search on (76) and following its successful 
synthesis, extensive COSY and NOESY experiments have suggested that two low energy 
conformations are predominant (Fig 1.18). 
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Fig 1.18: The two predominant low energy conformations of host (76) as found by a Monte 
Carlo conformational search 
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In both conformations, the cyclic peptide backbone shows approximate two-fold 
symmetry. The difference between the conformers lies in the configuration of the E- 
nitrogens. For the lower energy structure (1.18a), three of the e-nitrogen lone pairs are 
directed inwards whilst one lone pair is directed outwards. In the higher energy structure, 
all four lone pairs are directed inwards. The consequence is that whilst (1.18b) has an open 
cavity ready to receive guest molecules, that of (1.18a) is filled with a lysine side chain. 
Preliminary results of binding experiments with N-Ac-L-Ala and host (76) have 
indicated that this amino acid is bound within the host cavity'. Bailey intends to test the 
binding of alternative potential guest amino acids so as to study any enantioselectivity in the 
cavity. 
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1.6.2 Project aims 
The aim of this project was to build upon the work achieved within the group of 
Bailey, described above, by the synthesis of molecules (78) to (81). 
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The synthesis of polycyclic peptide (78) was to be attempted in order to study further 
the conformations of constrained cyclic peptides. In particular, it was important to discover 
whether the use of the biphenyl group as a crosslinker between adjacent lysine residues 
would affect the formation of the two low energy conformers analogous to (1.18a) and 
(1.18b). By potentially forming a larger cavity than (76), larger protected amino acids than 
N-Ac-L-Ala and potentially dipeptides may be bound. 
It was intended that (79) would serve as a model for the synthesis of (80), which 
would itself act as a model for such binuclear metal complexes as hemerythrin and 
hemocyanin (see Chapter 3)122. '23. Both of these molecules are oxygen transport agents for 
a variety of lower life forms and possess active sites analogous to (80). It was hoped that 
(80) would bind two iron or two copper ions and thence bind an oxygen molecule. 
The porphyrin based structure (81) was designed to bind metal ions such as Fee' and 
Cu2+ and thus act as a stereoselective oxidising agent by virtue of the co-ordination of 
substrates between porphyrin and cyclic peptide (Chapter 4). 
67 
CHAPTER 2: 
SYNTHESIS OF CROSSLINKED TRIPEPTIDES 
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2. Synthesis of crosslinked tripeptides 
2.1 General solution-phase peptide synthesis 
Ever since the idea of peptides and polypeptides was introduced by Emil Fischer in 
1906124, the synthesis of such compounds has been a long standing challenge to chemists 12, . 
The successful synthesis in 1953 by du Vigneaud of the cyclic octapeptide oxytocin - the 
first synthesis of a polypeptide hormone126- was a seminal achievement and represents the 
start of modern peptide synthesis125. Since that date a large number of new techniques for 
the racemisation free, specific coupling of amino acids have been developed'8, t27-130 , such 
that the solution phase synthesis of small peptides is now routine"'. 
Small synthetic peptides have been widely used as, for example, antibiotics, 
neuropeptides and anti-cancer drugs 132. The pages below will give a brief description of 
some of the techniques involved in solution-phase peptide synthesis. The use of these 
methods in the synthesis of a crosslinked tripeptide will then be described. 
2.1.1 Protecting roups18,125"30 
In order to prepare peptides by the coupling of amino acids, it is necessary to protect 
all those reactive functional groups that it is intended will not take part in the reaction. 
Consequently, one must protect the a-amino terminus, the carboxyl terminus and any 
potentially reactive side chains. 
When protecting an a -amino group it is important to suppress its nucleophilicity either 
by withdrawing its electron density or by making it sterically inaccessible behind a bulky 
protecting group. 
The a-amino function is frequently protected by alkoxycarbonyl groups since these 
groups commonly suppress racemisation in the peptide coupling (Section 2.1.3). Widely 
used alkoxycarbonyl protecting groups are benzyloxycarbonyl (Z)133, t-butoxycarbonyl 
(Boc)1 , 13' and 9-fluorenylmethoxycarbonyl (Fmoc)136-i38. These three groups are described 
as "orthogonal" to each other in that each is stable to the conditions required to remove the 
other two (Table 2.1). However, other non-alkoxycarbonyl based protecting groups are 
also frequently used, among these being p-toluenesulphonyl (tosyl)139, triphenylmethyl 
(trityl)140 and 2-nitrophenylsulphenyl (Nps)141" 
69 
Table 2.1: a-amino protection 
Structure Protecting group Removal conditions 
0 
PhCH2O 
Z Catalytic hydrogenolysis 
0 A Boc Acid labile 
tBuO 
o 
H Fmoc Base labile 
11 &0 
Me S Tosyl Strong reducing conditions 
0 or strong acid (Chapter 3) 
Ph3C Trityl Very acid labile, catalytic 
hydrogenolysis 
NO 
2 
s Nps Acid labile, catalytic 
llotr hydrogenolysis 
The most widely used means of protection of the a -carboxyl group is esterification. 
Simple methyl or ethyl esters can be used and survive most peptide bond forming 
procedures and most deprotective operations. Alkaline hydrolysis is the most common 
means of deprotection, although this can result in racemisation of the optically active a- 
carbon of the amino acid or the formation of a diketopiperazine as shown in Scheme 2.1. 
.1 
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Scheme 2.1 : Formation of a diketopiperazine 
O 
RHC NH 
_N 
IH 
CHR 
Me0 
0 
0 
HN CHR 
0 
Benzyl and t-butyl esters are also frequently prepared, with these deprotections 
involving analogous conditions to those for the corresponding a-amino protection, i. e. 
catalytic hydrogenolysis or acidic conditions, respectively. 
A variety of novel side chain protecting groups have also been developed. Carboxylic 
acids (eg. Glu, Asp), amino side chains (eg. Lys) or heteroaromatic side chains (eg. His) 
require full protection which is orthogonal to other protective groups being used. Thus, 
for example, in 1982 Jones developed the N'-benzyloxymethyl protecting group which is 
cleaved from N"-benzyloxymethyl histidine, His(N"-Bom) (8 1)125 by catalytic 
hydrogenolysis'42. However, new protective groups are continuously being developed'30 
with the N"-2-adamantyloxymethyl group, used for example, to form N"-2- 
adamantyloxymethyl histidine, His(N'-2-Adom) (82) being a particularly recent example - 
this being cleaved under strong acidic conditions'43. 
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N 
\ 
N\ýp\ýPh 
ýH 
H2N CO2H 
(82) 
2.1.2 Amino acid coupling reactions]-'u, 130,144 
N 
\NO 
, NAH 
H2N CO2H 
(83) 
The mixing of carboxylic acids and amines does not lead spontaneously to the 
formation of an amide bond but rather to the production of a salt. It is therefore necessary 
to activate one of the components. To this effect, carboxylic acid activation has been most 
frequently employed in peptide synthesis. Acid catalysis is of no help in such reactions due 
to the basicity of the amino reagent; thus a variety of other different techniques have been 
developed in order to effect the activation of acylamino acids. 
The classical method of activation, developed by Fischer, is to form the acid 
chloride'as However, whereas such species very efficiently form amide bonds on exposure 
to primary amines, they are also susceptible to significant side reactions. Consequently, 
most simple acylamino acids cyclise spontaneously to give oxazolones and thus racemic 
peptides (Section 2.1.3). 
An alternative method, introduced by Curtius is the formation of acyl azides146. These 
can be made by the reaction of hydrazine with carboxylic esters and thence by treatment 
with nitrous acid (Scheme 2.2). 
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Scheme 2.2 : Formation of an acid azide 
H 
R OMe a) R N, -, NH 2 
00 
a) N2H4, MeOH 
b) HNO2 (NO+) 
acyl hydrazide 
+ ýN b) 
R Ni 
N 
0 
resonance stabilized acid azide 
A key advantage of this method is that it is less susceptible to racemisation of the 
amino acid than other techniques. However, a number of side reactions can also be 
observed amongst which the Curtius rearrangement (Scheme 2.3) can give significant 
amounts of side products'47. 
Scheme 2.3 : Curtius rearrangement 
N, N 
R 
N 
"N 
Rj -N2 
R-N=C=O 
In the 1950s, the idea of using symmetrical and unsymmetrical acid anhydrides in 
peptide synthesis was introduced'a8 °. By dehydrating a-amino protected amino acids, 
symmetrical anhydrides can be formed. Such anhydrides are relatively reactive so peptide 
couplings are efficient and are also comparatively clean. The major disadvantage is the 
inevitable loss of half of the amino acid as carboxylate (Scheme 2.4). If the amino acid is 
protected, this can be expensive. 
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Scheme 2.4: Formation of peptide bond using symmetrical anhydrides 
RyOy#R 
00 
a) 
H 
RýIVýRý 
O 
+ RCO2H 
a) R'-NH2 
Alternatively, mixed anhydrides have been developed in which the challenge is to 
ensure reaction at the desired carbonyl group. Thus a mixed anhydride was formed by the 
reaction of the peptidic carboxylic acid with ethyl chloroformate. In the resultant anhydride 
(84) only the carbonyl of the amino acid is susceptible to nucleophilic attack, that of the 
carbonic acid being less electrophilic. Alternatively, steric interactions have been utilised 
in, for example, the formation of the pivalyl mixed anhydride (85). 
R OOEt 
00 
(84) 
RrO% 
Ir CMe3 
00 
(85) 
In 1955, the use of the coupling reagent dicyclohexylcarbodiimide (86) was 
's recommended by Sheehan and Hess'. Scheme 2.5 shows the mechanism by which this 
facilitates the formation of an amide bond. 
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Scheme 2.5 : Formation of a peptide bond using dicyclohexylcarbodiimide 
N7 H+ O 
R-<O 
N 
R' 
(86) 
z 
R--le 
0 
N-R 
H 
Unfortunately, this is not a clean reaction. Significant racemisation is known to occur 
and rearrangement of the intermediate O-acylisourea (87) can compete with peptide bond 
formation to produce an N-acylurea (89) (Scheme 2.6). 
NHR' 
NHR' 
(88) 
Co R 
R- NH 
N 
R"NH2 R H+ 
(87) 
Scheme 2.6: Rearrangement of an 0-acylisourea to an N-acylurea 
p R' 
NH 
H+ 
-H+ 
O 
R R' 
Ný 
OH N 
(89) (87) 
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This problem has been countered by the catalysis of the amide bond forming reaction. 
Thus, as shown in Scheme 2.7, active esters have been generated in situ by the addition of 
reagents such as 1-hydroxybenzotriazole (HOBt) (90) 152 HOBt, being a good 
nucleophile, reacts readily with the 0-acylisourea (87) before formation of (89) can occur. 
An active benzotriazole ester (91) of lower reactivity is formed which is still active with 
respect to aminolysis but is less likely to take part in side reactions. 
Scheme 2.7 : Formation of an active ester using 1-hydroxybenzotriazole 
C0 ' R 
RNH O 
NHR' 
0\N NHR' 
(88) RN H+ 
B t-O' 
+ 
O 
Bt IN O-Bt 
CýN 
N (91) 
OH 
CN 
NN 
(90) 
Difficulties in the removal of the sparingly soluble dicyclohexylurea (DCU) (88) have 
encouraged work to develop alternative carbodiimides which when used in peptide coupling 
reactions produce water soluble urea side products. An example of such a reagent is 1-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (92) ls'. 
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ji 
.. r. + 
r. _ý 
- . ', "0 
CH3 
/N-(CH2)3 
N==C=NCH2CH3. HC1 
CH3 
(CH3)2 cl- 
N NCHZCH3 
H 
(92) 
The formation of amide bonds by the reaction of amines with simple methyl or ethyl 
esters is a slow process. However, by using active esters with electron withdrawing 
substituents on the leaving group, these leaving groups can be stabilized and the amide bond 
can be formed more speedily. Other than the benzotriazole esters just mentioned, 
pentafluorophenyl esters, 4-nitrophenyl esters, 2,4,5-trichlorophenyl esters and succinimidyl 
esters are commonly used13o, lsa Such procedures are clean and relatively free from 
racemisation problems. 
A final common technique is the use of phosphonium reagents. Castro has developed 
the benzotriazolyloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) 
reagent (93) which forms the acyloxyphosphonium ester (Scheme 2.8)155. This ester is 
highly susceptible to nucleophiles. 
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Scheme 2.8 : Activation of carboxylate anion to nucleophilic attack using the BOP 
phosphonium reagent 
RC02- 
(Me2N)3P± OBt. PF6 
(93) 
O 
'0 P(NMe2)3 
R 
Nu- 
0 
R0 
)(1e2)3 
PF6- + "OBt 
0 
R Nu 
+ O=P(NMe2)3 
Nevertheless, whereas this reaction gives good yields of product and is a relatively 
clean procedure, racemisation can still be a problem. In addition, the formation of the 
highly toxic hexamethylphosphoramide is a serious concern. Thus alternative reagents such 
as benzotriazolyloxy-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBOP) (94)156 
and benzotriazolyloxy- 1,1,3,3-tetramethylammonium tetrafluoroborate (TBTU) (95) have 
also been developed. 
CN--Iý-OBLPF6 
3 
>-OBt. 
BF4 
(94) (95) 
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2.1.3 Racemisation's, 125,130 
One of the most serious side reactions that can occur in peptide synthesis is the 
racemisation of the a -carbon of the amino acid. If such a complication is significant, a 
mixture of epimers can be formed leading to difficult purification problems. 
There are two principle mechanisms by which racemisation can arise. As shown in 
Scheme 2.9, direct deprotonation of the a-carbon results in racemisation because the 
carbanion intermediate can gain a proton from either side. The rate of deprotonation is 
governed by the catalysing base, the solvent and the electron withdrawing effects of the 
groups P, R and X around the chiral centre (96). When X= NH-, O-alkyl or O', such 
racemisation is negligible. However, during activation and coupling, significant 
deprotonation can occur, particularly in the presence of strong unhindered bases in polar 
aprotic solvents such as DMF and DMSO. Deprotonation is a particular problem in the 
case of a -arylglycines due to the delocalisation and thus stabilisation of the negative charge 
of the deprotonated conjugate base. However, in the case of most peptide couplings, the 
rate of the coupling reaction is considerably greater than the rate of the deprotonation 
reaction just described, making racemisation problems by this pathway negligible. 
Scheme 2.9 : Mechanism of racemisation by direct enolisation 
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The key racemisation mechanism (see above Section 2.1.2) involves the formation of 
easily deprotonated oxazolones (Scheme 2.10). In many circumstances, with most good 
leaving groups, large scale or even total racemisation can occur. 
However, oxazolone formation is considerably reduced when the amino terminus is 
protected by an alkoxycarbonyl group such as Z, Boc or Fmoc. Further, alkoxyoxazolones 
are both less readily racemised and more susceptible to nucleophiles than oxazolones derived 
from simple amino acids. 
Scheme 2.10: Mechanism of racemisation by the formation of oxazolones 
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_ 2.2 Solid phase peptide synthesis '8 18,157 
A variety of peptidic natural products including enzymes such as Ribonuclease A'58 
have been synthesised by a different method, known as Solid Phase Peptide Synthesis 
(SPPS). This technique was pioneered in 1963 by R. B. Merriiield1S9 who won the 1985 
Nobel Prize for Chemistry for his work in this field. The basis of this technique is the 
covalent bonding of the carboxyl terminus onto a solid support from which the peptide chain 
can be constructed. Merrifield originally used a polystyrene resin'59, but many other 
polymers, for example, polydimethylacrylamide18 (Scheme 2.11), have also been employed. 
The Fmoc group is frequently used for protection of the a-amino terminus, with active 
esters used for peptide activation. The advantage of this method is that by using a vast 
excess of each reagent for each peptide coupling, near quantitative yields can be obtained. 
By-products and excess reagent can then be removed by simple filtration and washing. The 
whole process can be readily automated to allow the efficient synthesis of long chain 
peptides in a period of days rather than weeks or months, as in solution phase peptide 
synthesis. The method of preparation of the polydimethylacrylamide polymeric support is 
illustrated in Scheme 2.11 and its use in SPPS is illustrated in Scheme 2.12. 
However, although time consuming, solution phase peptide synthesis has a number 
of advantages over SPPS. Firstly, because each intermediate peptide is isolated during the 
synthesis, any problems with particular synthetic steps can be identified. Secondly, there 
is a limit to the quantity of peptide that a given resin can hold. Consequently, solution 
phase peptide synthesis is more suitable for the bulk synthesis of peptides. 
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Scheme 2.11: Preparation of the polydimethylacrylamide solid support in solid phase 
peptide synthesis 
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Scheme 2.12: A typical reaction sequence using solid phase peptide synthesis 
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2.3 Synthesis of crosslinked tripeptide precursors 
2.3.1 Synthetic strategy for the synthesis of polycyclic peptides 
As described in Section 1.6.2, three polycyclic peptide synthetic targets (78)-(80) were 
chosen as potential host molecules. Following experience gained from previous workers 
within the group' `5117, the strategy shown in Scheme 2.13, involving 5 key stages, was 
considered as being most suitable for their synthesis: 
a) The first step involved the synthesis of Boc-Lys(Ts)-Lys(Ts)-Gly-OMe (99) by 
solution phase methodology. The advantage of solution phase over solid-phase peptide 
synthesis's' was primarily its suitability for the production of relatively large quantities of this 
tripeptide precursor. 
b) Crosslinking of the lysine side chains to give the desired 4,4'-bis-methylbiphenyl or 
1,2-bis(2-ethoxy)ethane crosslinks was the second stage. Because of the nature of the e- 
amino groups on the lysyl side chains, there would be potential for three kinds of reaction 
to form the crosslinks - imine formation with carbonyl groups followed by reduction, amide 
formation and then reduction or nucleophilic displacement by the e-amine of a leaving 
group. The last of these three techniques was chosen for this project. In order to 
encourage efficient crosslinking to occur, it was vital that once one end of the crosslinker 
had reacted, the correct conformation for cyclisation was readily accessible. It was 
considered that the linear geometry of the imine bonds and the planar nature of the amide 
bonds would cause constraints that might inhibit easy crosslink formation. Conversely, 
nucleophilic reaction would allow greater conformational flexibility for cyclisation to occur. 
In addition, by substituting the e-nitrogen of each lysine side chain with an electron 
withdrawing tosyl group, the base catalysed deprotonation of the c-amine would occur more 
readily, thus encouraging efficient nucleophilic displacement. 
c) Cyclodimerisation of the resulting crosslinked tripeptides was to be attempted with 
a view to forming a cyclic hexapeptide which would be pre-crosslinked at the "1,2" and 
"4,5" residues. An advantage of such a cyclodimerisation160 procedure over the cyclisation 
of the appropriate linear hexapeptide16', was that it is easier to form the cyclic peptide with 
the crosslinks in the specific locations required. In addition, due to the C2 symmetry of the 
cyclic peptide, cyclodimerisation was particularly appropriate so as to reduce the number 
of steps in the synthesis. Scheme 2.14 shows routes previously followed within the group 
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Scheme 2.13 : Strategy for the synthesis of polycyclic peptides 
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(78) X= <-0-0-2114 
Y= llftý 
(79ý X=1 ý0 Ö 
(80) X= -7110 
Y 
with the aim of synthesising a cyclic hexapeptide. Cyclodimerisation of the linear tripeptide 
(106) [step y)] proved to be a more efficient route to the cyclic peptide (108) than the 
formation and then cyclisation of linear hexapeptide (107) [steps x) and z)], ". The 
cyclodimerisation route gave a 38 % yield of cyclic peptide (108) from linear tripeptide 
(106), whereas the best reported yield following the linear pathway was 20.5 % from the 
same tripeptide starting material. 
d) Deprotection of the E-amino groups of the lysyl side chains by removal of the four 
tosyl groups was the fourth stage. 
e) The synthesis was to conclude with the final crosslinking reactions at the "2,4" and 
"1,5" residues to form the appropriate final target molecule. 
Scheme 2.14: Formation of the Z protected cyclic hexapeptide (108) 
B oc-Lys (Z)-Lys(Z)-GIy-OMe 
(106) 
x) 
B oc-[Lys (Z)-Lys (Z)-Gly]2-OMe 
Z) 
(107) 
cyclo-[Lys(Z)-Lys(Z)-Gly]2 
(108) 
2.3.2 Synthesis of Boc- ys(Ts)-OH 
N-e-toluenesulphonyl-lysine (110) was synthesised from deprotected lysine (109) by 
others within the group of P. D. Bailey by the procedure outlined in Scheme 2.15128 
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Scheme 2.15 : Synthesis of Boc-Lys(Ts)-OH (97) 
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NHTs NHTs 
c) NH4OH 
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THE 
H2N CO2H BocHN CO2H 
(110) (97) 
Following the generous donation of 10 g of (110) this was reacted with di-tert-butyl 
dicarbonate in ethoxyethane with dilute aqueous sodium hydroxide as base128. Following 
the work-up procedure, a 33 % yield of Boc-Lys(Ts)-OH (97) was obtained. 
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2.3.3 Synthesis of protected tripeptide 
The tripeptide (99) was synthesised via the standard solution phase peptide synthesis 
methodology described earlier. Standard DCC/HOBt peptide couplings were used giving 
an overall yield of 63 %. However, due to an allergic reaction to DCC by one member of 
the research group, alternative peptide couplings using EDC (92) and HOBt (90) were used 
(Scheme 2.16). Due to the high solubility of EDC and its urea in water compared with 
DCU which is sparingly soluble in most common organic solvents, peptide couplings using 
EDC were easier to work up (simple water washes removed EDC and its urea) and gave 
slightly higher overall yields of product (67 %). 
The protective groups used in the synthesis of tripeptide (99) were chosen due to their 
orthogonal protective properties. Thus t-butyloxycarbonyl (Boc) is acid labile, the methyl 
ester is hydrolysed by the use of methanolic base and tosyl (Ts) is commonly removed by 
either strongly reductive methods (eg. Na in liquid ammonia) or by the use of strong acid 
(Chapter 3). 
Scheme 2.16 : Synthesis of the protected tripeptide precursor (99) 
Boc-Lys(Ts)-OH 
(97) 
a) 
Boc-Lys(Ts)-Gly-OMe 
b), c), d) 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
(99) 
a) H-Gly-OMe, 
DIPEA, DMF 
DCC/HOBt or EDC/HOBt 
b) 9: 1 TFA: H20 
c) DIPEA, DMF 
d) Boc-Lys(Ts)-OH, 
DCC/HOBt or EDGHOBt, DMF 
Yields: 
Dipeptide using: 
DCC 81 % EDC 83 % 
Tripeptide using: 
DCC 78 % EDC 81 % 
Overall using: 
DCC 63 % EDC 67 % 
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2.3.4 Synthesis of crosslinked tripeptide 
2.3.4.1 Crosslinking with 4,4'-bis-bromomethylbiphenyl 
In order to form the crosslinked tripeptide (110) it was first necessary to synthesise 
the crosslinker 4,4'-bis-bromomethylbiphenyl (113). This was achieved as shown in 
Scheme 2.17. 
Scheme 2.17: Synthesis of 4,4'-bis-bromomethylbiphenyl (113) 
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Following the treatment of diethyl-4,4'-biphenyldicarboxylate (111) with lithium 
aluminium hydride in dry THF, a quantitative yield of 4,4'-dihydroxymethylbiphenyl (112) 
was produced. Treatment of (112) with PPh3 and CBr4 under standard Mitsunobu 
conditions16' led to a 75 % yield of (113) following column chromatography on silica gel 
using ethyl acetate : petroleum ether (40: 60) as the eluant. The 'H NMR spectrum of 
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-(113), showed two doublets centred at S=7.46 and S=7.55, each with the same coupling 
constant of 8.24 Hz. Together with a CH2Br singlet at S=4.54, the spectrum was as 
expected120. FAB mass spectrometry showed the anticipated molecular ions at m/z = 338, 
340,342 in a 1: 2: 1 intensity pattern. This pattern is due to there being two equally 
abundant79Br and "Br isotopes. 
The conditions initially used to crosslink tripeptide (99) were based upon experience 
gained by earlier crosslinking reactions within the group120,121. The solvent used was DMF, 
the base was Cs2CO3 and all reactions were performed under rigorously dry conditions. The 
Cs' ion was thought to act as a template for cyclisation1° '°8 and the dry conditions were 
required to prevent displacement of leaving groups on the crosslinkers by OH-. In the first 
attempt at this crosslinking reaction, the crosslinker was added slowly using a syringe pump 
to a solution of the tripeptide and base in dry DMF under argon. Unfortunately, none of the 
desired product (100) was detected. A second attempt at this reaction under analogous 
conditions gave evidence of the correct material in the FAB mass spectrum of the crude 
reaction mixture in that peaks at 1064 [M + Cs]', 932 [M + H]+, 832 [M - Boc]* and 776 
[M - Ts]'were prominent. However, evidence for this compound was lost following silica 
gel column chromatography using 5-20 % methanol in dichloromethane e-as the eluant. 
In order to ascertain the most suitable model conditions for the crosslinking of 
aromatic bromomethyl compounds onto the tripeptide (99), 1,4- a, a'-dibromo-p-xylene was 
added using a syringe pump to stirred tripeptide and Cs2CO3 in DMF, both with and without 
e 3A molecular sieves. This reaction is illustrated in Scheme 2.18. 
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Scheme 2.18 : Synthesis of p-xylyl crosslinked tripeptide (114) 
1ý 
a), b) or c) 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 0 Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
(99) (114) 
a) 1,4-a, a'-dibromo p-xylene, Cs2CO3 (5 mol. equiv. ), DMF, 3A molecular sieves 
b) 1,4-a, a'-dibromo p-xylene, Cs2CO3 (5 mol. equiv. ), DMF 
c) 1,4-a, a'-dibromo p-xylene, Cs2CO3 (5 mol. equiv. ), DMF, H20 (ca. 35 mol. equiv. ) 
FAB mass spectrometry showed that when the reaction was carried out in dry 
conditions in the presence of molecular sieves (method a)), the required p-xylyl crosslinked 
tripeptide (114) was successfully synthesised. Thus, two relevant peaks, m/z = 855 
corresponding to the molecular ion of (114) and m/z = 755 due to the loss of the t- 
butoxycarbonyl (Boc) protecting group from (114) were obtained. Unfortunately, 
however, following silica gel column chromatography (9: 1 dichloromethane : methanol), 
only a2% yield of (114) was isolated. Conversely, when the reaction was run without 
molecular sieves (method b)), the absence of these peaks in the FAB mass spectrum 
suggested that none of the desired product was formed. The absence of a common spot 
in the TLCs of each reaction mixture (in which 19: 1 dichloromethane : methanol was used 
as the eluant) and the co-incidence of a TLC spot from the former reaction with authentic 
(114), produced by a previous group member12° confirmed the FAB mass spectrometry 
results. 
Because the use of molecular sieves in the crosslinking of (99) with 1,4-a, a'- 
dibromo p-xylene had been shown to be marginally more successful than the equivalent 
reaction without molecular sieves, an attempt was made to crosslink (99) with 4,4'-bis- 
bromomethylbiphenyl (113) also with the use of molecular sieves. Unfortunately, however, 
FAB mass spectrometry showed that this reaction was unsuccessful and that instead the 
starting tripeptide (99) had been recovered. Peaks at m/z = 886 due to [M + Cs]+, m/z = 
754 due to [M + H]'and m/z = 654 from [M - Boc] were prominent. Caesium iodide was 
added in two later reactions at room temperature in order to catalyse the nucleophilic 
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displacement of the bromide leaving groups and thus aid the cyclisation. Evidence of the 
required product (100) in the FAB mass spectrum came from a peak at m/z = 932 due to 
[M + H]* and m/z = 832 due to [M - Boc]*. However, starting material was also still 
present as shown by a peak at m/z = 654. Two dominant spots were observed by TLC 
using 19: 1 dichloromethane : methanol surrounded by other fainter, closely running, 
uncharacterised impurities. One of the dominant spots, at Rf = 0.30, co-ran with authentic 
starting tripeptide (99). The other spot ran at Rf = 0.35, in a similar location to the p-xylyl 
crosslinked tripeptide (114), as would be expected from their related polarities. It was thus 
assumed that the latter spot was due to the crosslinked tripeptide (100). Silica gel column 
chromatography using 5-20 % methanol in dichloromethane was used to attempt to isolate 
the desired product, but this was unsuccessful. 
It was thought that a possible reason why the reaction was not going to completion 
was that once one end of the crosslinker (113) had reacted with one of the lysyl side chains, 
there was a high energetic barrier for the tripeptide to be orientated into the correct 
conformation for ring closure. Although this would not explain the reason for the presence 
of starting material, such a situation would increase the number of by-products. 
Thus, a new caesium iodide catalysed reaction was heated to 65° C in an attempt to 
overcome any such energetic barriers and accelerate the ring closure reactions. 
Unfortunately, none of the desired product was shown to be produced by the FAB mass 
spectrum of the crude product. The attempted purification by silica gel column 
chromatography was again unsuccessful and FAB mass spectrometry of the impure fractions 
produced also showed no evidence either of the desired product or of starting material. The 
use of analogous conditions at room temperature, with a catalytic amount of caesium iodide 
and in which acetonitrile was used as solvent instead of DMF, was likewise shown by FAB 
mass spectrometry to be unsuccessful. However, the spectrum of the crude product did 
show peaks at m/z = 872 and m/z = 1004, peaks which were also to be observed later in the 
crosslinking of tripeptide (99) with 1,2-bis(2-chloroethoxy)ethane, described in Section 
2.3.4.2. Although neither of these peaks were ever unambiguously assigned, it is pertinent 
to note that the difference between them - 132 - is also the molecular mass of caesium. 
Following reactions with peptides in which caesium carbonate was present, as was the case 
in all of the above reactions, it was frequently the case that a mass ion plus caesium was 
observed. It is thus possible that these peaks at m/z = 872 and m/z = 1004 are from the 
same species. 
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Previously, as explained above, it was thought that the presence of water would 
discourage the desired crosslinlcing reaction from occurring. However, it was found from 
other crosslinking reactions (Section 2.3.4.2) that the presence of a small amount of water 
catalysed crosslinking reactions. As shown by the equation in Scheme 2.19, it was assumed 
that the presence of water encouraged the formation of stronger basic conditions thus 
facilitating nucleophilic reactions between tripeptide and crosslinker. However, it was 
thought that the addition of too much water would produce a basic solution of such strength 
as to hydrolyse the methyl ester of tripeptide (99). In such a circumstance, the isolated 
yield of crosslinked tripeptide (100) would be reduced. Thus it was assumed that only a 
small amount of water was required to be added to the crosslinking reactions. 
Scheme 2.19: Reaction of caesium carbonate with water 
Cs2CO3 + H2O º 2Cs+ + HC03" + OH" 
The effect played by the addition of water to a crosslinking reaction was explored in 
the reaction of tripeptide (99) with 1,4-a, a'-dibromo-p-xylene. This is illustrated in 
Scheme 2.18 as method c). In order that the quantity of water present in the reaction flask 
was known, it was felt to be necessary to ensure that prior to the addition of the dry 
reagents, all glassware employed was thoroughly dried. Thus to a flame dried reaction 
flask, dried caesium carbonate and tripeptide (99) were added to dry DMF under argon. 
One drop of water (ca. 35 mol. equiv. ) was added as an arbitrary but known quantity 
followed by the addition of 1,4-a, a'-dibromo-p-xylene. In a further change to previous 
experiments, it was decided to add the crosslinker in one batch rather than slowly using a 
syringe pump. Previously, it had been thought that with a low concentration of crosslinker 
with respect to tripeptide, the rate of cyclisation would be increased over the rate of polymer 
formation. However, it was now thought possible that the caesium from the caesium 
carbonate might act as a template encouraging cyclisation (Fig 2.1)106'108. If this were the 
case, then a syringe pump was not thought to be required. Following these new reaction 
conditions and after column chromatography (1 - 10 % methanol in dichloromethane), a 
40.5 % yield of the desired product (114) was achieved, higher than the 35 % best quoted 
yield of (114) achieved by a previous group member'zo. 
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Fig 2.1 : Possible role of caesium as a template for the formation of crosslinked tripeptide 
(114) 
//ý 
Ts, 1 
NI , 
Ts 
'Cs+. 
0 
Me3Cý-O'R'NH NH NH.,, CO2Me 
00 
Similarly, ca. 35 mol. equiv. of water were added to the crosslinking reactions 
involving 4,4'-bis-bromomethylbiphenyl (113), tripeptide (99) and caesium carbonate in 
DMF. In order to test the effect of the rate of addition of crosslinker on the yield of the 
desired product, the crosslinker was added under three different conditions; slowly over 24 
h using a syringe pump, adding the crosslinker in stages or adding all the crosslinker in one 
batch at the start of the reaction. In each case an excess of crosslinker was used in order 
to drive the reaction to completion. In a reaction involving the addition of crosslinker (113) 
and tripeptide (99) in DMF by syringe pump to a suspension of Cs2CO3 in DMF with ca. 35 
mol. equiv. of water, evidence that the desired product (100) had been synthesised came 
from FAB mass spectrometry in which a peak at m/z = 832 indicated a fragment ion 
involving the loss of the Boc group from (100). Comparison of the integrals of the 
aromatic protons (16H) against those of the methyl ester (3H) and the methyls of the tosyl 
groups (6H) in the 80 MHz 1H NMR spectrum, gave additional evidence of the desired 
product. Although for the other related attempted crosslinking reactions involving the 
addition of water, molecular ions or recognisable fragment ions of the desired product were 
not observed in the FAB mass spectra, 80 MHz 'H NMR spectroscopy indicated the 
presence of the desired product in all the cases described above. However, at no time could 
it be purified by silica gel column chromatography, due to the presence of a large number 
of unidentified by-products which TLC showed ran very closely to the desired product. 
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In an attempt to overcome any energetic barriers to cyclisation and thus achieve a 
cleaner product (100), the crosslinker was added in aliquots to tripeptide, DMF and Cs2CO3 
and a trace amount of water at 50° C. However, FAB mass spectrometry showed that no 
product (100) was formed. Similarly, the room temperature addition of crosslinker in 
aliquots to tripeptide (99), Cs2CO3 and a trace amount of water in acetonitrile failed to 
produce the desired product. 
The failure of these biphenyl crosslinking reactions to produce the desired compound 
(100) cleanly compared with the success of the crosslinking of 1,4-a, a'-dibromo p-xylene 
is notable. It is possible that the biphenyl moiety is too long and rigid to synthesise, cleanly 
and efficiently, a high yield of crosslinked tripeptide. Whilst one end of the biphenyl group 
would react with the E-nitrogen of a lysyl side chain, the formation of the correct 
conformation for cyclisation would involve considerable strain in the tripeptide molecule. 
Thus, the rate of cyclisation would be reduced allowing competing straight chain polymer 
forming reactions to predominate. The presence of a large quantity of baseline material in 
the TLCs of the crude reaction material is evidence for the presence of polymers. 
2.3.4.2 Synthesis of a 1,2-bis(2-ethoxy)ethane crosslinked tripeptide 
At the same time that the first attempts were being made to synthesise the 4,4'-bis- 
bromomethylbiphenyl crosslinked tripeptide (100), experiments were started with a view to 
synthesising the 1,2-bis(2-ethoxy)ethane crosslinked tripeptide (101). Thus a solution of 
1,2-bis(2-chloroethoxy)ethane was added by syringe pump to a solution of tripeptide (99) 
and Cs2CO3 in DMF. As with the attempted crosslinking of the biphenyl moiety, the 
conditions used were based upon previous experience within the group12oa21 Unfortunately, 
no peaks corresponding to the desired tripeptide (101) were detected by FAB mass 
spectrometry. 
Despite the fact that the addition of water was shown in Section 2.3.4.1 to encourage 
the crosslinking of 1,4-a, a'-dibromo-p-xylene with tripeptide (99), at the time when the 
first attempts were made to synthesise a 1,2-bis(2-ethoxy)ethane crosslinked tripeptide, it 
was thought that the presence of water caused the displacement of the leaving groups on 
the crosslinker and thus prevented efficient and successful crosslinking. Thus a reaction in 
which molecular sieves were added to the solution was attempted (Scheme 2.20). The FAB 
mass spectrum of the crude product indicated the presence of the desired crosslinked 
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tripeptide (101) by a peak at m/z = 868, due to [M +H]'. However starting material (99) 
was also shown to be present by the presence of a peak at m/z = 654 due to the loss of Boc 
from its molecular ion. The desired product (101) was successfully separated from the 
crosslinked tripeptide starting material by silica gel column chromatography (19: 1 
dichloromethane : methanol). However, attempts to separate (101) from other 
uncharacterised impurities, which TLC showed to be closely running to the desired product, 
were unsuccessful. The FAB mass spectrum, despite showing an intense amount of 
background noise and a large number of peaks due to uncharacterised impurities, gave 
distinct peaks due to (101) which are tabulated and assigned in Table 2.2. 
Scheme 2.20: Reaction of tripeptide (99) with 1,2-bis(2-chloroethoxy)ethane 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
(99) 
a) Cl o0 Cl 
e 
3A molecular sieves, Cs2CO3, DMF 
OO 
a) Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
(101) 
Table 2.2: FAB Mass Spectrum of the purified product (101) from the reaction in Scheme 
2.20. 
mlz Assignment 
1000 [M + Cs]* 
768 [M - Boc]+ 
711 [M - Ts]+ 
611 [M - Boc - TsJ* 
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As explained in Section 2.3.4.1, it wa's thought that by increasing the rate of the 
cyclisation reaction, tripeptide (99) would react more efficiently with the crosslinker and the 
number of side products would be reduced. However, an attempt to increase the rate of 
any cyclisation reaction by heating the mixture to 65° C failed. Indeed, FAB mass 
spectrometry of the crude product failed to show any peaks that could be assigned to the 
desired products. High mass peaks at m/z = 1004 and m/z = 872 were observed (as they 
had also been observed in a reaction to make the crosslinked tripeptide (100) - see Section 
2.3.4.1). Both these peaks were possibly due to the same unknown compound since the 
differencebetween them - 132 - is the same value as the Cs'ion. As was seen in Table 2.2, 
peaks assigned as [M + Cs]' were sometimes observed in the crude reaction products when 
Cs2CO3 was involved in the reaction. However, whilst this suggests that the m/z = 872 peak 
is the molecular ion of a compound, its structure could not be determined and neither peak 
could be assigned. If this peak were peptidic, one might expect a peak at m/z = 772 due 
to the loss of the Boc protecting group. This, however, was not observed. An attempted 
catalysis of the crosslinking using sodium iodide also failed to produce the required product. 
Instead, FAB mass spectrometry following silica gel column chromatography showed peaks 
at m/z = 776 (starting material plus sodium) and m/z = 654 (starting material minus Boc) 
suggesting that the starting material (99) had been recovered. A possible reason for the 
failure of this reaction was that sodium competed with any template effect of caesium thus 
reducing the chance of any product (101) being produced. 
In a further attempt to synthesise (101), acetonitrile was used as the solvent instead 
of DMF, molecular sieves and caesium carbonate were added and the reaction was heated 
to 65° C. The crosslinker was again added slowly using a syringe pump. However, this 
reaction was shown by FAB mass spectrometry to have failed. An attempt at room 
temperature catalysis of the crosslinking in acetonitrile using caesium iodide also failed. By 
using caesium iodide rather than sodium iodide, the problem of sodium competing with the 
template effect of caesium should have been overcome. However, in the FAB mass spectra 
of the crude samples from both reactions, the peaks observed in previous reactions at m/z 
= 872 and m/z = 1004 were again prominent. In the case of the latter reaction, m/z = 872 
was still present following silica gel column chromatography. An attempt to obtain an 
accurate mass of the m/z = 872 peak, with a view to characterisation, was, however, 
unsuccessful, due to the small size of the peak in the FAB mass spectrum of the columned 
material. 
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It was argued that 1,2-bis(2-chloroethoxy)ethane could be potentially too long for 
efficient ring closure. Its length and flexibility were possibly so great as to make the 
entropy cost on cyclisation prohibitive, ie., it had low preorganisation for binding'. 
Consequently, in order to test this theory, the shorter crosslinker, 2-chloroethyl ether was 
used in DMF together with caesium iodide and molecular sieves (Scheme 2.21). This 
reaction was carried out at 650 C in order to increase the rate of nucleophilic displacement 
of the Cl- leaving groups and thus hopefully encourage cyclisation. FAB mass spectrometry 
of the crude product did not, however, provide any evidence of the desired product (115). 
Peaks at m/z = 824 (corresponding to the molecular ion plus hydrogen and m/z = 724 
(molecular ion minus the t-butoxycarbonyl protecting group) were expected but were not 
observed. High mass peaks at m/z = 1136,1004,904,872 and 771 were present but were 
not assigned. 
Scheme 2.21: Reaction of tripeptide with 2-chloroethyl ether 
<-O --) 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe a) po, Boc-Lys(Ts)-Lys(Ts)-GIy-OMe 
(99) 
a) Cl 0 Cl 
(115) 
In order to model the desired crosslinking reaction, 1,6-dibromohexane was added by 
syringe pump to the tripeptide (99), in which as before, caesium carbonate was used as base 
and molecular sieves were used to ensure dryness. This reaction is shown in Scheme 2.22. 
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Scheme 2.22: Reaction of tripeptide with 1,6-dibromohexane 
(CH2)6 
Boc-Lys(Ts)-Lys(Ts)-GIy-OMe 
a) 
- Boc-Lys(Ts)-Lys(Ts)-GIy-OMe 
(99) (116) 
Br 
a) Br 
Cs2CO3, DMF 
Unfortunately, FAB mass spectrometry showed that this reaction had been 
unsuccessful. However, as explained in Section 2.3.4.1, it was then thought that the 
addition of water to the crosslinking reaction would encourage efficient and clean formation 
of the desired crosslinked tripeptide. Thus following analogous conditions to the 
crosslinkings using 1,4-a, a'-dibromo p-xylene and 4,4'-bis-bromomethylbiphenyl, one drop 
or ca. 35 mole equivalents (with respect to tripeptide) of water were added to dried Cs2CO3 
and dry tripeptide (99) in dry DMF. The 1,6-dibromohexane crosslinker in DMF was 
added by syringe pump over a period of 48 h. The addition of water was, as in the case of 
the formation of the p-xylyl crosslinked tripeptide (114), found to be critical to the success 
of the reaction and following silica gel column chromatography using 19: 1 dichloromethane 
: methanol as the eluant, a 45 % yield of the desired hexyl crosslinked tripeptide was 
obtained. The FAB mass spectrum showed peaks at dz = 858,836 and 736 corresponding 
to the molecular ion plus sodium, the molecular ion plus hydrogen and the molecular ion 
minus the Boc protecting group, respectively. The accurate mass of the [M + H]' ion (m/z 
= 836) was consistent with that expected. The 1H NMR spectrum is illustrated in Fig 2.2. 
Singlets due to the Boc protecting group (8 = 1.253), the tosyl methyls (8 = 2.391,2.412) 
and the methyl ester (S = 3.671) are clearly present. Two doublets from each of the para 
substituted tosyl groups are also observed (centred at 8=7.287,7.638). Alkyl CH2 
protons from the lysine side chains and the alkyl crosslinker are also observed as a broad 
multiplet (S = 1.2,2.1). It would. be expected that for this crosslinked tripeptide (116), the 
respective integrations of the combined Boc and alkyl peaks against those for the tosyl 
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aromatics, methyl ester and tosyl metliyls would be 29H to 8H to 3H to 6H respectively. 
This indeed is found to be the case. The 13C NMR was likewise as expected with the 
correct number of each kind of carbon expected, present. Thus, for example, 15 CH2 peaks 
would be expected from the lysyl side chains, the alkyl crosslinker (8 = 20 - 32) and the 
glycine residue (8 = 41). Four peaks due to CH2 adjacent to a nitrogen would also be 
anticipated (S = 46 - 50). All these peaks are observed. 
Before these reaction conditions were applied to the synthesis of a 1,2-bis(2- 
ethoxy)ethane crosslinked tripeptide (101), a new crosslinker, 1,2-bis(2-tosylethoxy)ethane 
(118) was synthesised. Following treatment of triethylene glycol with tosyl chloride, 
triethylamine and catalytic amounts of 4-N, N-dimethylaminopyridine (DMAP) in 
dichloromethane163 a 79 % yield of 1,2-bis(2-tosylethoxy) ethane (118) was achieved 
(Scheme 2.23). 
Scheme 2.23: Synthesis of 1,2-bis(2-tosylethoxy)ethane (118) 
I1 I\ /\ a) 
HO 00 OH TsO 00 OTs 
(117) (118) 
a) tosyl chloride, NEt3, DMAP, dichloromethane 
It was considered that instead of using a crosslinker with Cl" leaving groups, the use 
of tosyl leaving groups might be more suitable. Due to their greater ability to delocalise and 
thus stabilise negative charge following their nucleophilic displacement, tosyl groups are 
better leaving groups than C1. It was thus hoped that the nucleophilic substitution reactions 
involved in the crosslinking of the tripeptides would be more efficient using a ditosylated 
crosslinker rather than the dichloride. The use of a catalytic amount of water in the 
crosslinking of tripeptide (99) with 1,2-bis(2-tosylethoxy)ethane (118) again using Cs2CO3 
in DMF gave a consistent 45 % yield of the desired tripeptide (101) in two separate 
reactions. As with the successful 1,6-dibromohexane crosslinking reaction described above, 
crosslinker (118) in DMF was added by syringe pump to the basic suspension of Cs2CO3 and 
solution of tripeptide (99) in DMF and water. Table 2.3 lists the high mass peaks in the 
FAB mass spectrum of the crude material. 
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Table 2.3: High mass peaks in the FAB Mass Spectrum of the unoptimised crosslinking of 
tripeptide (99) with 1,2-bis(2-tosylethoxy)ethane (118). 
m/z Assignment 
940 unknown 
868 [(101) + H]+ 
768 [(101) - Boc]' 
711 [(101) - Ts]' 
654 [starting tripeptide (99) - Boc]' 
The TLC of the crude product from the reaction in DMF (for which the FAB mass 
spectrum was tabulated in Table 2.3), showed two closely running spots corresponding to 
starting material and the desired product. The presence of starting material on the TLC 
plate was shown by the co-running of authentic starting material. Although TLC evidence 
and the production of a clean 'H NMR spectrum of the desired product showed that 
successful separation of the product and starting material had been achieved, it was clearly 
important to ensure reaction of all of the starting material. Consequently, a two-fold excess 
of the crosslinker 1,2-bis(2-tosylethoxy)ethane (118) was added. In a further change to the 
reaction conditions, it was decided that addition of the crosslinker should be in three stages 
without the use of a syringe pump to a mixture of tripeptide and caesium carbonate in DMF 
and catalytic amounts of water. Previously, it had been thought that these crosslinking 
reactions would give higher yields if the crosslinker was added slowly to the tripeptide and 
base. By this means, it had been thought that with a low concentration of crosslinker with 
respect to tripeptide, the rate of cyclisation would be increased over the rate of polymer 
formation. However, as with the p-xylyl crosslinked tripeptide (114) it was later thought 
possible that the caesium carbonate might act as a template encouraging cyclisation (Fig 
2 106,108 3) If this were the case, then a syringe pump was not thought to be required. These 
were found to be the optimal conditions for the synthesis of (101). No tripeptide starting 
material was observed in the crude reaction product by TLC or by FAB mass spectrometry. 
Following silica gel column chromatography using 5-20 % methanol in dichloromethane, 
a yield of 54 % of the desired crosslinked tripeptide (101) was isolated.. Ina later reaction, 
a yield of 62 % was achieved. The FAB mass spectrum and a typical 111 NMR spectrum 
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of the reaction product (101) are illustrated in Figs 2.4 and 2.5. The peaks in the FAB mass 
spectrum are tabulated in Table 2.4. The 'H NMR spectrum of crosslinked tripeptide (101) 
shows a broad multiplet (8 = 1.2 - 1.9) due to the lysyl CH2 groups as well as singlets due 
to Boc (8 = 1.293), tosyl (8 = 2.428,2.447) and the methyl ester (8 = 3.711). Two sets 
of two superimposed doublets due to the two para substituted tosyl groups are also present 
(centred at 8=7.32 and 8=7.70). A broad multiplet (8 = 3.2 - 3.45) due to CH2 groups 
next to nitrogen is present as well as a multiplet (8 = 3.5 - 3.8) due to the crosslinker 
protons (CH2O). The integration of this CHZO multiplet is 8H, corresponding, as expected, 
to the 8H of the tosyl aromatics, the 3H of the methyl ester, the 6H of the tosyl methyls and 
the combined 21H of the lysyl CH2s and the Boc group. 
Fig 2.3 : Possible role of caesium as a template for the formation of crosslinked tripeptide 
(101) 
OO 
TsýN- 
- Cs+ - _N 
Ts 
O 
Me3 C ý'O 1 NH NH 
LNH, 
ý COZMe 
00 
Table 2.4 : High mass peaks in the FAB mass spectrum shown in Fig 2.4 of the optimised 
crosslinking of tripeptide (99) with 1,2-bis(2-tosylethoxy)ethane (118) 
m/z Assignment 
890 [(10 1) + Na]* 
868 [(101) + H]* 
768 [(101) - Boc]* 
712 [(101) - Ts]* 
651 unknown 
612 [(101) - Boc - Ts]' 
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The use of acetonitrile as solvent instead of DMF was shown by TLC and FAB mass 
spectrometry to result in a failure to produce (101). The TLC of the crude reaction product 
using 19: 1 dichloromethane : methanol as eluant, showed that the majority of the material 
did not move from the baseline. It is thus possible that mainly polymeric material had been 
formed. 
Following the scale up of the reaction in DMF, such that 5g of tripeptide (99) was 
crosslinked in one batch, yields of 50-60 % were maintained. The conditions found optimal 
for the formation of crosslinked tripeptide (101) are shown in Scheme 2.24. Thus, with the 
successful synthesis of glycol crosslinked tripeptide (101), the synthesis of target polycyclic 
peptides (79) and (80) could proceed. This is explained in Chapter 3. 
Scheme 2.24 : Optimised conditions for the synthesis of the 1,2-bis(2-ethoxy)ethane 
crosslinked tripeptide (101) 
a) CO 
O 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe Boc-Lys(Ts)-Lys(Ts)-Gly-OMe. 
(99) (101) 
a) Batchwise addition of TsO[(CH2)20]2(CH2)2OTs (1 mol. equiv. initially; 
after 24 h, 1/2 mol. equiv. and after another 24 h, 1/2 mol. equiv. ) 
Cs2CO3 (5 mol. equiv. ), 
H2O (ca. 35 mol. equiv. ), DMF [to give 0.01 M concentration of (99)], RT 
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2.4 Summary 
The tripeptide (99) was successfully synthesised by solution phase methodology. 
Tables 2.5 and 2.6 provide a summary of the results from the various crosslinking 
experiments described above. Evidence from FAB mass spectrometry and 'H NMR 
spectroscopy indicated that in the presence of catalytic amounts of water, the crosslinking 
of the tripeptide (99) with 4,4'-bis-bromomethylbiphenyl (113) was successful. The use of 
a syringe pump or addition of (113) in aliquots all gave evidence of the formation of the 
desired product (100). However, purification of the desired product (100) by column 
chromatography was unsuccessful due to the presence of a large quantity of uncharacterised 
reaction by-products which were found to run closely to (100) in the column TLC. 
Crosslinking with 1,4-a, a'-dibromo p-xylene was more successfully achieved but again 
required the presence of catalytic amounts of water. Isolation of the desired product (114) 
was achieved to give a yield of 40.5 %. Only in one reaction was the crosslinking with 1,2- 
bis(2-chloroethoxy)ethane successful, however, in this case, the presence of closely running 
uncharacterised by-products prevented the isolation of crosslinked tripeptide (101). Two 
possible reasons for this lack of success are that the chlorides are poor leaving groups and 
in all these reactions care was taken to ensure that a minimal amount of water was present. 
Crosslinking with 2-chloroethyl ether in these conditions was also unsuccessful. However, 
syringe pump addition of 1,6-dibromohexane to tripeptide (99) in the presence of catalytic 
amounts of water, gave a 45 % yield of crosslinked tripeptide (116). Addition of 1,2-bis(2- 
tosylethoxy)ethane by syringe pump to tripeptide (99) in the presence of catalytic amounts 
of water gave a 45 % yield of (101), whereas addition in aliquots gave the optimised yield 
of 62 %, following silica gel column chromatography. 
In conclusion, with the exception of the addition of the long rigid crosslinker 4,4'-bis- 
bromomethylbiphenyl (113), all crosslinkings in DMF in the presence of catalytic amounts 
of water were successful. Those in acetonitrile, or in dry conditions in DMF were 
unsuccessful. 
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Table 2.5 : Summary of results from the crosslinking of tripeptide (99) with various 
crosslinkers 
 
Crosslinker Solvent Base H2O Addition' Resultt 
added? 
-/ý Br 
P Br 
DMF, RT 
DMF, RT 
DMF, RT 
DMF, 
(65°C) 
CH3CN, 
RT 
DMF, RT 
DMF, RT 
DMF, RT 
DMF, RT 
CH3CN, 
RT 
DMF, 
(50° C) 
- Br 
DMF, RT 
DMF, RT 
Br DMF, RT 
ý--ý ý-, DMF, 
Cl 0 Cl (60°C) 
CSZCO3 XS () 
Cs2CO3 mol. sieves S () 
Cs2CO3, mol. sieves SX 
CsI 
Cs2CO3, mol. sieves SX 
CSI 
Cs2CO3, mol. sieves SX 
CsI 
Cs2CO3 mol. sieves SX 
CSZCO3 S () 
CS2CO3 B () 
Cs2CO3  Aliq () 
CS2CO3  Aliq X 
Cs2CO3  Aliq X 
Cs2CO3 XSX 
Cs2CO3 mol. sieves S2% 
Cs2CO3 B 40.5 % 
Cs2CO3, mol. sieves SX 
CsI 
See bottom Table 2.6 
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Table 2.6-: Summary of results from the crosslinking of tripeptide (99) with additional 
crosslinkers 
Crosslinker Solvent Base H2O Addition' Result 
added? 
DMF, RT Cs2CO3 X S X 
cl 0 Cl DMF, RT Cs2CO3 mol. sieves S () 
DMF, Cs2CO3 mol. sieves S X 
(65° C) 
DMF, RT Cs2CO3, mol. sieves S X 
NaI 
CH3CN, Cs2CO3 mol. sieves S X 
(650 C) 
CH3CN Cs2CO39 mol. sieves S X 
CsI 
DMF, RT Cs2CO3 mol. sieves S X 
Br(CH2)6Br 
DMF, RT Cs2CO3  S  45% 
DMF, RT CsZCO3  
TsO 00 OTs CH3CN, Cs2CO3  
RT 
DMF, RT Cs2CO3  
*S= Addition of crosslinker by syringe pump 
B= Addition of crosslinker in one batch 
Aliq = Addition of crosslinker in aliquots 
S 45 % 
Aliq X 
Aliq  62 % 
tX= reaction failed 
() = evidence of product 
but could not be 
purified 
= reaction successful 
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CHAPTER 3: 
TOWARDS THE SYNTHESIS OF POLYCYCLIC PEPTIDE HOST 
MOLECULES 
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3. Towards the synthesis of polycyclic peptide host molecules 
3.1 Hemerythrin and hemocyanin 
The transport of dioxygen around the body is a key biological process in multicellular 
organisms'. Three major classes of metalloproteins have evolved which are capable of 
performing this function by the reversible binding of oxygen; hemoglobins, hemerythrins and 
hemocyanins122,123, 'Ma Hemoglobin, with its porphyrin ring prothstetic group surrounded 
by a polypeptide chain is widely found in mammalian species 164. However, this chapter will 
describe an attempt to synthesise a polycyclic peptide which possesses the theoretical 
potential to model the active sites of hemerythrin and hemocyanin. In the following 
discussion, the nature of the active sites of these two molecules will be indicated, a brief 
overview of attempts by other researchers to mimic these oxygen carriers will be presented 
before my own attempted synthesis of polycyclic peptides is described. 
3.1.1 Hemerythrin'ZZ, 164,165 
Hemerythrins form a family of related oxygen carrying proteins. Contrary to what 
might be expected from the name of this family, no heure group porphyrin rings are present 
in these proteins. Instead, they consist of a folded polypeptide chain containing an active 
site which itself possesses two iron atoms. Depending upon the species of organism for 
which the molecule is an oxygen carrier, it can exist in various oligomeric forms up to an 
octamer, as in the case of the sipunculid worm phascolopsis gouldii. The molecular weight 
of a subunit of this molecule is ca. 13500 (108000 for the octamer)122. 
The structure of the active site of deoxyhemerythrin, based upon X-ray 
crystallographic analysis is illustrated in Fig 3.1. This active site structure is common to all 
species using hemerythrin as an oxygen carrier 122. 
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Fig 3.1 : Structure of the active site of hemerythrin 
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The two iron atoms in the active site are inequivalent. One iron atom is octahedrally 
ligated to the e-nitrogen atoms of three histidine residues, two oxygen atoms from aspartic 
acid and glutamic acid as well as an oxygen from a p-hydroxo bridge. The other iron is at 
the centre of a distorted trigonal bipyramidal moiety. It is bound to the c-nitrogen atoms 
of two histidine residues, the remaining two oxygens from Asp and Glu and an oxygen from 
the same hydroxyl bridge. 
A schematic diagram showing the uptake and release of dioxygen is shown in Scheme 
3.1. In oxyhemerythrin, dioxygen has been shown by X-ray diffraction studies to bind as 
a hydrophobic group end on to the previously pentacoordinate iron(II) ion. Both iron(U) 
ions are oxidised to iron(III), so the addition of dioxygen may be formally considered to 
involve the addition of 02 2% However, the mechanism by which this occurs is unknown122. 
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Scheme 3.1 :A schematic diagram of the uptake and release of dioxygen by hemerythrin 
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In the case of the themiste dyscrita oxyhemerythrin, five residues with atoms within 
4A of the dioxygen molecule are present. All of these, two leucines, one isoleucine, one 
phenylalanine and one tryptophan, are hydrophobic. Similarly, most hemerythrin dioxygen 
binding sites are surrounded by hydrophobic residues. The detailed role of these 
surrounding residues is, however, not fully understood at present. It is hoped that by 
constructing small molecules which model the Fe-g-O-Fe unit, a clearer understanding of 
the means by which dioxygen is bound may be ascertained. 
3.1.2 Hemocyanin113.11,165 
Hemocyanins are found in many kinds of arthropods and molluscs. These are large, 
multisubunit proteins that are likewise used to transport dioxygen. Limulus polyphemus 
hemocyanin is made up of 48 subunits of which subunit II is the best characterised with a 
molecular weight of about 73 kDa. The nature of the active site of subunit II of arthropod 
deoxyhemocyanin is illustrated in Scheme 3.2. The fundamental difference between this 
protein and hemerythrin is that hemocyanin possesses an active site based upon two Cu 
atoms rather than on two Fe atoms. Each copper atom is at the centre of a trigonal 
complex and is ligated to the protein by the e-nitrogens of three histidine residues. Each 
copper is formally in the Cu(I) oxidation state. 
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Scheme 3.2: Schematic diagram of the uptake of dioxygen by the active site of hemocyanin 
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As with hemerythrin, the oxygenation of arthropod hemocyanins may be formally 
considered to involve the oxidation of Cu(I) to Cu(II) and the binding of dioxygen in the 
022 oxidation state. Upon dioxygen binding each Cu(II) ion becomes bound to the NE 
atoms of the two closest histidine residues and also the two oxygen atoms in a square planar 
geometry (Scheme 3.2). The distance between the NE atom of the third histidine and each 
copper is considerably extended compared with the other two (2.5 A over 2.1 
A) and the 
nature of the bonding is not clearly understood. Thus dioxygen is bound in a tj2-µ 
geometry. This binding mode is consistent with the observed change in the Cu-Cu distance 
in subunit II of the limulus polyphemus hemocyanin. In its deoxygenated form, X-ray 
diffraction indicated a Cu-Cu distance of 4.6 ± 0.2 A. In the oxygenated form, however, 
this was reduced to 3.6 ± 0.2 A. 
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3.2 Synthetic biomimetic dioxygen complexes 
Several researchers have attempted to mimic the oxygen binding activity of 
hemerythrin and hemocyanin using small molecule complexes'66-168 A large number of such 
dimetal complexes are known of which diiron and dicopper complexes feature 
prominently169 "o. 
Four analogous alkoxo-bridged diiron(II) complexes have been synthesised by 
Lippard167, lei These are derived from N, N, N', N'-X4-2-hydroxy-l, 3-diamino propane, 
where X is one of several nitrogenous bases (119)-(122) (Scheme 3.3). 
Scheme 3.3 : Dioxygen binding by four alkoxo-bridged diiron(II) complexes derived from 
N, N, N', N'-X4-2-hydroxy-1,3-diamino propane 
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These compounds are related to hemerythrin in that they possess a carboxylate 
bridging group. ' However, whereas hemerythrin possesses two such carboxylate groups 
steric factors prevent the incorporation of a second carboxylate into these synthetic 
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niolecules. In addition, an alkoxo bridging group has not thus far been observed in a non- 
herne protein. 
The first of these compounds to be shown to form a dioxygen adduct was (119). At 
low temperature (T < -80° C), (120)-(122) likewise form stable dioxygen adducts. 
However, only complex (122) was found to show reversible binding to O2. Whereas -(119)- 
(121) are relatively symmetric, each having two 5-coordinate square pyramidal Fe(II) ions, 
complex (122) has only one square pyramidal ion - the other being coordinated to water and 
thus having octahedral geometry "Z. It is possible that the resultant steric crowding is 
alleviated by the observed lengthening of the Fe-N bonds. This bond lengthening indicates 
greater flexibility in the complex and facilitates the more reversible binding of small 
molecules to the metal centre. 
In another attempt to mimic the dioxygen binding of hemerythrin, the mononuclear 
complex (123) was synthesised'73. In this 5-coordinate iron(II) complex, the metal is bound 
to a tridentate, facially coordinating ligand hydrotris(diisopropylpyrazolyl)boräte, HB(3,5- 
'Pr2pz)3, and a chelating carboxylate ligand. On addition of dioxygen in non-coordinating 
solvents at temperatures below -20°C, a dinuclear peroxide adduct (124) is formed (Scheme 
3.4). 
Scheme 3.4 : Addition of dioxygen to a hydrotris(diisopropylpyrazolyl)borate iron(II) 
complex (123) 
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Below -500 C the binding is irreversible but between -500 C and -200 C, reversibility 
is shown by the exposure of (124) to an inert atmosphere. In such conditions, the starting 
. material (123) is regenerated. 
In an attempt to model the oxygen binding activity shown by hemocyanin166 a dicopper 
complex has been synthesised which possesses a related tridentate facially coordinating 
ligand hydrotris(dimethylpyrazolyl)borate, HB(3,5-Me2pz)3 14. Initially, the synthesis of 
this oxyhemocyanin model involved the formation of a µ-oxo dinuclear copper(II) complex 
[Cu(HB(3,5-Me pz))12O (125). Upon exposure to hydrogen peroxide in CHIC12 the desired 
µ-peroxo dinuclear copper(II) complex (126) was formed. The binding of peroxide shown 
by this complex is analogous to that shown by oxyhemocyanin in that it is a 112-µ peroxo 
complex (Scheme 3.5). 
Scheme 3.5 : Formation of a model of hemocyanin by the addition of hydrogen peroxide to 
p-oxo dinuclear copper(II) complex (125) 
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An alternative route to this complex was later developed in which more hindered 
hydrotris(pyrazolyl)borate ligands were used to enhance the stability and crystallinity of the 
complexes15. Upon addition of dioxygen to mono-nuclear copper(I) complex (127) the µ- 
peroxo copper(I) complex [Cu(HB(3,5 'Pr2pz)3)12(02) (128) was formed (Scheme 3.6). 
Following crystallisation of the product, X-ray diffraction was used to demonstrate the 
presence of the anticipated planar rl2-µ peroxide binding mode and also to show a Cu-Cu 
separation of 3.56 A- which compares favourably with the 3.6 ± 0.2 A Cu-Cu distance 
found in hemocyanin (Section 3.1.2). 
Scheme 3.6 : Formation of a model of hemocyanin by the addition of dioxygen to mono- 
nuclear copper(I) complex (127) 
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3.3 The structure of polycyclic peptide metal chelator (80) 
With a view to mimicking the oxygen binding activity of hemerythrin and hemocyanin, 
the polycyclic peptide (80) was designed as an appropriate target molecule. It was thought 
that two features of this molecule would play a key role in the formation of a dimetal 
complex of either iron or copper thus allowing it to mimic the oxygen binding activity of 
these enzymes. 
IN, 
N 
NN 
O 
O NHý<NH 
OO 
NH p 
p NH 
O 
NH p 
O 
N N 
(so) 
3.3.1 The macrocyclic ring of po ycyclic peptide (80) 
A key feature of this molecule is the macrocyclic ring containing polyether as well as 
nitrogen functionality which was to be constructed above the plane of the cyclic peptide. 
As shown in Scheme 3.7, it was this ring which it was hoped would bind either two iron 
atoms to form a hemerythrin model or two copper atoms to form a hemocyanin model. 
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Scheme 3.7 : The binding of dioxygen by both the diiron and the dicopper complexes of the 
macrocylic ring of the polycyclic peptide (80) 
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In the deoxyhemerythrin models described above, both-iron atoms are 5-coordinate 
and are bonded to three nitrogen and two oxygen functionalities. Likewise, if a diiron 
complex of (80) were to form, each iron atom would be able to bind to three nitrogens, from 
two amines and a pyridyl group, as well as to two oxygens, each from a polyether. Upon 
addition of dioxygen it was hoped that the µ-OZ complex would form. 
With a view to constructing a hemocyanin model, however, it was envisaged that each 
copper atom of a dicopper complex would only bind to the three nitrogen functionalities. 
This expectation is based upon the observed coordination patterns of copper in both 
hemocyanin and the model described in Section 3.2. As before, dioxygen complexation 
would hopefully take place in the T 2-µ-O2 mode. 
3.3.2 The cyclic peptide moiety of polycyclic peptide (80) 
The cyclic peptide was expected to play a role in binding by providing a hydrophobic 
pocket inside which the above complexation could occur. The above discussion of the 
structure of hemerythrin and hemocyanin described how their active sites are surrounded 
by hydrophobic residues. The use of hydrophobic amino acids such as glycine and lysine 
would potentially mimic these residues by forming a synthetic hydrophobic pocket within 
which oxygen binding could occur. 
The use of glycine and lysine confers a number of advantages to the structure of the 
molecule. Their use also assists in maximising the yields of the final molecule. The use of 
glycine in the cyclic peptide would encourage the formation of 13-turns17', thus providing 
a relatively rigid base to the host molecule (Scheme 3.8). Such a conformationally stable 
structure would thus be more preorganised for the binding of metal ions. In addition, two 
ß -turns stabilize the target cyclic peptide encouraging its efficient synthesis. 
Upon the coupling of peptide fragments, it is frequently a problem that racemisation 
can occur at the C-terminal residue. In Chapter 2, it was explained that the cyclic peptide 
synthesis would be attempted by a cyclodimerisation procedure using derivatised linear 
tripeptide fragments H-Lys-Lys-Gly-OH. The use of achiral Gly or N-alkylated Pro in the 
C-terminal position would overcome this problem of racemisation. However, the bulky 
amino acid Pro would be likely to reduce the yield of cyclic peptide due to steric inhibition 
of the peptide coupling. Consequently, the use of the small amino acid glycine would be 
more suitable for cyclodimerisation. 
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Finally, in the synthesis of the polycyclic peptide, chirality can be introduced by the 
use of chiral building blocks such as lysine. The four lysine amino acids incorporated allow 
the construction of the appropriate "bucket-shaped molecule" and provide the four covalent 
links required to connect this cyclic peptide structure with the metal-chelating macrocycle. 
Scheme 3.8 : The cyclic peptide base of the polycyclic peptide (80) showing the presence 
of intramolecular hydrogen bonding between lysyl residues and the formation of ß-turns 
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3.4 Towards the synthesis of polycyclic peptide metal chelators 
3.4.1 Cyclodimerisation studies 
Following the results described in Chapter 2 the crosslinked tripeptide (101) was 
synthesised. This molecule was used in the attempt to construct the host molecule (80) 
described above. 
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Scheme 3.9 : Synthesis of crosslinked cyclic peptide (103) 
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The initial conditions used to effect the cyclodimerisation of (101) were based upon 
those developed previously within the group' 11-117 . These are shown 
in Scheme 3.9. The 
process by which the optimised conditions for cyclodimerisation were determined is 
explained below. 
Of the four steps involved in the cyclodimerisation, the initial hydrolysis step 
consistently gave a quantitative yield of the tripeptide carboxylic acid (129). Table 3.1 
gives the main high mass peaks of the observed FAB mass spectrum together with their 
assignments. The 'H NMR and 13C NMR spectra were consistent with the desired 
compound. 
Table 3.1: High mass peaks in the FAB mass spectrum of tripeptide carboxylic acid (129) 
m/z Assignment 
892 [M + K]+ 
876 [M + Na]+ 
854 [M + H]+ 
776 [M - Boc + Na]+ 
754 [M - Boc]* 
Applying the conditions previously developed within the group115-117 , step b) involved 
the formation of a pentafluorophenyl (PFP) active ester. Following filtration of the reaction 
mixture - to remove precipitated dicyclohexylurea - and evaporation of the solvent, the 
brownish-white oil formed was triturated with hexane and ether to give the PFP ester (130). 
Step c) involved the removal of the Boc-nitrogen protecting group to give a similar 
brownish-white oil. Residual trifluoroacetic acid (TFA) was removed by washing in toluene 
and then residual toluene was removed by triturating with ether. In both cases, the 
products were not characterised but rather were used immediately for the next stage in the 
reaction. The TFA salt (131) was cyclodimerised following the conditions in step d) and 
following silica gel column chromatography using 5-20 % methanol in dichloromethane as 
eluant, an overall yield of cyclic peptide (103) of 9% was achieved. FAB mass 
spectrometry of the crude product shows a distinct peak at m/z = 1472 corresponding to the 
[M + H]+ ion of (103) as wellas a peak at m/z = 1493 due to [M + Na]+. In the FAB mass 
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spectrum of the columned material a peak at m/z = 1472, corresponding to the molecular 
ion plus hydrogen was observed. The reasonable purity of this material was suggested by 
the fact that it was a single spot by TLC. The 80 MHz 1H NMR spectrum was as expected 
with a singlet at 8=2.4 due to the tosyl methyl groups and a broad multiplet at 8=1.3 - 
2.1 due to the lysyl side chains. Multiplets due to CH2N and CH2O were present at S=3.0 
- 3.3 and 8=3.5, respectively. Finally, doublets due to the tosyl groups were observed at 
5=7.3and8=7.7. 
It is believed that pure cyclodimerisation precursors (130) and (131) are crucial to the 
efficient formation of the desired product. The presence of a small amount of hydrolysed 
PFP ester (131), for example, would theoretically promote straight chain oligomer and 
polymer formation. Indeed, following step b), hydrolysed PFP ester (129) had been 
observed on the baseline of the TLC when 19: 1 dichloromethane : methanol had been used 
as the eluant. Compound (129), however, was situated at Rf = 0.25 in the more polar TLC 
eluant, 2: 17: 1 methanol: chloroform : acetic acid. TLC showed that by means of column 
chromatography on silica gel, using 1: 1 chloroform : ethyl acetate as eluant, the PFP ester 
(130) could be isolated from (129). In later reactions, more polar ethyl acetate was used 
as eluant in order to improve the efficiency and speed of purification. In addition, by 
changing the reaction solvent in step b) from DMF to another dipolar aprotic solvent, dry 
ethyl acetate (stored over 4A molecular sieves under argon), the reaction products were 
found to be easier to handle and could be isolated as a white solid rather than a brownish- 
white oil. The reason for this is presumed to be because residual ethyl acetate with a boiling 
point of 770 C is easier to remove under reduced pressure than DMF which has a boiling 
point of 153° C. An indication that the PFP ester (130) was present came from the reaction 
TLCs in which those following the use of ethyl acetate were similar to those when DMF had 
been used as the reaction solvent. 
Following these changes to the conditions employed in step b), the consistent overall 
cyclodimerisation yields were increased to ca. 40 %. 
The use of EDC rather than DCC as a coupling reagent was a final modification to the 
reaction conditions. By using EDC rather than DCC, purification was assisted in that unlike 
residual DCC and its by-product DCU, which were removed by filtration, residual EDC and 
its by-product could be easily removed by a simple water wash. Using these new 
conditions, the optimal yield from the four cyclodimerisation steps increased to 63 % after 
column chromatography. The FAB mass spectrum of this compound showed the expected 
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[M + H]+ ion at m/z = 1472 and an accurate mass determination confirmed the predicted 
molecular formula. The 'H NMR and 13C NMR spectra were as expected and are 
illustrated in Figs 3.2 and 3.3. 
The 'H NMR spectrum showed the expected multiplet at 8=1.3 - 2.1 due to the 
CH2s in the lysyl side chains. The singlet at S=2.4 was due to the tosyl methyl groups. 
The two multiplets at S=3.0 - 3.3 and 8=3.5 were due to the CHIN and CHZO protons, 
respectively, whilst the multiplets at 8=4.1 and S=4.42 were due to glycine and lysine a- 
CHs. The four superimposed doublets in the aromatic region (8 = 7.3 - 7.7) were due to 
the two kinds of para-substituted tosyl aromatics. 
The 13C NMR showed peaks at 6= 21.50 and 8= 21.54 due to tosyl methyls and the 
expected number of 15 carbons from the CH2 groups. These 15 peaks are due to the 6 
CH2s of the lysine side chains (8 = 22.30 - 30.53), 1 CH2 from glycine (8 = 43.88), 4 due 
to CHIN (6 = 48.43 - 49.78) and 4 from CHZO (8 = 70.31 - 70.87). Fifteen CH2 peaks 
were expected because although there are 30 CH2 carbons in cyclic peptide (103), the 
molecule possesses 2-fold rotational symmetry. Two peaks due to lysine a-CH were 
present at S= 52.67 and 8= 55.57 whilst 3 resolved tosyl CH peaks (8 = 127.10 - 129.92) 
and 3 resolved tosyl C peaks (8 = 136.37 - 143.35) were observed. Finally, three carbonyl 
carbons (8 = 170.47 - 172.89) completed the complement of carbons in the molecule. 
Overall, the spectrum showed the sample to be relatively clean with no significant peaks due 
to impurities. 
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Unfortunately, following the scale up of this reaction from 500 mg of starting 
tripeptide (101) to 3.5 g of (101), the overall cyclodimerisation yield following the optimised 
conditions and after column chromatography was reduced to 16 %. It is not clear what the 
reason is for this reduction in yield. 
In order to test the effect upon the overall yield of using different alkali metal bases 
in step d), the base was varied from Cs2CO3 to K2C03 and Na2CO3. These were tested 
having used DCC rather than EDC as the coupling agent in step b). Previously"', it had 
been suggested within the group that the use of caesium ions in related cyclodimerisations 
enabled high yields to be obtained by a template effect106"1°8 However, overall yields were 
not significantly affected by the base used, remaining at ca. 40 %. It is thus suggested that 
a template effect is not a significant factor in determining the yield in this cyclodimerisation. 
This would be expected in view of the poor chelating ability of the C=O and N-H groups 
in the amide bonds of the cyclic peptide being synthesised. 
A summary of the optimised conditions for cyclodimerisation is given in Scheme 3.9. 
3.4.2 Detosylation of the cyclic peptide 
Following the successful synthesis of cyclic peptide (103) it was important to bring 
about the removal of the four tosyl protecting groups as the penultimate step in the target 
molecule synthesis. It was vital that all four tosyl groups were removed cleanly in order to 
avoid complex purification problems in the separation of tri-, di-, and mono-tosylated 
material from the desired detosylated product. In addition, it was important to ensure the 
maximum possible yield of the target molecule ready for the final step in the synthesis. 
A great variety of different reagents have been used in the deprotection of tosyl 
protected amines"'. Strongly acidic conditions such as the use of HF178.179 and 
HBr/AcOH180 have been used. More frequently, powerful basic conditions have also been 
employed. Thus Na/NH3(1)19,18', sodium amalgam 182,183 sodium naphthalenide'84'87 and 
anthracenide'$$ and sodium bis(2-methoxyethoxy)aluminium hydride189 have all been used 
to remove tosyl groups. More unusual conditions such as the use of electrolysis in 
tetramethylammonium chloride190 and even photolysis"' conditions have also been 
employed. However, the literature is clear that the optimum method is highly dependent 
upon the nature of the tosylated substrate and that conditions suitable for one molecule are 
not neccessarily suitable for another. Thus, whereas Mazur and Plume used HF to remove 
129 
N-tosyl groups from arginine residues in a nonapeptide"a, Okada and Sugihara found N- 
tosyl to be stable to HF192. Fujii observed HF to be useful for removing N-tosyl from 
histidine but not from arginine179. 
The initial conditions used in the attempt to the remove the tosyl group from cyclic 
peptide (103) was to heat with HBr/AcOH in phenol18'. However, this only produced a 
black tar which due to the lack of a molecular ion peak at m/z = 855 in the FAB mass 
spectrum was assumed not to contain the desired product. Greater success was achieved 
by treating (103) with sodium anthracenide in dry THE under argon. The resultant blue 
solution was stirred for 1h under argon. After purification of the product using analytical 
HPLC at pH 5 with a potassium phosphate aqueous buffer, the FAB mass spectrum of one 
of the three isolated products showed two high mass peaks which could be assigned to the 
desired product. These peaks were m/z = 894, assigned as the molecular ion of (105) plus 
potassium from the buffer and m/z = 856, due to the molecular ion plus hydrogen. 
Unfortunately, however, due to the lack of a suitable preparative column for purification of 
the product following any attempted scale up of the reaction, this procedure was not taken 
any further. 
Experiments by others within the group193 indicated that successful detosylation of 
cyclic peptides could be achieved using a 50 % sodium dispersion in paraffin using liquid 
ammonia solvent. Thus to a blue solution of the sodium dispersion in liquid ammonia was 
added a solution of cyclic peptide (103) in dry THE under argon. The resultant blue 
solution was stirred for 2 h. The use of acetic acid as a sodium quenching agent produced 
a large quantity of sodium acetate. A FAB mass spectrum of this crude product showed 
a peak at m/z = 856, potentially corresponding to the molecular ion of (105) plus hydrogen. 
Many other similarly sized high mass peaks between m/z = 715 and m/z = 1071 were also 
present but could not be assigned. Following removal of the sodium acetate by its 
dissolution in water, a second FAB mass spectrum again showed a peak at m/z = 856, but 
again this peak was not significantly above the general background noise of the spectrum. 
In view of these rather ambiguous results and the small quantity (ca. 2 mg) of material 
isolated, further attempts to isolate the desired product (105) were not undertaken. 
Success in the production and isolation of (105) was achieved by using sodium metal 
in liquid ammonia. To a blue solution of sodium in ammonia was added a solution of (103) 
in dry THE under argon. This blue reaction mixture was stirred for 2h and the. sodium 
quenched with ammonium chloride. The FAB mass spectrum of the crude reaction 
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products revealed a significant [M + H]+ peak at m/z = 856, with quadruple the intensity of 
the background noise. Silica gel column chromatography in which the eluant was 19: 1 
methanol : liquid ammonia was used to purify the desired product. By the addition of liquid 
ammonia to the methanol eluant, the polarity was increased and it was found that the 
deprotected amine cyclic peptides were eluted more efficiently from the column. The above 
reaction and purification procedure was attempted on two occasions. In the first, a yield 
of 36 % of deprotected cyclic peptide (105) was achieved. The second reaction gave a 
yield of 69 % of the desired product (Scheme 3.10). The reaction TLC (19: 1 methanol : 
liquid ammonia) showed a spot which whilst being stained brown on exposure to ninhydrin 
was not UV active. This was considered to be consistent with (105) in that the desired 
product has no UV active aromatic or conjugated chromophores. The ability of ninhydrin 
to stain this TLC spot is indicative of free amines. The FAB mass spectrum with its peaks 
at m/z = 855 and m/z = 856 due to [M]* and [M + H]* is consistent with that expected. It 
is reproduced in Fig 3.4. The lack of any aromatic protons and the loss of the tosyl methyl 
singlet in the 'H NMR spectrum (Fig 3.5), in which the sample is dissolved in CDC13 with 
trace CD3OD to aid solubility, clearly shows that all the tosyl groups have been removed. 
As would be expected, there is a broad multiplet at S=1.15 -1.95 due to the lysyl CH2s as 
well as multiplets at 8=2.45 - 2.6 and S=2.6 - 2.75 due to CH2N, a multiplet at 6=3.4 - 
3.55 due to CHZO and a multiplet at 6=4.0 - 4.2 due to the glycine and lysine a -CHs - the 
integrations being 3: 1: 1: 2: 1, respectively. 
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Scheme 3.10: Synthesis of polycyclic peptides from cyclic peptide advanced intermediates 
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3.4.3 Final crosslinking reactions 
In order to model the final step in the synthesis of the desired polycyclic peptide (80), 
a double crosslinking reaction between 1,4-a, a'-dibromo-p-xylene and the deprotected 
cyclic peptide (105) was attempted (Scheme 3.10). It was thus hoped to synthesise another 
polycyclic peptide (79) in addition to the hemerythrin and hemocyanin mimic (80). 
Following the precedent established within the group18, the deprotected cyclic peptide (105) 
was dissolved in 2,2,2-trifluoroethanol (TFE) under argon. It was stirred at 40° C, a 
temperature which was maintained throughout the reaction. To this solution were added 
by syringe pump over 12 h, DMF solutions of the 1,4-a, a'-dibromo p-xylene crosslinker 
and N, N-diisopropylethylamine (DIPEA) as base. The polar, aprotic DMF was used as the 
solvent rather than TFE because as shown in Scheme 3.11, the presence of DIPEA would 
deprotonate the TFE, the conjugate base of which would compete with the e-nitrogens of 
the cyclic peptide (105) to displace the Br- ions. Asa consequence, the crosslinker would 
possess only one efficient leaving group preventing it from forming the desired compound. 
Scheme 3.11: Displacement of bromide leaving groups by the TFE anion 
Br Br ýý 
+ Br CF3CH20 
Brý) CF3CH2O 
A DMF solution of crosslinker was initially added followed by a solution of equal 
equivalents of crosslinker and base, with the final addition being the remaining base solution. 
Each of these three solutions were added by syringe pump over a period of 12 h. This 
method was chosen so as to ensure that an excess of base compared to crosslinker was at 
no time present in the reaction mixture. The intended role of the base was to neutralise the 
HBr produced following the nucleophilic displacement of the Br' ions on each crosslinker 
molecule. However, if an excess of base were present, there would be an increased 
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likelihood of the TFE reaction solvent being deprotonated and the displacement illustrated 
in Scheme 3.11 occurring. It was hoped that the above reaction procedure would prevent 
this from resulting. 
Following these syringe pump additions, the mixture was stirred for a further 3 days 
in order to encourage the completion of the reaction. Silica gel column chromatography 
was attempted using 180: 19: 1 chloroform : methanol : liquid ammonia as eluant. As with 
the deprotected cyclic peptide (105), it was found that the addition of a small quantity of 
ammonia to the eluant aided the efficient elution of the products. TLC (95: 5 methanol : 
ammonia) showed the presence of a dominant spot at Rf = 0.55 surrounded by closely 
running but minor (less intense) spots. As would be expected from the presence of 
aromatic chromophoric groups on the desired product (79), this dominant spot was UV 
active. The FAB mass spectrum revealed high mass peaks at m/z = 1060 and m/z = 780 - 
the former being assigned as the [M + H]' ion of the desired product (79). This mass 
spectrum is displayed in Fig 3.6. 
The 'H NMR spectrum of the 10 mg sample, however, using CDC13 as the solvent 
with a trace of CD3OD to aid solubility, did not conclusively prove that (79) had been 
successfully synthesised. Whilst the presence of aromatic peaks were suggested by a broad 
band at S=7.2 - 7.6 and lysyl protons were possibly observed by the presence of a large 
broad multiplet at 6=1.1 - 2.0, additional features could not be determined due to the 
presence of a large quantity of solvent peaks and sample impurities. Repeated attempts to 
purify the sample by silica gel column chromatography were unsuccessful since, as explained 
above, the sample impurities ran very closely to the main product spot by TLC (95: 5 
MeOH: NH3 and 180: 19: 1 CHC13: MeOH: NH3). Following each attempt to purify the 
compound by column chromatography, 'H NMR experiments were attempted using either 
the CDC13 : CD3OD mixture or d7-DMF as solvents. However, no improvements were 
obtained. A typical 'H NMR spectrum in d7-DMF is illustrated in Fig 3.7, again showing 
the broad aromatic peak and the lysyl protons mentioned above. Whilst being consistent 
with the expected 'H NMR of the desired product it does not conclusively prove its identity. 
The sharp para-substituted aromatic proton peaks observed at 8=7.6 are not believed to 
be due to the desired product because identical peaks to these were also observed in the 'H 
NMR spectra of the reaction products from the attempted synthesis of (80). 
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It had been hoped that COSY 'H NMR spectroscopy would have aided the 
characterisation of any (79) that had been formed. This technique would also be useful if 
the polycyclic peptide (80) was to be isolated. By using this technique, the CH2 protons 
a, a' and a ", on (79) and (80) in Scheme 3.10 could be correlated and shown to couple 
to each other. It was also hoped to produce a NOESY 111 NMR spectrum to determine if 
any through space NOE interactions between, for example, the para-xylyl and the 
triethyleneglycol based crosslinks were observed. If this had been achieved, along with the 
production of clean, well resolved 'H NMR and 13C NMR spectra then strong evidence for 
the successful crosslinking of the 1,4-a, a'-dibromo-p-xylene crosslinker would have been 
produced. However, the poor quality of the spectra precluded this attempt at 
characterisation. 
The conclusion that must be drawn from these spectroscopic experiments is that whilst 
from mass spectrometric evidence, the cyclic peptide (79) was formed in this reaction, proof 
of this from 'H NMR spectroscopy was not forthcoming. Nevertheless, the ]ii NMR 
spectrum was consistent with the desired product. 
With a view to synthesising the polycyclic peptide (80), the above crosslinking 
reaction, in which 1,4-a, a'-dibromo p-xylene was replaced by an equivalent amount of 2,6- 
dibromomethylpyridine, was repeated. The crosslinker and base were added using a syringe 
pump in an identical manner to the attempted synthesis of (79). 
Two attempts at this reaction were made, each using 70 mg of deprotected cyclic 
peptide (105). However, as with the attempted synthesis of (79), TLC using the same 
solvent system showed a dominant UV active spot surrounded by small, less intense spots. 
The compounds producing these spots were uncharacterised. Despite repeated attempts 
to purify the reaction products by silica gel column chromatography using 180: 19: 1 
chloroform : methanol : liquid ammonia as eluant, TLC in the same solvent system showed 
that the product had not been purified. 
Following the first attempted synthesis of (80), FAB mass spectra were recorded after 
each attempt at column chromatography. It was expected that if cyclic peptide (80) had 
been formed, these spectra would show a peak at m/z = 1061 corresponding to the 
molecular ion or m/z = 1062 due to the molecular ion plus hydrogen. Unfortunately, no 
such peaks were observed. Following column chromatography of the reaction product 
from the second attempted synthesis of (80), a peak at m/z = 1062 was observed but was 
not significantly more intense than the general spectrum background noise. In addition, 
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because this peak was only observed in 1 out of 20 scans, it was not considered to be 
definitive evidence for the formation of the desired product. 
In order to aid the characterisation of any compound (80) that it was hoped had been 
produced, a 'H NMR spectrum of the crosslinker 2,6-dibromomethylpyridine was recorded 
in CDC13. This was compared with the 'H NMR spectra of the product from the 
crosslinkings. Thus, in the spectrum of the crosslinker, a singlet at 6=4.5 due to the 
CH2Br protons was present. The 3 aromatic protons gave the expected doublet at 6=7.35 
coupled to a triplet at 8=7.7. Unfortunately, however, the 'H NMR spectra of the 4 mg 
of the columned reaction products, using a CDC13 and CD3OD mixture, CD3OD and d7- 
DMF failed to reveal such a peak distribution. Indeed, with the exception of the para- 
substituted aromatic impurities described earlier, no aromatic protons were observed in any 
of the spectra. However, the presence of peptidic material in the samples was suggested 
by the presence of a broad multiplet at 8=1.2 - 1.7. Thus, as with FAB mass 
spectrometry, 'H NMR spectroscopy failed to reveal any evidence for the successful 
synthesis of (80) in either attempted synthesis. The small amount of material available for 
each 'H NMR spectrum (4 mg) precluded an analysis by13C NMR spectroscopy. 
A possible reason for the failure to observe the desired product (80) was that a large 
quantity of the 70 mg of cyclic peptide (105) used in each reaction may have been converted 
to polymeric material. This could occur by the reaction of one c-nitrogen on a lysyl side 
chain with one bromomethyl group on a crosslinker molecule. However, instead of the 
other bromomethyl group on the crosslinker reacting with the e-nitrogen on the adjacent 
lysine, it would conceivably be possible for it to react with an e-nitrogen on another cyclic 
peptide molecule. Such a process could occur many times, thus preventing the formation 
of (80) and instead leading to the formation of polymers. It was hoped that such a situation 
would be avoided by the use of a syringe pump and by using a large amount of reaction 
solvent in each reaction to produce a low concentration (5 x 10-3 M) of the cyclic peptide. 
However, it is possible that polymeric material was still formed. It would be expected that 
such material would not move from the baseline in a TLC experiment, even using such a 
polar eluant as 180: 19: 1 chloroform : methanol : liquid ammonia. This was indeed found 
to be the case in that a very intense baseline spot on the reaction TLCs was observed. 
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3.5 Summary 
Tetratosylated cyclic peptide (103) was successfully synthesised and was then 
successfully detosylated using Birch reduction conditions. Mass spectrometry indicated 
that the resultant deprotected cyclic peptide (105) was successfully crosslinked using a 1,4- 
a, a'-dibromo p-xylene crosslinker to form the target molecule (79) but this could not be 
proven by 'H NMR spectroscopy. Both attempts to crosslink (105) using 2,6- 
dibromomethylpyridine, in order to synthesise target molecule (80), were shown by FAB 
mass spectrometry and 'H NMR spectroscopy to be unsuccessful. 
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CHAPTER 4: 
TOWARDS THE SYNTHESIS OF A PORPHYRIN CAPPED 
CYCLIC PEPTIDE 
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4. Towards the synthesis of a porphyrin capped cyclic peptide 
4.1 Oxidations catalysed by metallopQrphyrins 
Herne enzymes such as cytochrome P-450 monooxygenases are capable of catalysing 
an array of intrinsically difficult reactions such as the regioselective epoxidation of alkenes 
and the hydroxylation of alkanes'4. Their role in nature is to oxidise inert and poorly water 
soluble substrates such as steroids, fatty acids, leukotrienes and prostaglandins. Cytochrome 
P-450 monooxygenases are also beneficial for the non-specific oxidation of toxic substances 
such as chemical carcinogens, enhancing their polarity and solubility and facilitating their 
excretion195. Such enzymes contain a metal ion surrounded by a porphyrin ligand, itself 
bound inside a protein cavity. As such, the porphyrin ligand acts as the prosthetic group 
of the enzyme and is the centre at which all the catalytic activity of the enzyme occurs. 
Frequently, this metalloporphyrin group is bound at the Fe ion by a single proximal amino 
acid residue. The nature of the catalytic activity of the enzyme is governed by the proximal 
ligand, the distal amino acid residues and the protein itself. 
Oxidation occurs in a catalytic cycle in which a single enzyme molecule can catalyse 
the oxidation of a large number of substrates. The "turnover" of substrates, defined as the 
number of substrate molecules converted to product following catalysis by a single catalyst 
molecule, can be many thousands. The catalytic cycle is illustrated in Scheme 4.1 and 
shows that the key intermediate in the cycle is thought to contain a metal atom in a high 
oxidation state that is bonded to an oxygen atom. This oxygen atom is then transferred to 
the substrate regenerating the enzyme for another catalytic cycle. 
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Scheme 4.1 : Catalytic cycle of cytochrome P-450 monooxygenase 
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Much progress has been made since 1979, in the mimicking of cytochrome P-450 
monooxygenases and in the understanding of the nature of their activity19'. Under 
anaerobic conditions, it is possible to bypass much of the biological pathway shown in 
Scheme 4.1 by the addition of oxygen transfer agents or "shunt reagents" such as PhIO, 
H202, NaIO4, NaOCI and RO2OH 197. Such shunt reagents can also be used to catalyse 
oxygen transfer using synthetic metalloporphyrins. The following discussion will briefly 
describe a number of oxidation reactions catalysed by metalloporphyrins before giving a 
short overview of the methods used to synthesise porphyrins and capped porphyrins. 
In 1979, Groves published the first paper describing the use of iodosylbenzene as a 
simple oxygen donor in olefin epoxidations and alkane hydroxylations (Scheme 4.2)198. The 
catalyst used was chloro-5,10,15,20-tetraphenylporphyrinatoiron(III). 
9PI) 
CyS (RH) 
P 
CyS 
(RH) 
Fe(II) 
CyS 
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Scheme 4.2 : Oxidation of alkanes and alkenes using a porphyrin catalyst and 
iodosylbenzene 
alkene (or alkane) + PhIO 
aý 
º epoxide (or alcohol) + PhI 
a) chloro-5,10,15,20-tetraphenylporphyrinatoiron (III) 
Groves showed that by the use of this porphyrin catalyst cyclohexene could be 
oxidised to give cyclohexene oxide and the allylic oxidation product cyclohexanol and that 
adamantane could be oxidised to adamantan-1-ol and adamantan-2-ol. 
Since this paper was published, much work has been undertaken to study these 
oxidation reactions and in particular to determine to what extent they can be used to 
synthesise stereochemically pure compounds19'. Thus, Groves and Viski reported the use 
of chiral iron porphyrin catalyst (132) in the asymmetric hydroxylation of a variety of 
unactivated hydrocarbons (Scheme 4.3)199.2°°. These hydrocarbon substrates are oxidised 
within the chiral cavity of the catalyst. The chirality of the bridging dinaphthyl group of the 
catalyst induces chirality in the reaction products. Ethyl benzene gave a 40 % yield of 1- 
phenylethanol with a 71: 29 ratio of the R and S enantiomers respectively - ie 42 % e. e. 
Asymmetric epoxidation reactions have also been catalysed by chiral porphyrin ligands 
incorporating optically active bitetralins and binaphthyls201203 Naruta and Maruyama have 
synthesised a porphyrin containing four such groups to form a chiral "twin coronet" 
porphyrin (133). In this system, the bitetralins bridge adjacent meso-phenyl groups. Again 
using iodosylbenzene as the oxygen transfer agent, styrene has been oxidised to its epoxide 
in 485 turnovers and with 58 % e. e. 
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Scheme 4.3 : "Oxidation of ethylbenzene using a chiral iron porphyrin catalyst 199,200 
H _H H 
OH 
CH3 CH3 
\/ 
Ar 10 Ar. 
However, the highest observed enantioselectivities were obtained in the epoxidation 
of electron deficient alkenes. In the case of 3,5-dinitrostyrene, despite a low turnover of only 
36, an e. e. of 96 % was achieved. 
Hr-- 
OMe 
R= "a 
Hz - 
(133) 
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It is hypothesised that the reason for the impressive enantioselectivity of the 3,5- 
dinitrostyrene is that the substrate is more strongly bound within the cavity than other 
substrates such as styrene. When styrene and its derivatives are bound within the cavity of 
the porphyrin catalyst, effective it -it* interactions can develop with the aromatic rings of 
the naphthyl groups. These interactions are stronger in the case of the more electron 
deficient 3,5-dinitrostyrene which it is also suggested has the correct orbital symmetry for 
efficient 7r-7c* orbital overlap with the naphthyl groups. With such strong binding, catalysis 
of epoxide formation can occur with good stereoselectivity. 
4.2 Tetraarylporphyrin synthesis 
It will be noticed that all of the porphyrin oxidation catalysts above possess meso-aryl 
groups. Indeed, in order to produce a cavity of sufficient size in a porphyrin host and for 
ease of synthesis, many such catalysts are based upon the 5,10,15,20-tetraphenylporphyrin 
group. 
The synthesis of 5,10,15,20-tetraphenylporphyrin was first reported by Rothemund 
in 193520``-207. In this process, benzaldehyde and pyrrole were reacted together in a sealed 
bomb at 1500 C for 24 h. Yields were about 10 % and the conditions employed were so 
severe that few substituted pyrroles or benzaldehydes could be converted to the 
corresponding porphyrin208. Modifications to these conditions were reported in the 1960s 
by Adler and Longo209,210 By refluxing benzaldehyde and pyrrole in propionic acid for 30 
min, a 20 % yield of tetraphenylporphyrin was obtained. With these milder conditions, 
derivatives of tetraphenylporphyrin have also been synthesised by the use of alternative 
aromatic aldehydes. Thus, for example, replacing benzaldehyde with 4-chlorobenzaldehyde 
gives a 20 % yield of meso-tetra(4-chlorophenyl)porphyrin. 
A key development in tetraarylporphyrin synthesis was reported by Lindsey in 1987208. 
The new reaction conditions reported in the synthesis of tetraphenylporphyrin were based 
upon three hypotheses: 
a) Tetraphenylporphyrinogen was expected to be the thermodynamically favoured 
product when benzaldehyde and pyrrole were condensed under acidic conditions. 
b) Benzaldehyde and pyrrole are such reactive molecules that high temperatures should 
not be. necessary to effect their reaction. 
c) By employing mild reaction conditions in their synthesis, a large variety of substituted 
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porphyrins should be accessible. 
Thus by reacting a 1: 1 mixture of pyrrole and benzaldehyde with a trace acid catalyst 
(eg. BF3. Et20)2" at room temperature in chloroform, tetraphenylporphyrinogen was formed. 
After 1 h, an excess of an oxidant such as tetrachloro-1,4-benzoquinone (TCQ) or 2,3- 
dichloro-5,6-dicyanobenzo-1,4-quinone (DDQ) was added and the mixture refluxed. This 
irreversibly converted porphyrinogen to porphyrin. The reaction yield was found to be 
dependent upon the initial concentration of reactants -a moderate concentration of 10.2 M 
enabled yields of 50-55 % to be achieved. 
Scheme 4.4 : Reaction scheme of the Lindsey method of porphyrin synthesis"' 
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Scheme 4.4 shows the route by which porphyrin synthesis occurs"'. Pyrrole and 
benzaldehyde condense reversibly to form straight chain tetrapyrromethane (134), which can 
either cyclise to the porphyrinogen (136) or continue polymerisation to give higher 
molecular weight polypyrromethanes (135). Porphyrinogen (136) is oxidised to give 
porphyrin (137). 
The above method of Lindsey is widely used in synthesis213,2'4.. Nevertheless, further 
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advances have been reported. Kuroda has prepared 2-acylpyrroles (138) by heating pyrrole 
with N, N-dimethylamides at 90-95° C 215" These were reduced quantitatively by a half 
equivalent of LiAIH4 and the resultant acid sensitive alcohols (139) were refluxed in 
propionic acid to give the target porphyrin (Scheme 4.5). 
Scheme 4.5 : Kuroda's method of porpyhrin synthesis from 2-acylpyrrolesus 
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Very recently, a new synthesis of tetraphenylporphyrin has been described in which 
high-valent transition metal salts (eg. TiC14, VOC13, VO(OEt)C12, VO(O'Pr)C12, Mn(OAc)3) 
are used as aromatizing agents21'. Since these species also act as Lewis acid catalysts in 
porphyrinogen formation, pyrrole and benzaldehyde can in this new procedure be stirred 
with the above salts to form porphyrin directly. In the case of TiCl4 and the Vv species, 
reactions are at room temperature. Depending upon the salt used, yields are generally 
comparable to or higher than those observed with the Lindsey method. In addition, higher 
yields have been obtained for derivatives of tetraphenylporphyrin such as para-methoxy- 
tetraphenylporphyrin and para-bromo-tetraphenylporphyrin. 
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4.3 Synthesis of capped porphyrins 
The Adler-Longo method of porphyrin synthesis described in Section 4.2 was 
exploited by Baldwin in the synthesis of the capped porphyrin (141)21x18. The aldehyde 
(140) was refluxed with pyrrole for 1.5 h in propionic acid to yield crude porphyrin. Any 
traces of dihydroporphyrin (chlorin) were oxidised by treating with DDQ. Purification gave 
a2% yield of capped porphyrin (141) (Scheme 4.6) 
Scheme 4.6 : Baldwin's synthesis of a capped porphyrin2"ý18 
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Kagan has synthesised a four-fold bridged bis-(5,10,15,20-tetraphenyl)porphyrin by 
a similar procedure, again using the Adler-Longo methodology21'. By refluxing 
tetraaldehyde (142) and pyrrole in propionic acid, a yield of up to 6% of product (143) was 
achieved (Scheme 4.7). 
Scheme 4.7 : Kagan's synthesis of a four-fold bridged bis-(5,10,15,20- 
tetraphenyl)porphyrin219 
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A similar strategy was employed more recently by Bruice in the synthesis of his 
pendant capped porphyrin (145)fl0. However, refluxing with pyrrole in propionic acid gave 
only a negligible yield of the desired product. Optimal conditions were found to be based 
upon the Lindsey method of porphyrin synthesis in which tetraaldehyde (144) was 
condensed with pyrrole in the presence of BF3. Et2O and oxidised using TCQ (Scheme 4.8). 
Product (145) was isolated in 7% yield. 
Scheme 4.8 : Bruice's synthesis of a pendant capped porphyrin2Z° 
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Such a pendant capped porphyrin was synthesised in order to mimic iron(III) 
porphyrin enzymes such as catalase. This enzyme has a phenolic hydroxyl, tyrosine residue, 
ligated to a metalloporphyrin. The pendant capped porphyrin (145) mimics catalase by 
featuring a phenolic group ligated via its oxygen to the Fe(III) and isolated from the other 
functional groups by the capping structure. 
An alternative, convergent strategy for the synthesis of quadruply bridged co-facial 
bis-porphyrins has been developed by Bruice (Scheme 4.9)214. The two porphyrins (T3- 
TsNHCH2PP)H2(146) and (T3-BrCH2PP)H2 (147) were synthesised by the Lindsey method 
of porphyrin synthesis described in Section 4.2 and then coupled in the presence of Cs2CO3 
under high dilution conditions in DMF (10-3 M). The desired dimer (148) was obtained in 
38 % yield. 
Scheme 4.9 : Bruice's synthesis of a four-fold bridged bis-(5,10,15,20- 
tetraphenyl)porphyrin2'a 
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4.4 Synthesis and derivatisation of porphyrins 
Experience gained from the synthesis of capped porphyrins and double-decker 
porphyrin dimers outlined in Section 4.3 indicated two potential synthetic strategies 
appropriate to the formation of porphyrins capped with cyclic peptides. These are outlined 
in schematic form in Scheme 4.10: 
a) A convergent strategy in which the cyclic peptide and the porphyrin are synthesised 
independently. In the presence of an appropriate base, the cyclic peptide and porphyrin can 
then be added together under high dilution conditions encouraging the efficient closure of 
the 4 connecting bonds between porphyrin and cyclic peptide. This procedure is related to 
the synthesis of double-decker porphyrin dimers as described by Bruice214. Its main 
advantage is that if both the cyclic peptide and the porphyrin components can be synthesised 
in high yield, then only one coupling step is required to afford the target molecule. 
However, despite the 38 % yield for a related coupling reaction mentioned in Section 2.3, 
such reactions in which four new bonds are formed would be expected to be highly 
dependent upon either the correct high dilution conditions or the presence of an appropriate 
template, if straight chain oligomer and polymer formation were to be avoided. 
b) A linear strategy in which benzaldehyde derivatives are coupled to a cyclic peptide to 
give a tetraaldehyde. Thence, following the procedure of Baldwin in Section 4.3 217,218, this 
could be treated with pyrrole under Adler and Longo, Lindsey or other appropriate 
conditions to yield the porphyrin capped cyclic peptide. By following this strategy, the 
potentially low yielding final coupling reaction of strategy a) above, is avoided. However, 
it is vital to ensure the pristine purity of the tetraaldehyde intermediate prior to final 
cyclisation, otherwise during this final "intermolecular" porphyrin forming reaction, any 
mono-, di- or tri-aldehydes present will encourage intermolecular porphyrin formation, 
leading to the production of oligomers and polymers. 
With a view to synthesising a porphyrin capped cyclic peptide by both of these 
synthetic strategies, the four molecules illustrated in Fig 4.1 were envisaged as being viable 
targets. It was hoped that following their syntheses and metallation, a proximal ligand such 
as a chloride ion could be bound to the open face of the porphyrin. Thus a porphyrin cavity 
would be formed capped by a chiral and - as was seen in Chapter 3-a rigid cyclic peptide. 
The rigidity of the cavity would allow good recognition and strong binding of guests. 
Because the cavity possesses chirality, it would potentially act as a chiral epoxidation and 
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hydroxylation catalyst in a manner related to the porphyrin catalysts described above. 
Scheme 4.10: Schematic diagram of the strategy for the synthesis of a porphyrin capped 
cyclic peptide 
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Fig 4.1 : Porphyrin capped cyclic peptide target molecules 
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4.4.1 Attempted capping of 5,10,15,20-tetrakis(3-bromomethylphenyDporphyrin 
The syntheses of (149) and (150) were attempted via the convergent strategy (a). 
The reaction scheme for the synthesis of (149) is outlined in Scheme 4.11. 
Scheme 4.11: Reaction scheme for the syntheses of the porphyrin capped cyclic peptide 
molecules (149) and (150) 
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The first step in the synthesis of porphyrin (155) was the formation of aldehyde (154) 
as the precursor to porphyrin formation. This was produced by treating nitrile (153) with 
DIBAL-H. Initially, the solvent used was chlorobenzene as suggested in the literature"'. 
However, due to the high boiling point of chlorobenzene (bp = 132° C) and the resultant 
difficulties experienced in its removal under reduced pressure, dichloromethane (bp = 40° 
C) was used as an alternative solvent. Using this solvent, aldehyde (154) was isolated in 
83 % yield, similar to the 82 % value quoted in the literature214. 
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Fig 4.2 : UV-Vis spectrum of porphyrin (155) 
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An attempt to synthesise porphyrin (155) was made by the Lindsey procedure using 
aldehyde (154) and pyrrole with BF3. Et2O as the Lewis acid catalyst208' 211, z12. The mixture 
was then refluxed using TCQ as oxidant and NEt3 as base. This procedure followed the 
literature precedent given by Bruice's synthesis of the identical porphyrin214. Evidence for 
the successful formation of porphyrin (155) was given by the presence of the expected Soret 
band in the UV-Vis spectrum at 418 nm. The smaller a, P -peaks also had the expected 
values of 451,514,549 and 648 nm. A typical UV-Vis spectrum of the sample is shown 
in Fig 4.2. In addition, the compound gave the predicted [M + H]+ (m/z = 987) molecular 
ion in the FAB mass spectrum. A peak at m/z = 907 indicated loss of Br from the 
molecular ion. However, despite this evidence for its successful production, all attempts at 
its isolation as evidenced by the TLC and UV-Vis spectroscopy were unsuccessful. The 
literature procedure214 suggested a series of solvent extractions using ether and 
dichloromethane followed by crystallisation of the compound from dichloromethane solution 
using methanol. This extraction procedure was repeatedly attempted but could not be 
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successfully reproduced. TLC evidence following each stage of these attempted 
purifications showed that a large number of products were still present in the sample 
mixture. Following the attempted precipitation and then filtration of the porphyrin from 
dichloromethane using methanol, the quantity of porphyrin in the precipitate and the filtrate 
were calculated. The literature value for the molar decadic absorptivity factor (e) of the 
Soret band of the porphyrin is c=3.24 x 10-3 m' W. Based upon this figure, the 
concentrations of porphyrin in the precipitate and the solution were calculated as being 30 
% and 23 %, respectively - not significantly different from the 33 % observed in the crude 
reaction mixture. Both precipitate and filtrate show peaks at m/z = 987 in their FAB mass 
spectra. Varying the ratios of dichloromethane and methanol and cooling the mixture to 0° 
C all failed to precipitate the desired pure porphyrin. Extraction into a selection of other 
solvents such as benzene, toluene, xylene, acetone, ethyl acetate, isopropanol and ethanol 
were attempted, but all failed. Similarly, silica gel column chromatography using 5-20 % 
methanol in dichloromethane as eluant was unsuccessful. Although the desired porphyrin 
was shown by UV-Vis spectroscopy of the column fractions and the presence of an m/z = 
987 peak in the eluted fraction, to be separated from the high proportion of non-porphyrinic 
baseline material, it could not be separated from other uncharacterised material running 
closely to it on the column TLC. The use of alternative column chromatography solvent 
systems such as chloroform : methanol, ether : dichloromethane and ethyl acetate : 40-60 
petroleum ether was equally unsuccessful in further separating these closely running 
compounds. 
An attempt was made to test if changing the oxidant in the synthesis from TCQ to the 
more powerful DDQ oxidant would result in a greater quantity of the desired porphyrin 
being synthesised. If any of the impurities in the above reactions were chlorins, then 
hopefully DDQ would oxidise them to the desired porphyrin. It was hoped that with fewer 
impurities, purification problems would be easier to overcome. In an additional experiment, 
ethanol (0.75 % v/v) was added with the boron trifluoride etherate catalyst. A literature 
precedent212 suggested that the Bronsted acid proton releasing activity of the ethanol, further 
catalysed the reaction of the aldehyde and pyrrole. However, the literature solvent 
extraction method214 described above did not result in successful isolation of the porphyrin 
following either experiment and the same problems as before were encountered in the 
column chromatographic isolation of the required porphyrin (155). 
In order to determine the reason for the failure to isolate porphyrin (155), it is 
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important to know the structures of the inseparable impurities in the reaction mixture. 
However, the use of FAB mass spectrometry and UV-Vis spectroscopy did not allow their 
characterisation. Other than the assigned peaks at m/z = 987 and m/z = 907, no high mass 
peaks were consistently observed in the various FAB mass spectra recorded following the 
different stages of the attempted purification of porphyrin (155). 
The synthesis of the cyclic peptide cyclo-(Lys-Lys-Gly)2 (159) was more successful. 
The cyclic peptide cyclo-(Lys(Z)-Lys(Z)-Gly)2 in which the e-nitrogens of the lysine side 
chains were protected by carbonyl benzyl groups had already been synthesised within the 
group by Dr. John Heffernan221. Following its generous provision, it was treated with a 
palladium on activated carbon catalyst suspended in 2,2,2-trifluoroethanol under a hydrogen 
atmosphere. The resultant product (159) was isolated in quantitative yield and gave a 
single spot by TLC - indicating its purity. The solvent system used for this TLC - 7: 7: 5: 1 
isopropanol : ethanol : water : ammonia - was used because it had been shown by others in 
the laboratory to be effective at moving similar deprotected cyclic peptides on silica gel TLC 
plates. The FAB mass spectrum of this product revealed a significant peak at m/z = 627, 
corresponding to the molecular ion of the desired compound (159) plus hydrogen. The 'H 
NMR spectrum of cyclo-(Lys-Lys-Gly)2 is illustrated in Fig 4.3. Despite the presence of 
solvent peaks from 2,2,2-trifluoroethanol and methanol, coupled doublets from the two 
inequivalent glycyl protons can be seen at 8=3.6 and 8=3.95. Although due to the two- 
fold rotational symmetry of (159), both glycine residues are magnetically equivalent, the two 
a-hydrogens on each glycine are in different environments due to the chirality of the lysine 
side chains. Because of these splittings, the fact that all four lysyl side chains are located 
on one side of the plane of the cyclic peptide can be shown to be the case. In addition, due 
to their location on a chiral carbon, the a-lysyl hydrogens induce magnetic inequivalence 
in the two adjacent hydrogens on the respective lysyl side chains. Thus each a-lysyl 
hydrogen is split into a doublet of doublets rather than the triplet which would have been 
expected if the a-lysyl carbon had been racemic. These doublets are located at 8=4.051, 
4.064,4.204 and 4.218. The fact that two such lysyl multiplets are present, giving 4 
doublets, is again due to the two-fold rotational symmetry of the molecule. These splittings 
are clearly observed in the expansion of the IH NMR spectrum of (159) shown in Fig 4.4. 
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Despite the fact that all attempts to isolate porphyrin (155) had failed, 10 mg of 
authentic (155) was available, having been very generously donated by Professor Bruice in 
California. With the aim of synthesising (150), 5 mg of this porphyrin was reacted with 1 
mol. equiv. of cyclo-(Lys-Lys-Gly)2 in the presence of Cs2CO3 in 1.5 cm3 DMF (1 x 10-3 M). 
However, none of the desired porphyrin capped cyclic peptide (150) was detected by FAB 
mass spectrometry. An ion at m/z = 1289 due to [M + H]' was expected but not observed. 
The reaction mixture was dissolved in 3-nitrobenzylalcohol (NOBA)223 and filtered in an 
effort to remove any polymeric material. However, likewise, no [M + H]+ ion 
corresponding to (150) was observed. A possible cause of the failure of this reaction was 
the inefficient deprotonation of the lysyl primary amines, leading to sluggish nucleophilic 
attack by these amines on the carbon adjacent to each bromide leaving group (Scheme 
4.10). A slow nucleophilic attack would lead to an increased chance of oligomer and 
polymer formation. 
It was felt that a tosyl group might stabilise any anion formed at the e-nitrogen of the 
lysyl side chains (Scheme 4.12), thus encouraging efficient ring closure reactions. 
Scheme 4.12 : Stabilisation of negative charge by the tosyl group 
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&\/ 
synthesised following a similar 
cyclodimerisation procedure to that described in Chapter 3. The four steps of this strategy 
shown in Scheme 4.13, gave an overall yield of this cyclic peptide of 30 %. FAB mass 
spectrometry gave the expected [M + H]* peak at m/z = 1243. The 1H NMR spectrum was 
identical with that of the same compound made by another group member 12`. 
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Scheme 4.13: Synthesis of cyclo-[Lys(Ts)-Lys(Ts)-Gly]2 
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d) Cs2CO3, DMF (sufficient for 5mM concentration 
of activated tripeptide precursor) 
In an attempt to form porphyrin capped cyclic peptide (149), 1 mg of porphyrin (155) 
was reacted with 1 mol. equiv. of cyclo-[Lys(Ts)-Lys(Ts)-Gly]2 in the presence of Cs2CO3 
base. Cyclic peptide and porphyrin were maintained at a concentration of 1x 10-3 M. These 
were similar conditions to those used by Bruice in the formation of his double-decker 
dimeric porphyrins described in Section 4.3214. However, no peak at m/z = 1609, due to 
the [M + H]' peak of the desired porphyrin capped cyclic peptide (149) was detected in the 
FAB mass spectrum, possibly due to the very small scale of the reaction. Any product 
formed would be present in extremely small quantities and might be masked by the presence 
of any polymeric impurities. 
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4.4.2 Attempted capping of 3-chlorosulphonyl-4-methoxyphenylporphyrin 
A convergent strategy was likewise attempted for the synthesis of porphyrin capped 
cyclic peptide (151). The reaction scheme followed is shown in Scheme 4.14. 
Scheme 4.14 : Reaction scheme for the synthesis of the porphyrin capped cyclic peptide 
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Porphyrin (157) was chosen as a suitable substrate with which to cap the cyclic 
peptide cyclo-(Lys-Lys-Gly)2, for three reasons: 
1) The expected ease of formation of a sulphonamide link with the deprotected primary 
amines of the lysine side chains224. 
2) Methodology was already well established for the formation of the tetrakis- 
chlorosulphonyl porphyrin225. 
3) The presence of the ortho-para directing 4-methoxy group substituted on each meso- 
phenyl group of porphyrin (156) would encourage the substitution of the chlorosulphonyl 
group in the 3-position. Molecular modelling shows this to be the best substitution for the 
group to achieve a relatively strain free capping of the cyclic peptide. In addition, because 
the group would not be ortho to the porphyrin ring, the meso-phenyl would be freely 
spinning at room temperature, thus equilibrating any atropisomers226-228. The methoxy 
group would also activate the ring to electrophilic substitution. 
Thus porphyrin (156) - purchased from Aldrich - was dissolved in chlorosulphonic 
acid and was heated to 100°C for 1 h. Following dilution of the acidic solution with ice and 
water, porphyrin (157) was extracted using dichloromethane. During the course of this 
extraction procedure it is common for an emulsion to form. It was found to be important 
that emulsions were broken up using a polar aprotic solvent such as acetonitrile rather than 
a polar, protic solvent such as ethanol. The use of ethanol was shown by FAB mass 
spectrometry to lead to the formation of the ethyl sulphonyl ester . The FAB mass 
spectrum of the desired product showed the expected [M + H]peak at m/z = 1129 as well 
as a fragment ion at m/z = 1029 due to the loss of the chlorosulphonyl group. TLC using 
dichloromethane eluant showed the compound to be pure with one purple spot present at 
Rf= 0.5. The 'H NMR, although broad, was as expected with a singlet at 8= -2.5 due to 
the 2 NH protons, a singlet at 8=4.5 due to the methoxy group, a singlet at 8= 8.5 due to 
the ß-pyrrole protons and the aromatic protons at 6=7.8,9.0 and 9.1 with the splittings 
expected for the phenyl substituents of the desired porphyrin (157). 
In order to model the proposed cyclic peptide capping reaction, porphyrin (157) was 
reacted with butylamine. This amine is related to those of the lysyl side chains in that both 
are primary amines with a C4 straight chain moiety. After optimisation, it was found that 
by stirring 1.2 mol. equiv. of butylamine and 2.5 mol. equiv. of DIPEA (equivalents 
measured per chlorosulphonyl group), in DMF at room temperature, porphyrin (158) was 
synthesised in 11.2 % yield following work up and column chromatography (1-5 % 
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methanol in dichloromethane). Porphyrin (158) gave a [M + H] peak at m/z = 1275 in the - 
FAB mass spectrum and as such provided confirmation of the identity of its precursor (157). 
The 'H NMR spectrum in CDC13 was likewise as expected with the anticipated splittings in 
the aromatic region. Nevertheless, although these splitings were quite distinct, some of the 
peaks were broader than would be desired. It was thought that this broadness was due to 
the formation of stacked porphyrin aggregates. Such species would cause line broadening 
as the magnetic ring current of different porphyrins interacted with each other. Previously, 
such porphyrin aggregates had been broken up and the 'H NMR spectra sharpened by the 
addition of deuterated trifluoroacetic acid to the CDC13 solvent229. The spectrum of the 
starting material, 4-methoxyphenylporphyrin (156), using this solvent system also gave sharp 
peaks. In the spectrum of (158), however, although the expected splittings, for example, 
those due to the methyl groups at the end of the n-butyl side chains, were clear and distinct, 
those due to the aromatic protons remained relatively broad. 
The cyclic peptide used to attempt the synthesis of (151) was the deprotected cyclic 
peptide cyclo-(Lys-Lys-Gly)2 (159), itself produced as described in Section 4.4.1. Cyclic 
peptide (159) (1 mol. equiv. ), porphyrin (157) (1 mol. equiv. ) and DIPEA (8 mol. equiv. ) 
were initially stirred together at RT at a concentration of 0.001 M. The lack of a [M + H]+ 
ion in the FAB mass spectrum showed that this reaction produced none of the desired 
product. It was felt that if the reaction rate was increased, this would favour porphyrin 
capped cyclic peptide formation over the formation of polymers. It was hypothesised that 
once one link between the porphyrin and cyclic peptide had been made, intramolecular 
substitution would rapidly occur before the resultant desired product could encounter other 
molecules. Thus, in order to increase this reaction rate, a reaction with similar 
concentrations of reactants to the above was initiated, with the temperature maintained 
constantly at 50° C. However, this likewise failed to produce the desired product. The 
FAB mass spectrum of the crude product failed to show the expected molecular ion at m/z 
= 1609. 
In a further reaction, a DMF solution of porphyrin (157) was added by syringe pump 
to a DMF solution of cyclic peptide (159) (1 mol. equiv. ) and DIPEA over 12 h. By this 
means it was hoped to reduce the concentration of porphyrin with respect to deprotonated 
cyclic peptide and thus further reduce the likelihood of the formation of polymeric material. 
The reaction mixture was stirred for a further 2 days at 5x 10-3 M, but again FAB mass 
spectrometry failed to show the [M + H]* ion peak of the desired compound (151). A large 
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amount of polymeric material is believed to have been formed - there being an intense 
baseline spot present when the reaction mixture was submitted to TLC with 
dichloromethane as eluant. This baseline, possibly polymeric material was removed by the 
addition of 3-nitrobenzylalcohol and filtration of the mixture. However, the remaining 
material, a faint collection of closely running spots by TLC and amounting to only 4 mg, 
failed to show any reproducible high mass peaks. Further purification of this material by 
column chromatography was not considered feasible in view of the small quantities 
available. In view of the disappointing results described above, it was assumed that none 
of the required product was present. Due to the absence of any reproducible high mass 
peaks in any of the capping reactions using porphyrin (157), none of the material produced 
from the reaction could be characterised. 
In the case of all of the above attempted capping reactions, FAB mass spectrometry 
was a key tool towards detecting (151). However, it is possible that with the large 
quantities of polymeric material formed, any tiny amount of (151) produced would be 
masked by these side products. Unfortunately, the removal of polymeric material by the 
use of NOBA, failed to allow the production of the required molecular ion peak, suggesting 
that at no stage was the desired porphyrin capped cyclic peptide (151) formed. 
A key reason for the failure of these reactions and also the capping reactions in 
Section 4.4.1 is possibly due to the rigidity of the porphyrin ring. Because of the rigid, 
planar nature of the porphyrin ring, the cyclic peptide would need to adopt a precise 
complementary conformation in order to form any porphyrin-capped cyclic peptide. This 
would severely reduce the probability of forming such a product. It is also pertinent to note 
that thus far, no attempt to cap the cyclic peptide cyclo-(Lys-Lys-Gly)2 has succeeded"8. 
The conformational restrictions required of the cyclic peptide in order to successfully 
achieve such a reaction may be too great to synthesise a significant amount of the required 
product. 
4.4.3 Attempted porphyrin synthesis from a cyclic peptide tetraaldehyde 
In a final attempt to synthesise a porphyrin capped cyclic peptide, the derivatisation 
of cyclic peptide cyclo-(Lys-Lys-Gly)2 (159) was attempted so as to form a tetraaldehyde. 
Such a product could theoretically be reacted with a pyrrole by an appropriate method"of 
porphyrin synthesis to form the desired porphyrin capped cyclic peptide (Scheme 4.15). 
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This strategy is analogous to that performed by Baldwin in his synthesis of a capped 
porphyrin (Section 4.3)2". 218 
Scheme 4.15 : Reaction scheme for the synthesis of the porphyrin capped cyclic peptide 
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The aldehyde chosen to react with the cyclic peptide and thus form tetraaldehyde 
(160) was succinimidyl-3-formyl benzoate (161). The succinimidyl ester was found by 
other members of the group193 to be a sufficiently active ester to react efficiently with 
primary amines but not so active as to form significant side products (see Section 2.1.2). 
The 3-isomer of this compound was used in the synthesis because molecular models 
indicated that unlike the 2- and 4-isomers, this isomer would encourage the synthesis of 
porphyrin (152) without undue conformational strain. 
Prior to the attempted synthesis of (160), a model reaction was performed in 
chloroform in which 4.8 mol. equiv. of the cheaper succinimidyl-4-formyl benzoate (163) 
was reacted with cyclo-(Lys-Lys-Gly)2. By using 4.8 mol. equiv. of (163), a slight excess 
of the reagent corresponding to 1.2 mol. equiv. for each of the cyclic peptide's four primary 
amines was employed with a view to driving the reaction to completion. No additional base 
was required as the N-hydroxysuccinimide produced in the reaction acted as the base. 
Succinimidyl-4-formyl benzoate (163) had itself been synthesised according to the 
reaction shown in Scheme 4.16. 
Scheme 4.16: Synthesis of succinimidyl-4-formyl benzoate (163) 
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Using the peptide coupling reagent, EDC, in DMF, the carboxylic acid group of 4- 
carboxybenzaldehyde was activated to nucleophilic substitution from the hydroxyl group of 
N-hydroxysuccinimide. A 39 % yield of the desired succinimidyl-4-formyl benzoate was 
isolated and was characterised by electron impact (EI) mass spectrometry and 'H NMR 
spectroscopy. The EI mass spectrum gave the expected molecular ion at m/z = 247 and a 
larger fragment ion at m/z = 246 due to loss of hydrogen from the aldehyde group to give 
an acylium ion. A large peak at m/z = 133 was probably due to the acylium ion formed 
from the loss of the N-oxysuccinimide group. Both the ions m/z = 247 and 246 gave the 
appropriate accurate mass values. The 'H NMR was as expected for (163) and is shown 
in Fig 4.5. Singlets due to the CH2 protons (8 = 2.89) and the aldehyde (S = 10.06) were 
present along with the two mutually coupled doublets (S = 7.96 and S=8.22) due to the 
para-substituted aromatic group. 
Fig 4.6 : TLC of the products from the reaction of cyclo-(Lys-Lys-Gly)2 (159) and 
succinimidyl-4-formyl benzoate (163) using 19: 1 dichloromethane : methanol as eluant 
solvent front 
" 
direction 
of solvent 
Following the model reaction between (163) and cyclo-(Lys-Lys-Gly)2 described 
above, TLC analysis (19: 1 dichloromethane : methanol) indicated the presence of two 
aldehydic compounds in the product mixture together with aldehydic baseline material (Fig 
4.6). The aldehydic nature of all these compounds was determined by staining with 2,4- 
dinitropheny1hydrazine ethanolic solution. The dominant spot on the TLC plate ran at Rf 
= 0.8 and also co-ran with succinimidyl-4-formyl benzoate, suggesting the presence of a 
large quantity of unreacted starting material in the compound. Indeed, FAB mass 
spectrometry of the crude product showed the presence of a large peak at m/z = 133 due 
173 
to (163). The molecular ion and [M - H]+ peaks of (163) at m/z ='247 and m/z = 246 were 
unfortunately too small to see above the background noise of the FAB mass spectrum. It 
was hoped that the lower running aldehydic spot at Rf = 0.3, which was much fainter than 
the spot due to (163), would be the desired tetraaldehyde product and indeed a small but 
distinct [M + H]+ peak at m/z = 1155 was observed in the FAB mass spectrum. The 
baseline material possibly contained some of the unreacted cyclic peptide tetraamine, 
although the molecular ion of this was not observed in the FAB mass spectrum of the crude 
reaction material. In addition, no molecular ions due to the mono-, di- or tri-substituted 
cyclic peptide were observed. 
The 'H NMR spectrum of the crude product in CDC13 is shown in Fig 4.7. Two 
features are notable: 
a) Aldehyde peaks are present at 6 =10.1 and 6= 10.0, the former having an integration 
8 times that of the latter. 
b) Two para-substituted aromatic patterns are present. The larger one is centred at 6= 
8.1 and the smaller is centred at 6=8.0. As with the aldehyde peaks, the peaks centred 
at 6=8.1 have an integration eight times those at 8=8.0. 
A comparison of the spectrum in Fig 4.7 with that of (163) shown in Fig 4.5, indicates 
that the larger aldehyde and aromatic peaks in the product 'H NMR spectrum are due to the 
starting material (163). It was hoped that the smaller aldehyde and aromatic peaks were 
due to the desired cyclic peptide tetraaldehyde. 
Silica gel column chromatography, with 19: 1 dichloromethane : methanol as eluant, 
was used in the attempt to isolate the desired tetraaldehyde. Unfortunately, separation of 
the two products was not successfully'achieved. A large proportion of both aldehydic 
products was adsorbed onto the silica and in addition, the small amount of material that was 
removed from the column was shown by 1H NMR spectroscopy to contain the same ratio 
of aldehydic and aromatic peaks as the crude product. Even the use of the polar methanol 
liquid ammonia solution as eluant failed to extract this bound product from the column. 
It is possible that some of the benzaldehyde groups'on each compound were autoxidised to 
carboxylic acids, due to their prolonged exposure to air whilst the column was run. These 
carboxylic acid groups would potentially bind to the hydroxyl groups on the silica gel. 
Proof that both aldehydic compounds do slowly bind to the silica gel came from a 2- 
dimensional TLC experiment, in 19: 1 dichloromethane : methanol. The TLC plate wasrun 
in the normal way in one direction and then was run a second time at right angles to the 
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previous direction. Follöwing the second TLC, baseline material from each compound was 
observed - this material having successfully moved up the TLC plate during the first run. 
Altogether, three such model experiments were attempted, two using chloroform as 
the reaction solvent and a third using DMF. However, in all these reactions, similar results 
and problems to those described above were encountered and the cyclic peptide 
tetraaldehyde required was not isolated. 
Despite the failure to isolate the cyclic peptide derivative of (163) described above, 
an attempt was made to synthesise and isolate the cyclic peptide tetraaldehyde (160). A 
batch of succinimidyl-3-formyl benzoate (161) had been synthesised within the group193 and 
following its generous provision, this was used to attempt the preparation of (160). 
In the first attempt to prepare cyclic peptide (160), cyclo-(Lys-Lys-Gly)2 (159) was 
reacted with 4.8 mol. equiv. of (161). The solvent used was d7-DMF. After stirring the 
mixture for 3 days under argon, the 'H NMR spectrum of the crude reaction mixture 
showed, as with the model reactions, two aldehydic peaks at 8= 10.0 and 8= 10.1. 
However, unlike the model reactions, the peak at the lower chemical shift, 8= 10.0, was 
larger than that at 8= 10.1 by a factor of 3. This suggests that, if the peaks are assigned 
in the same way as in the earlier reactions described above, with the peak at 8= 10.0 being 
due to the cyclic peptide tetraaldehyde and that at S= 10.1 being due to the starting 
aldehyde (161), the reaction equilibrium has been driven further towards the products. 
However, because the S= 10.0 peak is due to a species containing four aldehydic groups, 
there is still a larger amount of (161) than (160). 
The reaction TLC, using 19: 1 dichloromethane : methanol as eluant, was similar to 
those of the model reactions, in that two aldehydic spots at Rf = 0.8 and 0.3 as well as an 
aldehydic baseline spot were present. Again, because the reaction was incomplete, it was 
assumed that any cyclic peptide starting material (159) or mono-, di- or tri-substituted cyclic 
peptide would remain on the TLC baseline due to their possession of polar primary amine 
groups. 
An attempt was made to isolate the desired tetraaldehyde from the starting material 
(161) by washing the mixture three times with toluene. It was previously observed that 
(161) could be dissolved in toluene and it was assumed that in a similar manner to other 
peptidic compounds, cyclic peptide (160) would remain insoluble in toluene. Unfortunately, 
this attempted purification method was unsuccessful. The TLCs of the toluene washings 
as well as the product residue, showed that both aldehydic compounds at Rf = 0.8 and 0.3 
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had been removed by the toluene. An attempt to drive this reaction to completion by the 
addition of caesium carbonate base was likewise unsuccessful. It was thought that the base 
would deprotonate the primary amines of the cyclic peptide (159), enhancing their 
nucleophilicity and encouraging their reaction with (161). This reaction was allowed to stir 
under argon for 2 days. However, the reaction mixture TLC showed no significant 
depletion of the spot at Rf = 0.8 due to (161) with respect to that at Rf= 0.3. Likewise, 
following removal of the base by filtration, the ratios of the aldehydic and aromatic peaks 
in the 'H NMR remained unaltered. 
In a second attempt to prepare cyclic peptide (160), cyclo-(Lys-Lys-Gly)2 (159) was 
again reacted with 4.8 mol. equiv. of (161). However, unlike in the earlier reaction, the 
solvent used was CDC13, with 5 mol. equiv. of DIPEA base added to try to drive the 
reaction to completion. 
Unfortunately, the `H NMR spectrum, on the basis of the aldehydic peaks at 8= 10.0 
and S= 10.1, again suggested the presence of both the desired product (160) and the 
aldehydic starting material (161). However, unlike the earlier attempt to prepare (160), the 
integrations of the peaks were equal, suggesting a reduction in the amount of (160) 
prepared. Despite the presence of extra base, the reason for this is possibly due to reduced 
polarity of the CDC13 solvent compared to d7-DMF, reducing the likelihood of the polar by- 
product N-hydroxysuccinimide from forming. 
A repeated attempt to remove the starting material by washing with toluene was, as 
before, unsuccessful. Aqueous sodium hydrogen carbonate solution was used to try to 
selectively remove starting material. It was hoped that by using this basic aqueous solution, 
the ester bonds of the starting material would be hydrolysed (Scheme 4.17). The acidic 
products from this hydrolysis, 3-carboxybenzaldehyde (164) and N-hydroxysuccinimide 
(165) would, hopefully, be soluble within the NaHCO3 solution and would be selectively 
removed from a solution of cyclic peptide in dichloromethane by a simple aqueous wash. 
The amide bonds of any (160) that had been formed would be stable to this weak aqueous 
base. 
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Scheme 4.17: Hydrolysis of succinimidyl-3-formyl benzoate (161) 
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The reaction mixture was washed three times with saturated sodium hydrogen 
carbonate solution for 45 min, after a previous experiment had shown that it takes such a 
length of time for (161) to dissolve in this solution. 
Following the aqueous wash, however, TLC (19: 1 dichloromethane : methanol) of the 
residual product material as well as TLC of the aqueous washings showed that all the 
material had remained on the baseline and that the spots at Rf = 0.3 and 0.8 had been lost. 
'H NMR spectroscopy in CDC13 (with a trace of CD3OD to aid solubility) confirmed that 
most of the aldehydic material had been lost. It is not clear why this occurred, but it is 
possible that whilst in solution the benzaldehyde derivatives were autoxidised to benzoic 
acid derivatives. The high polarity of this material would explain why it remained on the 
baseline of the TLC plate. The lack of carboxylic acid peaks in the 'H NMR would be 
explained by the presence of CD3OD in the 1H NMR solvent. 
A reaction was tried with remaining unpurified tetraaldehyde (160) to see if any of the 
desired porphyrin capped cyclic peptide (152) could be formed despite the presence of the 
starting aldehyde (161). It was felt that because the formation of (152) involves the linking 
of aldehydes on the same molecule ("intramolecular") as opposed to the intermolecular 
porphyrin synthesis involving (161), if the reaction was performed at high dilution, some of 
the desired porphyrin (152) might form. Thus 50 mg of the mixture of tetraaldehyde (160) 
and aldehyde (161) were heated in the presence of 12 mg of pyrrole in 5 ml propionic acid 
to 141° C. Unfortunately, the lack of a Soret band at about 420 nm in the UV-Vis 
spectrum, showed that no porphyrin had been formed. 
As a result of these failures and due to lack of time, the attempt to synthesise the 
porphyrin capped cyclic peptide by the above procedure was likewise abandoned. 
CHO 0 
a) i 
+ HO-N 
CO2H 
0 
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4.5 Summary 
None of the target molecules (149) to (152) were successfully synthesised. In the 
case of (149) and (150), this was due to problems encountered in the purification of the 
required porphyrin precursor (155). With (151), failure was due to unsuccessful capping 
of the cyclic peptide by the porphyrin (157). Synthesis of (152) failed due to problems in 
the purification of the required tetraaldehyde precursor (160). 
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CHAPTER 5: 
EXPERIMENTAL 
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5. Experimental 
5.1 General 
5.1.1 Instrumentation/physical methods 
NMR spectra were recorded at the University of York using Bruker MSL 300 (300 
MHz, 'H; 75 MHz, 13C), JEOL EX 270 (270 MHz, 'H; 67.5 MHz, 13C), JEOL FX90Q (90 
MHz, 'H; 22.5 MHz, 13C), Bruker WP80SY (80 MHz, 'H) or Varian EM360A (60 MHz, 
'H) spectrometers. At Heriot-Watt University, NMR spectra were recorded using Bruker 
DPX400 (400 MHz, 'H; 100 MHz, 13C), Bruker AC200 (200 MHz, 'H; 50 MHz, "C), 
Bruker WP200 (200 MHz, 'H; 50 MHz, 13C) or Bruker WP80SY (80 MHz, 'H) 
spectrometers. Chemical shifts were measured on the 8 scale using tetramethylsilane as the 
internal standard. 
Infra-red spectra were recorded on a Perkin-Elmer 1605 FTIR machine. Melting 
points were measured using a Gallenkamp melting point apparatus and are uncorrected. 
Mass spectra were recorded at York using a VG AUTOSPEC spectrometer (both EI 
and FAB) and at Heriot-Watt using a VGMS9 spectrometer (again both EI and FAB). 
UV-Vis spectra were recorded at room temperature on a Hewlett Packard 8452A 
diode array spectrometer and analysed using a Hewlett Packard HP9500 UV-Vis 
ChemStation. A1 cm pathlength quartz cuvette was used. 
Elemental analyses were conducted at Napier University and at Zeneca 
Pharmaceuticals Ltd. 
Syringe pump additions were conducted using a B. Braun Perfusor Securor FT 
instrument and a machine designed and built by Mr. Bill Stirling, Technical Services, 
Department of Chemistry, Heriot-Watt University. 
5.1.2 Chromatography 
Analytical TLC was carried out on Merck aluminium sheet silica gel 60 F254 plates. 
A variety of solvent systems were used and are indicated in the text with the relevant 
compounds. Visualisation was generally achieved under UV light (254 nm), treating with 
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iodine vapour or by using one of the following dyeing reagents. 
a) Ninhydrin. A solution of ninhydrin (0.3 g) in butan-l-ol (100 cm) and glacial 
ethanoic acid (3 cm') was used. Free amino groups gave purple or brown spots following 
the heating of the TLC plate. 
b) Phosphomolybdic acid. A filtered solution of phosphomolybdic acid (5 % v/v) in 
absolute ethanol was used. Compounds gave blue spots on yellow backgrounds. 
c) 2,4-Dinitrophenylhydrazine. A solution of 2,4-dinitrophenylhydrazine (1 g) in 
sulphuric acid (37 %, 10 cm3) and ethanol (1000 cm) was used. Compounds with 
aldehydic groups gave orange, brown spots following heating of the TLC plate. 
Flash chromatography was performed using silica gel 60 (purchased from Camlab). 
Approximately 20 g of silica was used for every gram of material to be purified230. 
HPLC was performed on a Bio-rad 1330 HPLC with UV detection. The column 
used was a Spherisorb 50D52C18 reverse-phase column. 
5.1.3 Solvents and Reagents 
When purified solvents were used, they were purified as described below. Otherwise 
standard laboratory grade solvents were used except for methanol (AR), acetonitrile (HPLC 
grade), acetone (AR), N, N-dimethylformamide (anhydrous), ethanol (AR) and ethyl acetate 
(AR). 
Dichloromethane and chloroform were pre-dried over calcium chloride and distilled 
from phosphorus pentoxide. 
Toluene and diethyl ether were dried over sodium. 
Tetrahydrofuran was distilled from sodium under argon gas. 
Deuterated NN-dimethylformamide was supplied by Goss Scientific Instruments Ltd. 
Reagents were used as purchased unless preliminary TLC indicated the need for 
distillation or recrystallisation from appropriate solvents. 
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5.2 Experimental relating tos chapter 2 
5 . 2.1 Addition of t-butoxycarbonyl protecting group to 
lysine 
Preparation of N- a-t-butoxycarbonyl-N e-toluenesulphonyl-lysine (97) 
Boc-Lys(Ts)-OH 
A solution of N-E-toluenesulphonyl-lysine (1.12 g 3.73 mmol) in tetrahydrofuran (7.5 
cm3), water (3.7 cm3) and 1M NaOH (3.7 cm) was cooled in an ice-water bath. Di-tert- 
butyl pyrocarbonate was added and the stirring was continued at room temperature for 1 
h. The solution was concentrated under reduced pressure to 3.5 cm3, cooled in an ice- 
water bath, covered with a layer of ethyl acetate (20 cm3) and acidified with a dilute solution 
of KHSO4 to pH 2-3. The aqueous phase was extracted with ethyl acetate (20 cm3 x 2). 
The ethyl acetate extracts were combined, washed with water (20 cm3 x 2) dried over 
anhydrous Na2SO4 and the solvent removed under reduced pressure. Flash column 
chromatography (1- 10 % methanol in dichloromethane) yielded 434 mg (33 %) of a clear 
oil. 
'H NMR (CDC13, RT, 200 MHz); 
8/ppm 1.3 - 1.8 (m, 6H, CH2CH2CH2CH2N), 1.649 (s, 9H, C(CH3)3), 2.408 (s, 3H, 
CH3, Ts), 2.903 (m, 2H, CH2NHTs), 4.263 (m, 1H, a-CH, Lys), 5.391 (m, 1H, NH), 5.537 
(m, 1H, NH), 7.29 (d, 2H, J=8.15 Hz, CH, Ts), 7.73 (d, 2H, J=8.15 Hz, CH, Ts), 9.3- 
10.7 (s, br, 1H, COOH) 
13C NMR (CDC13, RT, 50 MHz); 
8/ppm 21.389 (CH3, Ts), 22.092 (CH2, Lys), 28.196 (CH3, Boc), 28.715,31.647, 
(CH., Lys), 42.593 (CH2NHTs), 53.091 (CH, Lys), 80.076 (C, Boc), 126.947,129.592 
(CH, Ts), 136.673,143.222 (C, Ts), 155.765 (C=O, Boc), 176.465 (C=O) 
MS FAB+ve (NOBA matrix) C18H28N206S M+ calculated as 400 
m/z = 401 [M + H]+, 301 [M - Boc]+, 255 [M - Boc - COOH]* 
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IR, ums, cm' (KBr disc) 
3288.2 (br), 1725.9,1517.5,1368.3,1322.5,1157.5,1093.1,857.3,815.1,733.7, 
662.2 
Rf 2: 1: 17 (methanol : acetic acid : chloroform): 0.35 
mp (° C): oil 
5.2.2 General methods in peptide synthesis 
5.2.2.1 General method for peptide couplings using EDC/HOBt peptide coupling 
reagents 
The N-a-protected amino acid/peptide together with 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide hydrochloride (1 mol. equiv. ) and 1-hydroxybenzotriazole (1 mol. equiv. ) 
were dissolved in NN-dimethylformamide under argon and the mixture stirred for 1h at 0° 
C followed by 40 min at room temperature. After re-cooling to 00 C, the amino component 
and N, N-diisopropylethylamine (10 % v/v of DMF, pH 9) in N, N-dimethylformamide were 
added and the stirred mixture allowed to warm up slowly to room temperature. Once the 
reaction had gone to completion as shown by TLC, the N, N-dimethylformamide was 
removed under reduced pressure with residual solvent being removed by forming an 
azeotrope with toluene (5 cm3 x 3). The resultant solid was dissolved in dichloromethane 
and the solution washed with 2x saturated NaHCO3,0.7 M citric acid, distilled water and 
2x saturated brine. The organic layer was then dried over MgSO4, filtered and the solvent 
removed under reduced pressure. The resultant solid was triturated in hexane and diethyl 
ether and the solvents removed under reduced pressure to yield the required product as a 
white solid. 
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5.2.2.2 N-t-butoxycarbonyl deprotection 
The protected peptide was dissolved in 90 % trifluoroacetic acid in 10 % water and 
stirred at room temperature for approximately 1h or until the starting material had 
disappeared as shown by TLC. The solvent was removed under reduced pressure and any 
residual solvent removed by forming an azeotrope 3 times with toluene. Each time toluene 
was removed under reduced pressure. The oily product was triturated with diethyl ether 
until a white solid was formed. This was not characterised but was used immediately. For 
general coupling the trifluoroacetate salt was dissolved in N, N-dimethylformamide with 
sufficient N, N-dimethylformamide to give an apparent pH 9. This solution was then added 
at 0°C to the relevant reaction mixture. 
5.2.3 Peptide couplings 
Preparation of N- a-t-butoxycarbonyl-N c toluenesulphonyl-lysyl-glycine-methyl-ester 
Boc-Lys(Ts)-Gly-OMe 
Using DCC/HOBt as peptide coupling reagents 
N-a-t-Butoxycarbonyl-N-e-toluenesulphonyl-lysine (550 mg, 1.375 mmol), 1- 
hydroxybenzotriazole (186 mg, 1.375 mmol) and dicyclohexylcarbodiimide (283 mg, 1.375 
mmol) were dissolved in N, N-dimethylformamide (3 cm) and the mixture stirred for 1h at 
0°C followed by 40 min at room temperature. The mixture was re-cooled to 0°C before 
the addition of glycine methyl ester (172 mg, 1.375 mmol) dissolved in N, N- 
dimethylformamide (3 cm) (with N, N-diisopropylethylamine added to give an apparent pH 
9). The mixture was then allowed to slowly warm up to room temperature. Once the 
reaction had gone to completion as shown by TLC, the solvent was removed under reduced 
pressure with residual solvent being removed by forming an azeotrope with toluene (5 cm3 
x 3). The toluene was removed under reduced pressure. The dipeptide was dissolved in 
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ethyl acetate (30 cm3) and undissolved dicyclohexylurea removed by filtration. The solution 
was washed with 2x sat. NaHCO3,0.7 M citric acid, distilled water and 2x sat. brine. The 
organic layer was then dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The resultant solid was triturated in hexane and diethyl ether and then the solvents 
removed under reduced pressure to yield 525 mg (81 %) of the required dipeptide as a white 
solid. 
N-a-t-Butoxycarbonyl-N-e-toluenesulphonyl-lysine (550 mg, 1.375 mmol), 1- 
hydroxybenzotriazole (186 mg, 1.375 mmol) and 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide hydrochloride (264 mg, 1.375 mmol) were dissolved in N, N- 
dimethylformamide (3 cm) and the mixture stirred for 1h at 00 C followed by 40 min at 
room temperature. The mixture was re-cooled to 0°C before the addition of glycine methyl 
ester (172 mg, 1.375 mmol) dissolved in NN-dimethylformamide (3 cm) (with N, N- 
diisopropylethylamine added to give an apparent pH 9). The mixture was allowed to slowly 
warm up to room temperature. Once the reaction had gone to completion as shown by 
TLC, the solvent was removed under reduced pressure with residual solvent being removed 
by forming an azeotrope with toluene (5 cm3 x 3). The toluene was removed under reduced 
pressure. The dipeptide was disssolved in dichloromethane (50 cm) and the solution was 
washed with 2x sat. NaHCO3 0.7 M citric acid, distilled water and 2x sat. brine. The 
organic layer was then dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The resultant solid was triturated in hexane and diethyl ether and then the 
solvents removed under reduced pressure to yield 536 mg (83 %) of the required dipeptide 
as a white solid. Data agreed with the literature values given in brackets [ ]120. 
'H NMR (CDC13, RT, 200 MHz); [(CDCI3, RT, 90 MHz)]; 
6/ppm 1.3-1.8 [1.20-1.80] (m, 6H, CH2CH2CH2CH2N), 1.645 [1.411] (s, 9H, 
C(CH)3), 2.417 [2.417] (s, 3H, CH3, Ts), 2.892 [2.915] (t, 2H, J=6.14 Hz, CH2NHTs), 
3.738 [3.718] (s, 3H, OCH), 4.0-4.2 [4.0-4.1] (m, 3H, CH2, Gly, a-CH, Lys), 5.40 [5.46] 
(m, 2H, NH), 6.99 (m, br, 1H, NH), 7.29 [7.30] (d, 2H, J=8.27 Hz [8.2], CH, Ts), 7.73 
[7.72] (d, 2H, J=8.27 Hz [8.2], CH, Ts) 
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13C NMR (CDC13, RT, 50 MHz); [(CDC13, RT, 22.5 MHz)]; 
S/ppm 21.410 [21.210] (CH3, Ts), 22.106 [22.224] (CH2, Lys), 28.201 [28.186] 
(CH3, Boc), 28.775,31.835 [28.947,31.887] (CH2, Lys), 40.965,42.572 [41.101,42.895] 
(CH2 Gly; CH2NHTs), 52.320 [52.212] (OCHS), 53.889 [54.224] (CH, Lys), 80.029 
[80.460] (C, Boc), 128.937,129.573 [127.001,129.652] (CH, Ts), 136.859,143.148 
[136.945,143.189] (C, Ts), 155.835 [155.460] (C=O, Boc), 170.243,172.498 [170.002, 
172.614] (C=O) 
MS FAB+ve (NOBA matrix) C21H33N307S M'calculated as 471.2 
m/z: 472 [M + H]+, 372 [M - Boc]* 
MS FAB+ve (NOBA matrix) [M + H]' accurate mass 
Calculated 472.2117 
Found 472.2113 
IR, u... cm' (KBr disc); 
3412.4,2933.3,1753.5,1666.5,1617.6,1525.5,1438.4,1367.5,1325.9,1211.9, 
1159.6,1093.9,816.0,661.8 
Rf 2: 17: 1 (methanol : chloroform : acetic acid) 0.57 [0.57] 
19: 1 (dichloromethane : methanol): 0.4 
mp (° C): 140-145 [142-146] 
186 
Preparation of N a-t-butoxycarbonyl-N c toluenesulphonyl-lysyl-N E-toluenesulphonyl- 
lysyl-glycine-methyl-ester (99) 
Boc-Lys(Ts)-Lys(Ts)-GIy-OMe 
N-a-t-Butoxycarbonyl-N-E-toluenesulphonyl-lysyl-glycine-methyl-ester (517 mg, 1.1 
mmol) was dissolved in 90 % trifluoroacetic acid in 10 % water and stirred at room 
temperature for approximately 1h or until the starting material had disappeared as shown 
by TLC. The solvent was removed under reduced pressure and any residual solvent 
removed by forming an azeotrope 3 times with toluene. Each time the toluene was 
removed under reduced pressure. The oily product was triturated with diethyl ether until 
the trifluoroacetic acid salt was formed as a white solid. This was dissolved in N, N- 
dimethylformamide (3 cm3), N, N-diisopropylethylamine was added to give an apparent pH 
9 and the solution cooled to 0° C. 
N-a-t-Butoxycarbonyl-N-e-toluenesulphonyl-lysine (440 mg, 1.1 mmol), 1- 
hydroxybenzotriazole (149 mg, 1.1 mmol) and dicyclohexylcarbodiimide (226 mg, 1.1 
mmol) were dissolved in N, N-dimethylformamide (3 cm) and the mixture stirred for 1h at 
0°C followed by 40 min at room temperature. The mixture was re-cooled to 0° C and then 
the above solution of N-e-toluenesulphonyl-lysyl-glycine-methyl-ester trifluoroacetic acid 
salt was added. The mixture was allowed to slowly warm up to room temperature. Once 
the reaction had gone to completion as shown by TLC the solvent was removed under 
reduced pressure with residual solvent being removed by forming an azeotrope with toluene 
(5 cm3 x 3). The toluene was removed under reduced pressure. The tripeptide was 
dissolved in ethyl acetate (30 cm) and undissolved dicyclohexylurea removed by filtration. 
The solution was washed with 2x sat. NaHCO3,0.7 M citric acid, distilled water and 2x 
sat. brine. The organic layer was then dried over MgSO4, filtered and the solvent removed 
under reduced pressure. The resultant solid was triturated in hexane and diethyl ether and 
then the solvents removed under reduced pressure to yield 646 mg (78 %) of the required 
tripeptide as a white solid. 
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N-a-t-Butoxycarbonyl-N-e-toluenesulphonyl-lysyl-glycine-methyl-ester (517 mg, 1.1 
mmol) was dissolved in 90 % trifluoroacetic acid in 10 % water and stirred at room 
temperature for approximately 1h or until the starting material had disappeared as shown 
by TLC. The solvent was removed under reduced pressure and any residual solvent 
removed by forming an azeotrope 3 times with toluene. Each time the toluene was 
removed under reduced pressure. The oily product was triturated with diethyl ether until 
the trifluoroacetic acid salt was formed as a white solid. This was dissolved in N, N- 
dimethylformamide (3 cm3), N, N-diisopropylethylamine was added to give an apparent pH 
9 and the solution was cooled to 0° C. 
N-a-t-Butoxycarbonyl-N-E-toluenesulphonyl-lysine (440 mg, 1.1 mmol), 1- 
hydroxybenzotriazole (149 mg, 1.1 mmol) and 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide hydrochloride (211 mg, 1.1 mmol) were dissolved in N, N- 
dimethylformamide (3 cm3) and the mixture stirred for 1h at 0° C followed by 40 min at 
room temperature. The mixture was re-cooled to 0° C and then the above solution of N-e- 
toluenesulphonyl-lysyl-glycine-methyl-ester trifluoroacetic acid salt was added. The 
mixture was allowed to slowly warm up to room temperature. Once the reaction had gone 
to completion as shown by TLC, the solvent was removed under reduced pressure with 
residual solvent being removed by forming an azeotrope with toluene (5 cm3 x 3). The 
toluene was removed under reduced pressure. The tripeptide was dissolved in 
dichloromethane (50 cm3) and the solution was washed with 2x sat. NaHCO3,0.7 M citric 
acid, distilled water and 2x sat. brine. The organic layer was then dried over MgSO4, 
filtered and the solvent removed under reduced pressure. The resultant solid was triturated 
in hexane and diethyl ether and then the solvents removed under reduced pressure to yield 
671 mg (81 %) of the required tripeptide as a white solid in 81 % yield. Data agreed with 
the literature values given in brackets [] 120. 
1H NMR (CDC13, RT, 270 MHz); [(CDC13, RT, 300 MHz)] 
S/ppm 1.2-1.9 [1.32-1.60] (m, 12H, CH2CH2CH2CH2N), 1.392 [1.412] (s, 9H, 
C(CH3)3), 2.414 [2.401] (s, 6H, CHs Ts), 2.90 [2.90] (m, br, 4H, CH VHTs), 3.707 
[3.695] (s, 3H, OCH3), 4.016 [4.018] (m, 2H, CH2, Gly), 4.153 [4.175] (m, 1H, Lys a- 
CH), 4.507 [4.500] (m, 1H, Lys a-CH), 5.581 [5.618] (m, br, 1H, NH), 5.722 [5.836] (m, 
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br, 1H, NH), 5.819 [5.910] (m, br, 1H, NH), 7.26 [7: 223] (m, br, 111, NH), 7.287 [7.281] 
(d, 4H, J=7.9 Hz [8.2], CH, Ts), 7.419 [7.426] (m, br, 1H, NH), 7.727 [7.735] (d, 4H, J 
= 7.9 Hz [8.2], CH, Ts) 
13C NMR (CDC13, RT, 67.90 MHz); [(CDC13, RT, 75 MHz)] 
S/ppm 21.518 [21.750] (CH3, Ts), 21.839,22,273 [22.157,22.710] (CH2, Lys), 
28.294 [28.610] (CH3, Boc), 28.671,30.502,31.559,33.352 [28.655,31.108,31.901, 
33.892] (CH2, Lys), 41.204,41.959,42.714 [41.161,42.113,42.810] (CH29 Gly; 
CH2NHTs), 52.260 [52.242] (OCH), 53.190,54.851 [53.110,54.701] (CH, Lys), 80.333 
[80.014] (C, Boc), 126.954,127.049,129.710 [126.928,129.810] (CH, Ts), 136.882, 
136.996,143.300 [137.002,143.003] (C, Ts), 156.267 [156.004] (C=O, Boc), 170.291, 
172.500,173.104 [170.165,172.310,172.996] (C=O) 
MS FAB+ve (NOBA matrix) C34H51N5010S2 M+ calculated as 753.3 
m/z: 886 [M + Cs]+, 776 [M + Na]+, 754 [M + H]*, 654 [M - Boc]' 
MS FAB+ve (NOBA matrix) [M + H]+ accurate mass 
Calculated 754.3156 
Found 754.3153 
Elemental analysis (%) 
Calculated C 54.17 H 6.82 N 9.29 
Found C 54.29 H 6.80 N 9.27 
IR, Umax, cm 1(KBr disc); 
3413.0,2930.2,1638.6,1617.0,1526.3,1367.8,1324.1,1158.2,1093.9,816.1 
Rf 2: 37: 1 (methanol : chloroform : acetic acid) 0.68 [0.68] 
19: 1 (dichloromethane : methanol): 0.3 
mp (° C): 148-152 [151-154] 
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5.2.4 Synthesis of crosslinkers 
Preparation of 4,4'-bis-hydroxymethylbiphenyl (112) 
OH 
HO 
Diethyl biphenyl-4,4'dicarboxylate (5 g, 16.8 mmol) in tetrahydrofuran (120 cm3) was 
stirred at room temperature under argon. The reaction mixture was cooled to 0° C and 
lithium aluminium hydride (2.55 g, 67.2 mmol) was added. Stirring was continued for 16 
h until shown to be complete by TLC. The reaction was quenched with H2O (3 cm) and 
2M NaOH (10 cm). More water (10 cm3) was added and the precipitated inorganic by- 
products removed by filtration. The solvent was removed under reduced pressure and any 
residual water was removed by forming an azeotrope with toluene (5 cm3 x 3). The toluene 
was removed under reduced pressure to yield 3.52 g (98 %) of a white solid. Data agreed 
with the literature values given in brackets [ ]120. 
'H NMR (d6-DMSO, RT, 270 MHz); [(d6-DMSO, RT, 250 MHz)] 
8/ppm 4.63 [4.56] (s, 4H, CH2OH), 5.35 (s, br, 2H, CH2OH), 7.48 [7.49] (d, 4H, i 
= 8.01 Hz, CH, biphenyl), 7.70 [7.61] (d, 4H, J=8.01 Hz, CH, biphenyl) 
13C NMR (d6-DMSO, RT, 67.90 MHz); [(d6-DMSO, RT, 62.5 MHz)] 
8/ppm68.641 [68.191] (CHZOH), 126.250 [130.186] (CH, Ar), 127.024 [131.895] 
(CH, Ar), 128.481 [130.002] (C, Ar), 131.614 [132.011] (C, Ar) 
MS EI C14HI402 M* calculated as 214 
m/z: 214 [M]+, 197 [M - OH]+9 183 [M - CH2OH] , 165 [M - CH2OH - OH] ; 77 
[C6H5]' 
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MS EI M+ accurate mass 
Calculated 214.0994 
Found 214.0999 
IR u., cm' (Nujol mull) 
3270,2956,2855,1661,1562,1463,1378,1208,1048,1012,848,803 
Rf 3: 2 (40: 60 petroleum ether : ethyl acetate) 0.30 [0.30] 
1: 1 (40: 60 petroleum ether : ethyl acetate) 0.40 
mp (° C): 113-115 [114-116] 
Preparation of 4,4'-bis-bromomethylbiphenyl (113) 
- 
Br 
/ \ 
\ / 
Br 
4,4'-Bis-hydroxymethylbiphenyl (3.60 g, 16.8 mmol) and carbon tetrabromide (11.17 
g, 33.6 mmol) in acetonitrile (250 cm) were stirred at room temperature under argon. 
Triphenylphosphine (8.81 g, 33.6 mmol) was added and the stirring continued for 24 h, until 
shown to be complete by TLC. The solvent was removed under reduced pressure and flash 
column chromatography (using gradient elution from 19: 1 40-60 petroleum ether : ethyl 
acetate to 3: 2 40-60 petroleum ether : ethyl acetate) yielded 4.23 g (75 %) of a white solid. 
Data agreed with that obtained from a previously prepared authentic sample [] 120. 
lH NMR (CDC13, RT, 270 MHz); [(d6-DMSO, RT, 200 MHz)] 
8/ppm 4.54 [4.67] (s, 4H, CH2Br), 7.46 [7.56] (d, 4H, CH, biphenyl, J=8.24 Hz), 
7.55 [7.69] (d, 4H, CH, biphenyl, J=8.24 Hz) 
191 
13C NMR (CDC13, RT, 67.90 MHz); [(d6-DMSO, RT, 50 MHz)] 
S/ppm 33.239 [39.163] (CH), 127.502 [133.085] (CH, biphenyl), 129.578 [133.476] 
(CH, biphenyl), 137.109 [134.947] (C, biphenyl), 140.563 [134.624] (C, biphenyl) 
MS EI C14H12Br2 M+ calculated as 339.9 (79Br, 81Br) 
m/z 342 [M]+ (281Br), 340 [M]+ (81Br, 79Br), 338 [M]' (279Br), 261 [M - 79Br] `, 259 
[M - "Br]', 180 [M - 2Br]+ 
MS EI C14H1279Br2 M+ accurate mass 
Calculated 337.9306 
Found 337.9313 
IR, Umax, Cm' (KBr disc); 
1636.9,1497.3,1436.4,1398.1,1227.4,1204.0,1120.0,1002.8,825.9,797.6,751.1, 
721.4,697.1 
Rf 5: 2 (40: 60 petroleum ether : ethyl acetate) 0.80 [0.78] 
19: 1 (40-60 petroleum ether : ethyl acetate) 0.65 
mp (° C) 89-91 [89-92] 
Preparation of 1,2-(bis-2-tosylethoxy)ethane (118) 
TsO 00 OTs 
Triethylene glycol (4 g, 26.7 mmol), tosyl chloride (15.24 g, 0.08 mmol), triethylamine 
(16.16 g, 0.16 mmol) and a catalytic amount of 4-N, N-dimethylaminopyridine (DMAP) 
were stirred in dichloromethane (200 cm) at 00 C under argon. The reaction mixture was 
allowed to warm up to room temperature and stirred for 16 h until shown to be complete 
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by TLC. The reaction mixture was washed with 2M hydrochloric acid (100 cm), sat. 
NaHCO3 (100 cm3), distilled water and sat. brine. The organic layer was dried over 
MgSO4, filtered and the solvent removed under reduced pressure. Flash column 
chromatography (1: 140-60 petroleum ether : ethyl acetate) of the resultant solid gave 9.65 
g (79 %) of a white solid. 
'H NMR (CDCl3, RT, 270 MHz); 
S/ppm 2.45 (s, 6H, CH3, Ts), 3.53 (s, 4H, TsOCH2CH2OCH2-), 3.65 (t, 4H, J=4.7 
Hz, TsOCH2CH2O-), 4.14 (t, 4H, J=4.7 Hz, TsOCH2CH2O-), 7.34 (d, 4H, CH, Ts, J= 
8.3 Hz), 7.79 (d, 4H, CH, Ts, J=8.3 Hz) 
13C NMR (CDCI3, RT, 67.90 MHz); 
8/ppm 21.631 (CH3, Ts), 68.724,69.196,70.668, (CH2, glycol), 127.955,129.861 
(CH, Ts), 132.919,144.867 (C, Ts) 
MS FAB+ve (NOBA matrix) C, 20H26O$S2 M+ calculated as 458 
m/z 481 [M + Na]+, 459 [M + H]+, 155 [Ts]`, 91 [PhCH2];, 77 [Ph)' 
MS FAB+ve (NOBA matrix) [M + H]+ accurate mass 
Calculated 459.1147 
Found 459.1143 
IR, u., cm i (KBr disc) 
2897.2,1596.4,1352.7,1261.4,1172.0,1132.6,1016.1,982.4,911.9,851.1,804.8, 
778.8,665.1 
Rf 1: 1 (40-60 petroleum ether : ethyl acetate) 0.5 
mp (° C) 80-82 
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5.25 General procedure for crosslinking reactions 
The methods described below are the optimised conditions developed for the 
crosslinking of tripeptide (99) 
5.2.5.1 Using syringe pump 
Caesium carbonate (5 mol. equiv. ) was stirred in N, N-dimethylformamide under 
argon. Water (ca. 35 moL equiv. ) was added followed by tripeptide (1 mol. equiv. ). The 
crosslinker (1 mol. equiv. ) in N, N-dimethylformamide was added over approximately 24 h 
using a syringe pump. In order to ensure completeness, more crosslinker (2 x 0.5 mol. 
equiv. ) in NN-dimethylformamide was added over approximately 12 h using a syringe 
pump. The reaction mixture was stirred for a further 24 h before being filtered to remove 
the caesium carbonate. The solvent was removed under reduced pressure. Ethyl acetate 
was added and the mixture filtered to remove any remaining caesium carbonate. The 
solution was washed with water (x 2) and sat. brine (x 2), dried over MgSO4, filtered and 
the solvent removed under reduced pressure. The crude product was purified by flash 
column chromatography. 
5.2.5.2 Without syringe pump 
The caesium carbonate (5 mol. equiv. ) was stirred in N, N-dimethylformamide under 
argon. Water (ca. 35 mol. equiv. ) was added followed by tripeptide (1 mol. equiv. ) and 
crosslinker (1 mol. equiv. ). After 24 h, more crosslinker (0.5 mol. equiv. ) was added 
followed by a further batch (0.5 mol. equiv. ) after 12 h. Both batches were dissolved in 
MN-dimethylformamide. Following the addition of all the crosslinker, the mixture was 
stirred for a further 24 h before being filtered to remove the caesium carbonate. The solvent 
was removed under reduced pressure. Ethyl acetate was added and the mixture filtered to 
remove any remaining caesium carbonate. The solution was washed with water (x 2) and 
sat. brine (x 2), dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography. 
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5.2.6 Preparation of crosslinked tripeptides 
Attempted preparation of N-a-t-butoxycarbonyl-[(N-c toluenesulphonyl-lysyl-N-E 
toluenesulphonyl-lysyl)-4(NE), 4'(N)-(bis-methylphenadiyl)J-glycine-methyl-ester (100) 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
Many attempts were made to synthesise the above compound. Representative examples 
of these experiments are described below: 
Dry caesium carbonate (216 mg, 0.167 mmol) and N-a-t-butoxycarbonyl-N-e-tosyl- 
lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol) were stirred in dry N, N- 
dimethylformamide (10 cm3) under argon at RT. 4,4'-Bis-bromomethylbiphenyl (22.6 mg, 
0.067 mmol) in NN-dimethylformamide (5 cm3) was added by syringe pump over a period 
of 36 h and the mixture stirred for a further 3 days to ensure completion. The solvent was 
removed under reduced pressure. Ethyl acetate was added and the mixture filtered to 
remove any remaining caesium carbonate. The solution was washed with water (x 2) and 
sat. brine (x 2), dried over MgSO4, filtered and the solvent removed under reduced pressure. 
Repeated flash column chromatography (gradient elution from 99: 1 dichloromethane : 
methanol to 90: 10 dichloromethane : methanol) failed to produce a pure sample of the 
desired product, but FAB MS suggested the successful synthesis of the desired compound. 
Dry caesium carbonate (216 mg, 0.67 mmol), N-a -t-butoxycarbonyl-N-e-tosyl-lysyl- 
N-e-tosyl-1ysy1-glycine-methyl-ester (50 mg, 0.067 mmol) and 3A molecular sieves were 
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stirred in dry NN-dimethylformamide (10 cm) under argon at RT. 4,4'-Bis- 
bromomethylbiphenyl in N, N-dimethylformamide (5 cm) was added by syringe pump over 
a period of 36 h and the mixture was stirred for a further 3 days to ensure completion. The 
mixture was worked up as above but FAB MS indicated that only the starting tripeptide had 
been isolated. 
Method C 
Dry caesium carbonate (216 mg, 0.67 mmol), N-a-t-butoxycarbonyl-N-e-tosyl-lysyl- 
N-c-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol), 3A molecular sieves and 
catalytic amounts of caesium iodide were stirred in dry N, N-dimethylformamide (10 cm) 
under argon at RT. In an alternative reaction, dry acetonitrile (10 cm) was used as the 
solvent under identical reaction conditions. 4,4'-Bis-bromomethylbiphenyl (22.6 mg, 0.067 
mmol) in N, N-dimethylformamide (5 cm') (or acetonitrile (5 cm3) in the parallel reaction) 
was added by syringe pump over a period of 36 h and the mixture stirred for a further 3 days- 
to ensure completion. The mixture was worked up as above. Evidence was available by 
FAB MS in the DMF reaction for the successful synthesis of the desired compound but it 
could not be purified by repeated flash column chromatography (using gradient elution from 
99: 1 dichloromethane : methanol to 90: 10 dichloromethane : methanol). No evidence was 
available for the successful synthesis of the target molecule by FAB MS in the acetonitrile 
reaction. 
Method D 
Dry caesium carbonate (216 mg, 0.67 mmol), N-a -t-butoxycarbonyl-N-c-tosyl-lysyl- 
N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol), 3A molecular sieves and 
catalytic caesium iodide were stirred in dry N, N-dimethylformamide (10 cm) under argon 
at 650 C. 4,4'-Bis-bromomethylbiphenyl (22.6 mg, 0.067 mmol) in N, N-dimethylformamide 
(5 cm') was added by syringe pump over a period of 36 h and the mixture stirred for a 
further 3 days to ensure completion. The mixture was worked up as above, however, no 
evidence was available from FAB MS or 'H NMR spectroscopy for the successful synthesis 
of the desired compound. 
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Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(30 cm) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added 
followed by N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol). 4,4'-Bis-bromomethylbiphenyl (48.5 mg, 0.44 mmol) in N, N- 
dimethylformamide (10 cm) was added by syringe pump over a period of 48 h at RT and 
the mixture was stirred for a further 48 h at RT to ensure completion. The mixture was 
worked up as above. FAB MS and IH NMR spectroscopy indicated the successful synthesis 
of the desired compound but flash column chromatography failed to achieve its isolation. 
In two reactions, dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N- 
dimethylformamide (40 cm') under argon in a flame dried flask. Water (ca. 250 mg, 14 
mmol) was added followed by N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-e-tosyl-lysyl- 
glycine-methyl-ester (300 mg, 0.4 mmol) and 4,4'-bis-bromomethylbiphenyl (148.5 mg, 0.44 
mmol - in the second reaction the quantity was 270 mg, 0.8 mmol). The mixture was stirred 
for 24 h under argon at RT. The mixture was worked up as above. FAB MS and 'H NMR 
spectroscopy of the reaction products from each reaction indicated the successful synthesis 
of the desired compound but flash column chromatography failed to achieve its isolation. 
Dry caesium carbonate (108 mg, 0.34 mmol) was stirred at RT in dry acetonitrile (7 
cm') under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added followed 
by N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 
0.067 mmol) and 4,4'-bis-bromomethylbiphenyl (22.5 mg, 0.067 mmol). After 24 h, more 
4,4'-bis-bromomethylbiphenyl (22.5 mg, 0.067 mmol) was added. The mixture was stirred 
for a further 24 h to ensure completion. However, FAB MS and 1H NMR spectroscopy 
showed this reaction to have been unsuccessful towards- the synthesis of the desired 
compound. 
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Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(40 cm) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added 
followed by N-a-t-butoxycarbonyl-N-E-tosyl-lysyl-N-e-tosyl-Iysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol) and 4,4'-bis-bromomethylbiphenyl (135 mg, 0.4 mmol) and the mixture 
stirred at 50° C. After 24 h, more 4,4'-bis-bromomethylbiphenyl (67.5 mg, 0.2 mmol) was 
added followed by the addition of another batch of 4,4'-bis-bromomethylbiphenyl (67.5 mg, 
0.2 mmol) after a further 12 h. The reaction mixture was stirred for a further 24 h under 
argon at 50° C to ensure completion. The mixture was worked up as above but FAB MS 
and 'H NMR spectroscopy failed to show the presence of the desired compound. 
Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(40 cm3) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added 
followed by N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-c-tosyl-lysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol) and 4,4'-bis-bromomethylbiphenyl (135 mg, 0.4 mmol) and the mixture 
stirred under argon at RT. After 24 h, more 4,4'-bis-bromomethylbiphenyl (67.5 mg, 0.2 
mmol) was added followed by the addition of another batch of 4,4'-bis-bromomethylbiphenyl 
(67.5 mg, 0.2 mmol) after a further 12 IL' The reaction mixture was stirred for a further 24 
h at RT to ensure completion before being filtered to remove the caesium carbonate. The 
solvent was removed under reduced pressure. Ethyl acetate was added and the mixture 
filtered to remove any remaining caesium carbonate. The solution was washed with water 
(x 2) and sat. brine (x 2), dried over MgSO4, filtered and the solvent removed under reduced 
pressure. Repeated flash column chromatography (gradient elution from 99: 1 
dichloromethane : methanol to 90: 10 dichloromethane : methanol) failed to produce a pure 
sample of the desired product, but evidence was available for the successful formation of the 
target compound. 
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'H NMR (CDC13, RT, 80 MHz); 
S/ppm 1.1-1.9 (m, 12H, CH2CH2CH2CH2N), 1.35 (s, 9H, C(CH3)3), 2.4 (s, 6H, CH31 
Ts), 2.8-3.2 (m, 8H, CH2NTs), 3.7 (s, 3H, OCH3), 4.0 (m, br, 3H, CH2, Gly, Lys a-CH), 
4.3 (m, br, 1H, Lys a-CH), 4.7 (m, br, 1H, NH), 7.2-7.8 (m, 16H, CH, Ts, biphenyl) 
MS FAB+ve (NOBA matrix) C48H61N5010S2 M+ calculated as 931.3 
m/z 1064 [M + Cs]"', 932 [M + H]+, 832 [M - Boc]+, 776 [M - Ts]+ 
MS FAB+ve (NOBA matrix) [M + H]+ accurate mass 
Calculated 932.3938 
Found 932.3943 
Rf 19: 1 (dichloromethane : methanol) 0.35 
Preparation ofN-a-t-butoxycarbonyl-[(N-c toluenesulphonyl-lysyl-N-E toluenesulphonyl- 
lysyl)- a(NE), a'(N )Para-xyl-diylJ-glycine-methyl-ester (114) 
1ý 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
Three attempts were made to synthesise the above compound. These experiments are 
described below: 
In each of two separate reactions, dry caesium carbonate (216 mg, 0.67 mmol) and 
N-a-t-butoxycarbonyl-N-e-tosyl-1ysyl-N-e-tosyl-1ysyl-glycine-methyl-ester (50 mg, 0.067 
mmol) were stirred in dry N, N-dimethylformamide (10 cm3) under argon at RT. In one 
199 
reaction, 3A molecular sieves were added whilst in the other they were not present. 1,4- 
a, a'-Dibrom4 p-xylene (17.5 mg, 0.067 mmol) in N, N-dimethylformamide was added by 
syringe pump over a period of 24 h and the mixture stirred for a further 3 days to ensure 
completion. The solvent was removed under reduced pressure. Ethyl acetate was added 
and the mixture filtered to remove the molecular sieves and any remaining caesium 
carbonate. The solution was washed with water (x 2) and sat. brine (x 2), dried over 
MgSO4, filtered and the solvent removed under reduced pressure. FAB MS of the crude 
samples indicated the presence of the desired product from the reaction containing 
molecular sieves but not from the reaction without molecular sieves. Flash column 
chromatography of the former reaction mixture (9: 1 dichloromethane : methanol), yielded 
1.2 mg (2 %) of the desired compound as shown by FAB MS and TLC 
Optimised method 
Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(40 cm) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added 
followed by N-a-t-butoxycarbonyl-N-c-tosyl-lysyl-N-c-tosyl-lysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol) and 1,4-a, a'-dibromo-p-xylene (95.6 mg, 0.4 mmol) and the reaction 
stirred at RT. After 24 h, more l, 4-a, a'-dibromo-p-xylene (47.8 mg, 0.2 mmol) was added 
followed by the addition of another batch of 1,4-a, a'-dibromo-p-xylene (47.8 mg, 0.2 
mmol) after a further 12 h. The reaction mixture was stirred for a further 24 h under argon 
at RT to ensure completion before being filtered to remove the caesium carbonate. The 
solvent was removed under reduced pressure. Ethyl acetate was added and the mixture 
filtered to remove any remaining caesium carbonate. The solution was washed with water 
(x 2) and sat. brine (x 2), dried over MgSO4, filtered and the solvent removed under reduced 
pressure. Flash column chromatography (gradient elution from 99: 1 dichloromethane : 
methanol to 90: 10 dichloromethane : methanol) yielded 138 mg (40.5 TO of a white solid. 
Data agreed with the literature values given in brackets [ ]120. 
'H NMR (CDC13, RT, 270 MHz); [(CDCI3, RT, 300 MHz)]; 
S/ppm 1.0-1.7 [1.2-1.5] (m, 12H, CH2CH2CH2CH2N), 1.351 [1.356] (s, 9H, 
C(CH3)3), 2.459 [2.482] (s, 6H, CH3, Ts), 2.6-3.4 [2.7-3.4] (m, 8H, CH2NTs), 3.694 
[3.702] (s, 3H, OCH3), 3.783 [4.026] (m, 2H, CH2, Gly), 4.167 [4.261] (m, 1H, Lys a- 
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CH), 4.41 [4.80] (t, br, 1H, NH), 4.672 [4.433] (m, 1H, Lys a-CH), 5.17 [5.29] (d, br, 1H, 
NH), 6.89 [6.78] (d, br, 1H, NH), 7.300 [7.366] (d, 4H, J=8.1 Hz [8.4], CH, Ts), 7.346 
[7.291] (s, 4H, CH, xylyl), 7.733 [7.748] (d, 4H, J=8.1 Hz [8.4], CH, TO 
13C NMR (CDC13, RT, 67.90 MHz); [(CDC13, RT, 75 MHz)] 
8/ppm 21.121 [21.230] (CH2, Lys), 21.537 [21.882] (CH3, Ts), 22.197,24.896, 
25.897 [22.452,23.172,26.012] (CH2, Lys), 28.162 [28.211] (CH3, Boc), 29.653,33.730 
[29.021,30.610] (CH2, Lys), 41.148 [41.117] (CH2, Gly), 47.490,47.943,51.907 [47.642, 
48.111] (CH2NHTs), 52.152 [52.101] (OCH), 52.511 [52.211] (CH, Lys), 53.643 [55.377] 
(CH2NHTs), 56.607 [52.715] (CH, Lys), 80.635 [80.810] (C, Boc), 127.049,127.124 
[ 127.001,127.073] (CH, Ts), 128.502,128.993,129.295 [128.880,129.002,129.220] (CH, 
xylyl), 129.899,129,936 [130.002,131.002] (CH, Ts), 135.580 [135.501] (C, xylyl), 
135.901,136.260 [136.302,136.970] (C, Ts), 136.694 [135.915] (C, xylyl), 143.564, 
143.734 [143.601] (C, Ts), 156.909 [156.930] (C=O, Boc), 170.027,172.217,172.707 
[170.112,172.020,172.940] (C=O) 
MS FAB+ve (NOBA) matrix C42H57N5010S2 M+ calculated as 855.3 
m/z 878 [M + Na]+, 856 [M + H]*, 756 [M - Boc]+, 711 [M - Ts]+ 
MS FAB+ve (NOBA) matrix [M + H]+ accurate mass 
Calculated 856.3625 
Found 856.3623 
IR, u.., cm' (Nujol mull); 
3386.6,2924.5,2855.2,2362.2,1660.7,1456.1,1377.4,1333.6,1156.2,849.0, 
815.6 
Rf 2: 37: 1 (methanol : chloroform : acetic acid) 0.70 [0.69] 
19: 1 (dichloromethane : methanol) 0.35 
mp (° C) 177-180 [179-18 1] 
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Preparation of N a-t-butoxycarbonyl-[(N e-toluenesulphonyl-lysyl-N-e-toluenesulphonyl- 
lysyl)-1(N6), 6(NE')-hexadiyl]-glycine-methyl-ester (116) 
(CH2)66 
Boc-Lys(Ts)-Lys(Ts)-G1y-OMe 
Two attempts were made to synthesise the above compound. These experiments are 
described below: 
Dry caesium carbonate (432 mg, 1.33 mmol), N-a-t-butoxycarbonyl-N-e-tosyl-lysyl- 
e N-E-tosyl-lysyl-glycine-methyl-ester (100 mg, 0.13 mmol) and 3A molecular sieves were 
stirred in dry N, N-dimethylformamide (25 cm3) under argon at RT. 1,6-Dibromohexane 
(35.6 mg, 0.15 mmol) in N, N-dimethylformamide (20 cm3) was added by syringe pump over 
a period of 36 h and the mixture stirred for another 48 h to ensure completion. The solvent 
was removed under reduced pressure. Ethyl acetate was added and the mixture filtered to 
remove any remaining caesium carbonate. The solution was washed with water (x 2) and 
sat. brine (x 2), dried over MgSO4, filtered and the solvent removed under reduced pressure. 
However, FAB MS and TLC failed to show any evidence of the desired compound. 
Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(30 cm3) under argon in a flame dried flask. Water (ca. 250. mg, 14 mmol) was then added 
followed by N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycine methyl-ester (300 
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mg, 0.4 mmol). 1,6-Dibromohexane (97.2 mg, 0.4 mmol) in N, N-dimethylformamide (10 
cm3) was added by syringe pump over a period of 48 h and the mixture stirred under argon 
at RT for a further 48 h to ensure completion. The mixture was filtered to remove the 
caesium carbonate and the solvent was removed under reduced pressure. Ethyl acetate was 
added and the mixture filtered to remove any remaining caesium carbonate. The solution 
was washed with water (x 2) and sat. brine (x 2), dried over MgSO4, filtered and the solvent 
removed under reduced pressure. Flash column chromatography (gradient elution from 99: 1 
dichloromethane : methanol to 90: 10 dichloromethane : methanol) yielded 151.4 mg (45 %) 
of a white solid. Data agreed with that previously found 120. Literature values are given in 
brackets [ ]. 
1H NMR (CDC13, RT, 200 MHz); [(CDC13, RT, 300 MHz)] 
S/ppm 1.2-2.1 [1.2-1.9] (m, br, 20H, CH2, alkyl), 1.253 [1.317] (s, 9H, C(CH3)3). 
2.391 [2.439] (s, 3H, CH3, Ts), 2.412 [2.475] (s, 3H, CH3, Ts), 2.9-3.1 [2.6-2.7] (m, br, 
4H, CH2NRTs), 3.1-3.35 [2.9-3.3] (m, br, 4H, CH2NRTs), 3.671 [3.731] (s, 3H, OCH3), 
3.85-4.10 [3.93-4.12] (m, 3H, CH2, Gly, a-CH, Lys), 4.354 [4.417] (m, 1H, a-CH, Lys), 
5.519 [5.590] (m, 1H, NH), 7.287 [7.317] (m, 4H, CH, Ts [d, J=8.5 Hz]), 7.428 [7.501] 
(m, 1H, NH), 7.638 [7.643] (m, 4H, CH, Ts [d, J=8.5 Hz]), 7.71 (m, 1H, NH) 
13C NMR (CDC13, RT, 50 MHz); [(CDCl3, RT, 75 MHz)] 
S/ppm 20.739 [21.120] (CH2, alkyl), 21.297 [21.910] (CH3, Ts), 22.235,24.415, 
24.552,24.752,26.553,26.857 [22.811,24.911,24.996,26.956,27.118] (CH2, alkyl), 
27.905 [28.131] (CH3, Boc), 28.189,29.321,31.489 [28.772,29.815,31.902] (CH2, alkyl), 
40.989 [41.354] (CH29 Gly), 46.527,47.821,48.320,50.013 [46.872,48.171,48.860, 
50.510] (CH2NHTs), 51.853 [57.002] (OCH), 53.114,56.571 [52.160,53.611 ] (CH, Lys), 
80.052 [80.502] (C, Boc), 126.573,126.843,129.462,129.662 [126.720,127.001, 
129.410,129.910] (CH, Ts), 135.238,136.385,142.901,143.487 [135.650,136.612] (C, 
Ts), 156.418 [156.701] (C=O, Boc), 169.662,172.317,173.378 [169.985,172.714, 
173.510] (C=O) 
MS FAB+ve (NOBA matrix) C46H61N5O10S2 M* calculated as 835.4 
m/z 858 [M + Na]*, 836 [M + H]*, 736 [M - Boc]*, 680 [M - Ts]*, 580 [M - Boc - 
Ts]' 
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MS FAB+ve (NOBA matrix) [M + H]* accurate mass 
Calculated 836.3938 
Found 836.3935 
IR, u., cm' (nujol mull) 
3386.5,2925.0,2855.6,1661.4,1463.3,1377.9,1338.1,1158.3,1090.9,1020.7, 
848.8,721.8 
Rf 2: 37: 1 (methanol : dichloromethane : acetic acid) 0.7 [0.71] 
19: 1 (dichloromethane : methanol) 0.33 
mp (C) 182-185 [183-186] 
Attempted preparation of N-a-t-butoxycarbonyl-[(N-c toluenesulphonyl-lysyl-Ne- 
toluenesulphonyl-lysyl)-(1-ethoxy)(NE), (2-ethoxy')(NE')-oxyl-glycine-methyl-ester (115) 
O co 
Boc-Lys(Ts)-Lys(Ts)-Gly-OMe 
Dry caesium carbonate (216 mg, 0.67 mmol), N-a-t-butoxycarbonyl-N-e-tosyl-lysyl- 
N-c-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol), 3A molecular sieves and 
catalytic amounts of caesium iodide in dry N, N-dimethylformamide (10 cm3) were stirred 
under argon at RT. 2-Chloroethyl ether (10.4 mg, 0.074 mmol) in N, N-dimethylformamide 
(5 cm3) was added by syringe pump over a period of 36 h and the mixture stirred for a 
further 24 h to ensure completion. The solvent was removed under reduced pressure. 
Ethyl acetate was added and the mixture filtered to remove any remaining caesium 
carbonate. The solution was washed with water (x 2) and sat. brine'(x 2), dried over 
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MgSO4, filtered and the solvent removed under reduced pressure. However, neither a peak 
at m/z = 824 due to [M + H]+ nor a peak at m/z = 724 due to [M - Boc]* were observed in 
the FAB MS, indicating that the desired compound was not synthesised. 
Preparation of N- a-t-butoxycarbonyl-[(N- e-toluenesulphonzyl-lysyl-N E toluenesulphonyl- 
lysyl)-(1-ethoxy)(N6), (2-ethoxy')(N")-1,2-ethyll-glycine-methyl-ester (101) 
T0/0 -ý Boc-Lys(Ts)-Lys(Ts)-GIy-OMe 
Many attempts were made to synthesise the above compound. Representative examples 
of these experiments are described below: 
Dry caesium carbonate (432 mg, 1.33 mmol) and dry N-a-t-butoxycarbonyl-N-c- 
tosyl-lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (100 mg, 0.133 mmol) were stirred in dry 
N, N-dimethylformamide (20 cm3) under argon at RT. 
1,2-Bis(2-chloroethoxy)ethane (27.3 mg, 0.146 mmol) in N, N-dimethylformamide (5 
cm3) was added by syringe pump over a period of 24 h and the mixture stirred for a further 
3 days to ensure completion. The solvent was removed under reduced pressure. Ethyl 
acetate was added and the mixture filtered to remove any remaining caesium carbonate. The 
solution was washed with water (x 2) and sat. brine (x 2), dried over MgSO4, filtered and 
the solvent removed under reduced pressure. However, FAB MS did not reveal any 
evidence of the desired product. 
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Dry caesium carbonate (432 mg, 1.33 mmol), dry N-a-t-butoxycarbonyl-N-c-tosyl- 
lysyl-N-E-tosyl-lysyl-glycine-methyl-ester (100 mg, 0.133 mmol) and 3A molecular sieves 
were stirred in dry N, N-dimethylformamide (20 cm3) under argon at RT. 1,2-Bis(2- 
chloroethoxy)ethane (27.3 mg, 0.146 mmol) in N, N-dimethylformamide (5 co) was added 
by syringe pump over a period of 24 h and the mixture stirred for a further 3 days to ensure 
completion. The reaction was worked up as above. FAB MS of the crude product 
showed the presence of the desired compound. Flash column chromatography (19: 1 
dichloromethane : methanol) separated the desired product from the starting tripeptide (99), 
but failed to produce a pure sample of product. However, FAB MS of the relevant column 
fractions indicated the presence of the desired product. 
In two separate experiments dry caesium carbonate (216 mg, 0.067 mmol), dry N- a- 
t-butoxycarbonyl-N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol) 
and 3A molecular sieves were stirred in dry NN-dimethylformamide (10 cm3) (or dry 
acetonitrile (10 cm3)) under argon at 65° C. 1,2-Bis(2-chloroethoxy)ethane (13.7 mg, 
0.073 mmol) in N, N-dimethylformamide (5 cm3) was added by syringe pump over a period 
of 24 h and the mixture stirred for a further 3 days to ensure completion. 'The reaction was 
worked up as above but FAB MS failed to show any evidence of the desired compound in 
either reaction. 
Dry caesium carbonate (432 mg, 1.33 mmol), dry N-a-t-butoxycarbonyl-N-e-tosyl- 
lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (100 mg, 0.133 mmol), 3A molecular sieves and 
catalytic amounts of sodium iodide were stirred in dry N, N-dimethylformamide (20 cm) 
under argon at RT. 1,2-Bis(2-chloroethoxy)ethane (27.3 mg, 0.146 mmol) in N, N- 
dimethylformamide (5 cm3) was added by syringe pump over a period of 24 h and the 
mixture stirred for a further 3 days to ensure completion. The reaction was worked up as 
above. However, following flash column chromatography (19: 1 dichloromethane : 
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methanol), FAB MS showed that only the starting materials were isolated. 
Dry caesium carbonate (216 mg, 0.067 mmol), dry N-a-t-butoxycarbonyl-N-e-tosyl- 
lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 0.067 mmol) and catalytic amounts of 
caesium iodide were stirred in dry acetonitrile (10 cm3) under argon at RT. 1,2-Bis(2- 
chloroethoxy)ethane (27.3 mg, 0.146 mmol) in acetonitrile (5 cm3) was added by syringe 
pump over a period of 24 h and the mixture stirred for a further 3 days to ensure 
completion. The reaction was worked up as above. However, FAB MS of the crude 
sample and each of the fractions following flash column chromatography (19: 1 
dichloromethane : methanol) failed to reveal any evidence of the desired compound. 
Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(30 cm3) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was then added 
followed by dry N-a-t-butoxycarbonyl-N-e-tosyl-lysyl-N-E-tosyl-lysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol). 1,2-Bis(2-tosylethoxy)ethane (201 mg, 0.44 mmol) in N, N- 
dimethylformamide (10 cm) was added by syringe pump over a period of 48 h and the 
mixture stirred for a further 48 h under argon at RT to ensure completion. The mixture was 
worked up as above and following flash column chromatography (gradient elution from 98: 2 
dichloromethane : methanol to 95: 5 dichloromethane : methanol), 155 mg (45 %) of the 
desired compound as a white solid was isolated. 
Dry caesium carbonate (108 mg, 0.34 mmol) was stirred in dry acetonitrile (7 cm3) 
under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added followed by 
dry N-a-t-butoxycarbonyl-N-E-tosyl-lysyl-N-e-tosyl-lysyl-glycine-methyl-ester (50 mg, 
0.067 mmol) and 1,2-bis(2-tosylethoxy)ethane (12.4 mg, 0.067 mmol). After 24 h, more 
1,2-bis(2-tosylethoxy)ethane was added. The mixture was stirred under argon at RT for 
a further 24 h to ensure completion. However, FAB MS and 'H NMR spectroscopy 
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showed this reaction to have been unsuccessful in the synthesis of the desired compound. 
Optimised method 
Dry caesium carbonate (648 mg, 2 mmol) was stirred in dry N, N-dimethylformamide 
(40 cm3) under argon in a flame dried flask. Water (ca. 250 mg, 14 mmol) was added 
followed by N-a-t-butoxycarbonyl-N-E-tosyl-lysyl-N-E-tosyl-lysyl-glycine-methyl-ester 
(300 mg, 0.4 mmol) and 1,2-bis(2-tosylethoxy)ethane (182.5 mg, 0.4 mmol). After 24 h, 
more 1,2-bis(2-tosylethoxy)ethane (91.3 mg, 0.2 mmol) was added followed by the addition 
of another batch of 1,2-bis(2-tosylethoxy)ethane (91.3 mg, 0.2 mmol) after a further 24 h. 
The reaction mixture was stirred for a further 24 h to ensure completion before being 
filtered to remove the caesium carbonate. The solvent was removed under reduced 
pressure. Ethyl acetate was added and the mixture filtered to remove any remaining 
caesium carbonate. The solution was washed with water (x 2) and sat. brine (x 2), dried 
over MgSO4, filtered and the solvent removed under reduced pressure. Flash column 
chromatography (gradient elution from 99: 1 dichloromethane : methanol to 90: 10 
dichloromethane : methanol) yielded 345.4 mg (62 %) of a white solid. 
lH NMR (CDC13, RT, 200 MHz); 
8/ppm 1.2-1.9 (m, br, 12H, CH2CH2CH2CH2N), 1.293 (s, 9H, C(CH3)3), 2.428 (s, 
3H, CH3, Ts), 2.447 (s, 3H, CH3, Ts), 3.2-3.45 (m, br, 8H, CH2NRTs), 3.5-3.8 (m, br, 8H, 
CHZO), 3.711 (s, 3H, OCH3), 3.85-4.18 (m, br, 3H, CH2, Gly; a-CH, Lys), 4.40 (m, 1H, 
a-CH, Lys), 5.50 (d, 1H, J=5.39 Hz, NH), 7.20 (d, 1H, J=5.91 Hz, NH), 7.32 (m, 4H, 
CH, Ts), 7.70 (m, 4H, CH, Ts), 7.80 (d, 1H, J=7.89 Hz, NH) 
13C NMR (CDC13, RT, 50 MHz); 
S/ppm 20.782 (CH2, Lys), 21.426 (CH3, Ts), 22.273,28.581 (CH2, Lys), 28.023 
(CH3, Boc), 28.334,31.127 (CH2, Lys), 41.096 (CH2, Gly), 48.512,48.707,49.502,49.893 
(CH2NHTs), 51.983 (OCH3), 53.152,56.277 (CH, Lys), 70.508,71.188 (OCH2)180.156 
(C, Boc), 126.798,126.989,129.578,129.785 (CH, Ts), 135.348,138.863,143.057, 
143.694 (C, Ts), 156.685 (C=O, Boc), 169.776,172.374,173.086 (C=O) 
.1 
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MS FAB+ve (NOBA matrix) C4oH61N5O12S2 M+ calculated as 867.4 
890 [M + Na]+, 868 [M + H]+, 768 [M - Boc]*, 712 [M - Ts]+, 612 [M - Boc - Ts]* 
MS FAB+ve (NOBA matrix) [M + H]+ accurate mass 
Calculated 868.3836 
Found 868.3838 
Elemental Analysis: (%) 
Calculated C 55.35 H 7.08 N 8.07 
Found C 55.43 H 7.10 N 8.06 
IR, u,,, u, cm' (KBr disc) 
3411.1,2931.0,1640.1,1616.5,1521.0,1455.2,1336.2,1157.4,1089.8,816.8, 
728.6,652.9 
[a]D20 -32.04 
Rf 19: 1 (dichloromethane : methanol) 0.4 
mp (° C) 58-64 
' 
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5.3 Experimental relating to chapter .3 
5.3.1 General method for the cyclodimerisation tripe tides 
The tripeptide was dissolved in 30 %1M potassium hydroxide solution in methanol 
and the solution stirred at room temperature until the reaction had gone to completion as 
judged by TLC. The methanol was removed under reduced pressure. The remaining 
solution was acidified using 1M HCl to pH 3 (universal indicator paper) the solution diluted 
with water and the desired product extracted (x 5) with dichloromethane. The organic 
extracts were combined and the solvent removed under reduced pressure. The resultant 
solid was dried to yield the free acid as a white solid. 
The tripeptide free acid, pentafluorophenol (1.5 mol. equiv. ) and 1-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (2 mol. equiv. ) were 
dissolved in dry (stored over 4A molecular sieves) ethyl acetate under argon. The mixture 
was stirred for 24 h until shown to be complete by TLC. The mixture was filtered and the 
solution washed with sat. brine to remove residual EDC. The crude product was purified 
through a short column by flash column chromatography in order to remove unreacted 
tripeptide carboxylic acid. 
N-t-butoxycarbonyl deprotection was achieved by dissolving the pentafluorophenyl 
ester in 1: 1 trifluoroacetic acid : dichloromethane. The mixture was stirred for 
approximately 1h or until the starting material had disappeared as shown by TLC. The 
solvent was removed under reduced pressure and any residual solvent removed by forming 
an azeotrope 3 times with toluene. Each time the toluene was removed under reduced 
pressure. The oily product was triturated with diethyl ether until a white solid was formed. 
Assuming 100 % deprotection, caesium carbonate (or sodium or potassium carbonate) 
(5 mol. equiv. ) and N, N-dimethylformamide (0.005 M) were added under argon and the 
reaction mixture left to stir for approximately four days. The solution was filtered to 
remove caesium carbonate and the solvent removed under reduced pressure. The crude 
product was purified by flash column chromatography 
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5.3.2 Cyclodimerisation of tripeptides 
Preparation of N-a-t-butorycarbonyl-[(N-c-toluenesulphonyl-lysyl-N-e-toluenesulphonyl- 
lysyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethyl]-glycine (129) 
Co 
Boc-Lys(Ts)-Lys(Ts)-Gly-OH 
N- a -t-butoxycarbonyl-[(N-e-tosyl-N-E-lysyl-N-e-tosyl-lysyl)-(2-ethoxy)(NE), (2- 
ethoxy')(NE')-1,2-ethane]-glycine-methyl-ester (1.35 g, 1.56 mmol) was dissolved in 30 % 
1M potassium hydroxide solution in methanol (70 cm) and the solution stirred at room 
temperature until the reaction had gone to completion as judged by TLC. The methanol 
was removed under reduced pressure and the remaining solution was acidified using 1M 
HCl to pH 3 (universal indicator paper). The solution was diluted with water and the 
desired product was extracted (x 5) with dichloromethane. The organic extracts were 
combined and the solvent removed under reduced pressure. The resultant solid was dried 
to yield 1.3 g (98 %) of the free acid as a white solid. 
lH NMR (CDC13, RT, 200 MHz); 
6/ppm 1.2-2.1 (m, br, 12H, CH2CH2CH2CH2N), 1.273 (s, 9H, C(CH3)3), 2.386 (s, 
3H, CH3, Ts), 2.401 (s, 3H, CH3, Ts), 2.8-3.3 (m, br, 8H, CHZNRTs), 3.3-3.7 (m, 8H, 
CH2O), 3.97 (m, 2H, CH2, Gly), 4.08 (m, 1H, a-CH, Lys), 4.44 (m, 1H, a-CH, Lys), 5.6 
(m, 1H, NH), 7.27 (m, 4H, CH, Ts), 7.38 (d, 1H, J=8.0 Hz, NH), 7.66 (m, 4H, CH, Ts), 
7.75 (d, 1H, J=8.2 Hz, NH), 8.5-9.2 (s, br, COOH) 
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13C NMR (CDC13, RT, 50 MHz); 
8/ppm 21.056 (CH2, Lys), 21.423 (CH3, Ts), 22.501,26.795 (CH2, Lys), 28.043 
(CH3, Boc), 28.595,28.853,31.177 (CH2, Lys), 41.497 (CHF, Gly), 48.487,48.836, 
49.183,49.703 (CH2NHTs), 53.013,56.144 (CH, Lys), 70.395,70.836,70.992 (CH2O)9 
80.359 (C, Boc), 128.844,128.973,129.591,129.781 (CH, Ts), 135.455,136.741, 
143.088,143.835 (C, Ts), 156.407 (C=O, Boc), 171.759,172.901,173.524 (C=O) 
MS FAB+ve (NOBA matrix) C39H59N5012S2 M* calculated as 853.3 
m/z 892 [M + K]+, 876 [M + Na]*, 854 [M + H]*, 776 [M - Boc + Na]*, 754 [M - 
Boc]+ 
MS FAB+ve (NOBA matrix) [M + Na]* accurate mass 
Calculated 876.3495 
Found 876.3499 
IR, u,,, x, cm' 
(KBr disc); 
3413.7,2934.0,1654.2,1522.3,1457.8,1335.4,1157.1,1089.8,816.3,729.6,654.1 
Rf 2: 1: 17 (methanol : acetic acid : chloroform) 0.25 
19: 1 (dichloromethane : methanol) 
mp (° C) 67-70 
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Preparation of cyclo-[N- c tosyl-lysyl-N-E-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2- 
ethoxy')(NE')-1,2-ethyl-(N c-tosyl-lysyl-N-c-tosyl-lysyl-glycyl)-(2-ethoxy)(N6), (2- 
ethoxy')(Ne)-1,2-ethane] (103) 
ýo/o) 
cyclo-[Lys(Ts)-Lys(Ts)-Gly]2 
N- a -t-butoxycarbonyl-[(N-e-tosyl-lysyl-N-e-tosyl-lysyl)-(2-ethoxy)(NE), (2- 
ethoxy')(NE')-1,2-ethyl]-glycine (450 mg, 0.53 mmol), pentafluorophenol (146 mg, 0.79 
mmol) and dicyclohexylcarbodiiraide (DDC) (220 mg, 1.07 mmol) were dissolved in dry 
N, N-dimethylformamide (10 cm) under argon. The mixture was stirred for 24 h until 
shown to be complete by TLC. The reaction mixture was filtered to remove the by- 
product, dicyclohexylurea. The solvent was removed under reduced pressure and the 
resultant brown oil was triturated in hexane (x 3) and diethyl ether (x 2), to give a brownish- 
white solid which was not characterised but was used for the next stage of the procedure. 
N- a -t-butoxycarbonyl-[(N-e-tosyl-lysyl-N-e-tosyl-lysyl)-(2-ethoxy) (Ne), (2- 
ethoxy')(NE')-1,2-ethyl]-glycine-pentafluorophenyl ester (537.6 mg, 0.53 mmol) was 
dissolved in 1: 1 trifluoroacetic acid : dichloromethane (30 cm3) and stirred at room 
temperature for approximately 1 h, when TLC showed the starting material to have 
disappeared. The solvent was removed under reduced pressure and any residual 
trifluoroacetic acid removed by forming an azeotrope three times with toluene. The toluene 
was removed under reduced pressure. The oily product was triturated three times with 
diethyl ether to form a white solid. This was not characterised but used immediately. 
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Assuming 100 % deprotection, caesium carbonate (859 mg, 2.64 mmol) and N, N- 
dimethylformamide (105 ml, 0.005 M) were added under argon and the mixture stirred for 
four days. In other experiments, sodium carbonate (279 mg, 2.64 mmol) or potassium 
carbonate (369 mg, 2.64 mmol) were also used as the base and gave similar yields of cyclic 
peptide. The solution was filtered to remove the alkali metal carbonate and the solvent 
removed under reduced pressure. The crude product was dissolved in ethyl acetate, filtered 
to remove residual caesium carbonate, washed with water (100 co x 2) and sat. brine (100 
cm3) and dried over MgSO4. The mixture was filtered and the solvent removed under 
reduced pressure. Flash column chromatography (gradient elution from 99: 1 
dichloromethane : methanol to 90: 10 dichloromethane : methanol) yielded 35 mg (9 %) of 
a white solid. 
N- a -t-butoxycarbonyl-[(N-e-tosyl-lysyl-N-e-tosyl-lysyl)-(2-ethoxy)(NE), (2- 
ethoxy')(NE')-1,2-ethyl]-glycine(450 mg, 0.53 mmol), pentafluorophenol (146 mg, 0.79 
mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) were 
dissolved in dry (stored over 4A molecular sieves) ethyl acetate (10 cm') under argon. The 
mixture was stirred for 24 h until shown to be complete by TLC. The solution was filtered 
and washed with sat. brine to remove any residual EDC. The solvent was removed under 
reduced pressure. Flash column chromatography using a short silica gel column and using 
ethyl acetate as the eluant, followed by removal of the solvent under reduced pressure and 
washing with diethyl ether gave a white solid which was not characterised but was used for 
the next stage in the procedure. 
N- a -t-butoxycarbonyl- [(N-e-tosyl-lysyl-N-e-tosyl-lysyl)-(2-ethoxy) (N`), (2- 
ethoxy')(NE')-1,2-ethyl]-glycine-pentafluorophenyl ester (537.6 mg, 0.53 mmol) was 
dissolved in 1: 1 trifluoroacetic acid : dichloromethane (30 cm3) and stirred at room 
temperature for approximately 1 h, when TLC showed the starting material to have 
disappeared. The solvent was removed under reduced pressure and any residual 
trifluoroacetic acid removed by forming an azeotrope three times with toluene. The toluene 
was removed under reduced pressure. The oily product was triturated three times with 
diethyl ether to form a white solid. This was not characterised but was used immediately. 
Assuming 100 % deprotection , caesium carbonate (859 mg, 2.64 mmol) and N, N- 
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dimethylformamide (105 cm', 0.005 M) were added under argon and the reaction mixture 
stirred for four days. The solution was filtered to remove the caesium carbonate and the 
solvent removed under reduced pressure. The crude product was dissolved in ethyl acetate, 
filtered to remove residual caesium carbonate, washed with water (100 cm3 x 2) and sat. 
brine (100 cm3) and dried over MgSO4. The mixture was filtered and the solvent removed 
under reduced pressure. Flash column chromatography (gradient elution from 99: 1 
dichloromethane : methanol to 90: 10 dichloromethane : methanol) yielded 244 mg (63 %) 
of a white solid. 
lH NMR (CDC13 trace CD3OD, RT, 400 MHz); 
S/ppm 1.3-2.1 (m, br, 24H, CH2CH2CH2CH2N), 2.404 (s, 6H, CH3, Ts), 2.411 (s, 
6H, CH3, Ts), 3.0-3.3 (m, br, 16H, CH2NRTs), 3.5 (m, 16H, CH2O), 4.1 (m, br, 6H, CH2; 
Gly, a-CH, Lys), 4.42 (m, br, 2H, a-CH, Lys), 7.286 (d, 4H, J=8.0 Hz, CH, Ts), 7.295 
(d, 4H, J=8.0 Hz, CH, Ts), 7.659 (d, 4H, J=8.0 Hz, CH, Ts), 7.670 (d, 4H, J=8.0 Hz, 
CH, Ts) 
13C NMR (CDC13 trace CD30D, RT, 100 MHz); 
S/ppm 21.50,21.54 (CH3, Ts), 22.30,22.74,27.92,28.20,30.33,30.53 (CH2, Lys), 
43.88 (CH2, Gly), 48.43,48.99,49.63,49.78 (CH2NRTs), 52.67,55.57 (CH, Lys), 70.31, 
70.48,70.69,70.87 (CH2O), 127.10,129.77,129.92 (CH, Ts), 136.37,136.46,143.35 (C, 
Ts), 170.47,172.13,172.89 (C=O) 
MS FAB+ve (NOBA matrix) C68H98N, o018S4 M' calculated as 1470.6 
m/z 1472 [M + H]+, 1316 [M - Ts]*, 1162 [M - 2Ts]* 
MS FAB+ve (NOBA matrix) [M + H]* accurate mass 
Calculated 1471.6022 
Found 1471.5956 
Elemental analysis: (%) 
Calculated C 55.49 H 6.71 N 9.52 
Found C 55.30 H 6.69 N 9.48 
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IR, u,,, x, cm 
1(KBr disc); 
3332.1,3063.6,2931.6,2361.3,2336.7,2244.9,1923.7,1649.6,1597.5,1530.0, 
1454.9,1336.1,1144.0,990.3,816.0,728.6,654.6 
Rf 19: 1 (dichloromethane : methanol) 0.20 
mp (° C) 118-121 
5.3.3 Detosylation of the cyclic peptide 
Preparation of cyclo-[lysyl-lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethyl-(lysyl- 
lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethane] (105) 
F_\ 
OO 
cyclo-[Lys-Lys-G1y] 2 
A 1.0 M stock solution of sodium anthracenide was prepared by dissolving anthracene 
(1.000 g, 5.60 mmol) and sodium (0.115 g, 5.00 mmol) in dry tetrahydrofuran (50 cm3) 
under a stream of nitrogen. After stirring for 2 h, dissolution was complete and a dark blue 
colour persisted. Cyclo-[N-E-tosyl-lysyl-N-c-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2- 
ethoxy')(N")-1,2-ethyl-(N-c-tosyl-lysyl-N-e-tosyl-lysyl-glycyl)-(2-ethoxy)(N`), (2- 
ethoxy')(NE)-1,2-ethane] (100 mg, 0.068 mmol) in dry tetrahydrofuran (50 cm3) was stirred 
at 00 C under argon. The sodium anthracenide solution (27.5 ml, 2.72 mmol) was added 
and stirring continued for 1 h. The reaction was quenched with sat. sodium chloride 
solution. , The solvent was removed under reduced pressure and the sample dried to give 
a brown residue. 
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A sample of this residue (10.3 mg) was dissolved in pH 5 potassium phosphate 
aqueous buffer (1 cm3) and the sample analysed using a reverse phase analytical HPLC 
column. Three distinct fractions were observed and isolated and each analysed by FAB 
MS. Whereas the second and third fractions showed no evidence of the presence of the 
desired product, the first fraction gave peaks at both m/z = 854 [M]+ and 893 [M + K]4, 
indicating the presence of the desired product. 
Method B: Hydrogen bromide/acetic acid 
To cyclo-[N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycyl)-(2-ethoxy)(N), (2-ethoxy')(NE')-1,2- 
ethyl-(N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethane] 
(100 mg, 0.068 mmol) in phenol (76.6 mg, 0.815 mmol) was added 1: 1 hydrogen bromide 
: acetic acid in a5 cm3 Wheaton vial. The vial, fitted with a superseal under a screw cap 
was heated in a sand bath to 70° C for 16 h. The vial was then cooled by placing in ice. 
However, work up was not deemed to be appropriate as the above procedure gave only a 
black tar. FAB MS of this crude product failed to show any peaks that could be assigned 
to the desired product. 
To a 3-necked flask fitted with a cold-finger condenser and drying tube was added 
liquid ammonia (ca. 100 em) under argon. The liquid was cooled to -70° C and 50 % 
sodium dispersion in paraffin (422 mg, 9.17 mmol) was added with stirring to give a dark 
blue solution. Cyclo-[N-e-tosyl-lysyl-N-e-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2- 
ethoxy') (Ne')-1,2-ethyl-(N-e-tosyl-lysyl-N-e-to syl-lysyl-glycyl)-(2-ethoxy) (NE), (2- 
ethoxy')(NE')-1,2-ethane] (450 mg, 0.305 mmol) was dissolved in dry tetrahydrofuran (25 
cm3) and added dropwise to the reducing solution. Stirring was continued for 2h and the 
reaction quenched with glacial acetic acid (2 cm). The liquid ammonia was allowed to 
evaporate and the residue suspended in 1: 1 methanol : water (20 cm3). Kieselguhr was 
added, the suspension filtered and the solvent removed under reduced pressure. Residual 
acetic acid was removed by forming an azeotrope with toluene and by leaving the sample 
in a vacuum desicator containing sodium hydroxide pellets. 
The residue was dissolved in 2,2,2-trifluoroethanol and the sodium acetate salt 
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removed by filtration. A sample of the residue from the 2,2,2-trifluoroethanol solution was 
analysed by FAB MS. Although a peak at m/z = 856 due to [M + H]* was observed it was 
not significantly more intense than the background noise of the spectrum. 
Method D: Sodium/liquid ammonia reduction 
To a 3-necked flask fitted with a cold-finger condenser and drying tube was added 
liquid ammonia (ca. 100 cm) under argon. The liquid was cooled to -70° C and sodium 
(300 mg, 13.04 mmol) was added with stirring to give a dark blue solution. Cyclo-[N-E- 
tosyl-lysyl-N-e-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(N")-1,2-ethyl-(N-e-tosyl- 
lysyl-N-E-tosyl-lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethane] (400 mg, 0.271 
mmol) was dissolved in dry tetrahydrofuran (15 cm3) and added dropwise to the reducing 
solution. Stirring was continued for 2h and the reaction quenched with ammonium 
chloride (800 mg, 15 mmol). The liquid ammonia was dissolved in 2,2,2-trifluoroethanol, 
the mixture filtered to remove sodium chloride and the solvent was removed under reduced 
pressure. Flash column chromatography (19 :1 methanol : liquid ammonia) yielded 160 
mg (68.8 %) of a white solid. 
'H NMR (CDC13, RT, 200 MHz); 
S/ppm 1.15-1.95 (m, br, 24H, CH2CH2CH2CH2N), 2.45-2.6 (m, 8H, CH2NHR), 2.6- 
2.75 (m, 8H, CH2NHR), 3.4-3.55 (m, 16H, CH2O), 4.0-4.2 (m, 8H, 2CH2, Gly; 4a-CH, 
Lys) 
MS FAB+ve (NOBA matrix) C40H74N10O10 M* calculated as 854.6 
m/z 856 [M + H]* 
Rf 19: 1 (methanol : ammonia) 0.15 
19: 1 (dichloromethane : methanol) 0.00 
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5.3.4 Final crosslinking reactions 
Attempted synthesis of (79) by slow addition of 1,4-a, a'-dibromo p-xylene to cyclo-[lysyl- 
lysyl-glysl)-(2-ethoxy)(N'), (2-ethaq')(N)-1,2-ethyl-(lysyl-lysyl-glycyl)-(2-ethoxy)(N), (2- 
ethoxy')(NE')-1,2-ethane] (105) 
NN 
O 
O 
CNHH 
0 
NH O 
/NNH 
O0 
Cyclo-[lysyl-lysyl-glycyl)-(2-ethoxy)(Ne), (2-ethoxy')(Ne)-1,2-ethyl-(lysyl-lysyl- 
glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethane] (84.4 mg, 0.0987 mmol) was dissolved 
in 2,2,2-trifluoroethanol (14 cm3) and the mixture stirred at 40° C under argon. 1,4-a, a'- 
dibromo-p-xylene (26.1 mg, 0.0987 mmol) in N, N-dimethylformamide (2 cm) was added 
by syringe pump over a period of 12 h and stirring continued. 1,4-a, a'-dibromo p-xylene 
(26.1 mg, 0.0987 mmol) and N, N-diisopropylethylamine (12.76 mg, 0.0987 mmol) in N, N- 
dimethylformamide (2 cm3) was then added by syringe pump over a period of 12 h and 
stirring continued. Finally, N, N-diisopropylethylamine (12.76 mg, 0.0987 mmol) in N, N- 
dimethylformamide (2 cm) was added by syringe pump over a period of 12 h and stirring 
continued. The mixture was stirred for a further 72 h before the solvent was removed 
under reduced pressure. Residual solvent was removed by forming an azeotrope three 
times with toluene and removing the toluene under reduced pressure. Flash column 
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chromatography (180: 19: 1 chloroform : methanol : ammonia) yielded 29 mg of a white 
solid. FAB MS analysis of this product gave a distinct peak at m/z = 1060, indicative of 
the mass ion of the desired product. However, TLC evidence suggested it was still impure. 
.. Repeated flash column chromatography failed to satisfactorily purify the desired product. 
'H NMR spectroscopy of the 10 mg sample, in CD3OD, CDC13, D20 and d7-DMF, although 
consistent with the desired product, failed to prove its identity. 
'H NMR (d7-DMF, RT, 400 MHz); 
S/ppm 1.1-1.9 (m, br, 24H, CH2CH2CH2CH2N), 3.1-3.5 (HOD), 3.5-3.6 (m, 16H, 
CHZO), 4.05-4.35 (m, 8H, 2x CH2, Gly; 4x a-CH, Lys), 7.2-7.6 (m, br, 8H, CH, xylyl) 
MS FAB+ve (NOBA matrix) C56H86Ni0010 M+ calculated as 1058.7 
m/z 1060 [M + H]+ 
Rf 180: 19: 1 (chloroform : methanol : ammonia) 0.35 
Attempted synthesis of (80) by slow addition of 2,6-bis(bromomethyl)pyridine to cyclo- 
[lysyl-lysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethyl-(lysyl-lysyl-glycyl)-(2- 
ethoxy)(NE), (2-ethoxy')(NE')-1,2-ethane] (105) 
N 
NN 
O 
O NH 
NH 
OO 
NH O 
O NH 
OO 
NH 
01>-, ý 
O 
NNN 
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Cyclo-[lysyl-1ysyl-glycyl)-(2-ethoxy)(NE), (2-ethoxy') (NE')-1,2-ethyl-(lysyl-lysyl- 
glycyl)-(2-ethoxy)(Ný, (2-ethoxy')(NE')-1,2-ethane] (90 mg, 0.105 mmol) was dissolved in 
2,2,2-trifluoroethanol (16 cm3) and the mixture stirred at 400 C under argon. 2,6- 
Bis(bromomethyl) pyridine (27.9 mg, 0.105 mmol), in N, N-dimethylformamide (2 cm) was 
added by syringe pump over a period of 12 h and stirring continued. 2,6- 
Bis(bromomethyl)pyridine (27.9 mg, 0.105 mmol) and N, N-diisopropylethylamine (13.6 mg, 
0.105 mmol) in N, N-dimethylformamide (2 cm3) was then added by syringe pump over a 
period of 12 h and stirring continued. The mixture was stirred for a further 72 h before the 
solvent was removed under reduced pressure. Residual solvent was removed by forming 
an azeotrope three times with toluene and removing the toluene under reduced pressure. 
Analysis of the crude product by FAB MS failed to indicate the presence of the desired 
product. Following repeated flash column chromatography (180: 19: 1 chloroform : 
methanol : ammonia) and analysis of the fractions by FAB MS, a peak at m/z = 1062 due 
to [M + H]+ was observed in 1 out of 20 scans but its intensity was not significantly above 
those of surrounding uncharacterised peaks. No evidence of the desired product was 
observed when the 4 mg sample was submitted to 'H NMR spectroscopy using CD3OD, 
CDC13, D20 and d7-DMF as the solvents. 
MS FAB+ve (NOBA matrix) C54H84Ni2010 M+ calculated as 1060.7 
m/z 1062 [M + H]* 
Rf 180: 19: 1 (chloroform : methanol : ammonia) 0.35 
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5.4 Experimental relating to chapter 4 
5.4.1 Porphyrin synthesis 
Preparation of 3-bromomethylbenzaldehyde (154) 
CHO 
i 
To a solution of 3-bromomethylbenzonitrile (1 g, 5.10 mmol) in dichloromethane (1 
cm) at 0° C under argon, a1M solution of diisobutylaluminium hydride in dichloromethane 
(6.1 cm3) was added over 20 min. The resulting solution was stirred for 1.5 h at 00 C. It 
was then diluted with dichloromethane (25 cm3) and the reaction quenched by the addition 
of 2M hydrochloric acid (25 cm3) and shaking the mixture for 10 min. The organic and 
aqueous layers were separated and the aqueous layer extracted with dichloromethane (20 
cm3 x 3). The organic solutions were combined, washed with water (25 cm) and sat. brine 
(25 cm), dried over MgSO4 and then filtered. The solvent was removed under reduced 
pressure and the resultant oil solidified by cooling to 0° C. The solid was triturated with 
diethyl ether and the solvent removed under reduced pressure to yield 842 mg (83 %) of the 
desired product as shiny-white crystals. 
Note: The above are optimised conditions of synthesis. The literature precedent suggested 
the use of chlorobenzene as the solvent with diisobutylaluminium hydride in hexanes as the 
reagent. However, due to its high boiling point, chlorobenzene (bp = 132° C) was difficult 
to remove under reduced pressure even using toluene to form an azeotrope. Thus 
dichloromethane (bp = 40° C) was used as the solvent. Data agreed with the literature 
values given in brackets [ ]214. 
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'H NMR (CDC13, RT, 270 MHz); 
8/ppm 4.538 [4.54] (s, 2H, CH2), 7.522 [7.52] (dd, 1H, 7.52 Hz [8], 7.76 Hz [8], 
CH, C5), 7.665,7.813 [7.67,7.82] (2d, 2H, J=7.52 Hz [8], J=7.76 Hz [8], CH, C4, C6); 
7.901 [7.90] (s, 1H, CH, C2), 10.103 [10.02] (s, 1H, CHO) 
13C NMR (CDC13, RT, 67.90 MHz); 
8/ppm 32.1 [32.0] (CH2,129.6,129.7,129.8 [129.6,129.7,129.8] (3CH, Ar), 134.9 
[134.8] (CH, Ar), 136.8,138.3 [136.8,138.9](C, Ar), 191.6 [191.6] (CHO) 
MS EI C8H7O79Br M+ calculated as 198 
m/z 201 [M + H]+ (81Br), 200 [M]* (8'Br), 199 [M - H]' ("Br), [M + H]* (79Br), 198 
[M]* (79Br), 197 [M - H]+ (79Br), 171 [PhCH2S1Br]*, 169 [PhCH279Br]+, 119 [M - Br]+, 91 
[PhCH2]* 
MS EI [M]+ (79Br) accurate mass 
Calculated 197.9680 
Found 197.9675 
IR, uI, cm-' (nujol mull) 
2956.3,2925.8,2854.6,1713.6,1690.5,1586.1,1465.0,1301.8,1211.7,1156.8, 
810.2,784.1,695.6 
Rf 19: 1 (40-60 petroleum ether : ethyl acetate) 0.22 
mp (° C) 45-48 [46-49] 
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Attempted preparation of 5,10,15,20-tetrakis(3-bromomethylphenyl)porphyrin (155) 
NIH N-( 
Ar 
-N HN ý 
Ar 
Br 
Ar= 
To a mixture of 3-bromomethylbenzaldehyde (1 g, 5.03 mmol) and pyrrole (0.34 g, 
5.03 mmol) in chloroform (500 cm) was added a 2.5 M solution of boron trifluoride 
etherate in chloroform (0.9 cm3). The resulting solution was stirred at room temperature 
for 1 h. Triethylamine (0.22 g, 2.18 mmol) and then tetrachloro-1,4-benzoquinone (TCQ) 
(0.923 g, 3.75 mmol) were added and the mixture refluxed for 1 h. 2,3-Dicyano-5,6- 
dichloro-1,4-benzoquinone (DDQ) (0.851 g, 3.75 mmol) was also used as an oxidising 
agent in place of TCQ but without significant improvement in the reaction yield. Following 
a precedent212, ethanol (3.75 cm3,0.75 % v/v) was also added at the reflux stage but again 
without any noticeable improvement in the reaction. The crude product was analysed by 
FAB MS and UV/Vis spectroscopy. 
In order to effect the purification of the desired porphyrin, three different methods 
were attempted. 
a) The solvent was removed under reduced pressure and the residue triturated with 
diethyl ether and then filtered. The filtrate was evaporated and the residue triturated with 
dichloromethane and then filtered. The filtrate was concentrated to ca. 15 cm3 and 
methanol (20 cm) was added. However, unlike the description in the literature , the214 
porphyrin could not be precipitated despite different ratios of dichloromethane and methanol 
being used and despite the cooling of the mixture to 0° C in an ice-water bath. 
b) The solvent was removed under reduced pressure and the residue triturated with a 
variety of solvents, ie., acetone, benzene, dichloromethane, ethanol, ethyl acetate, 
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isopropanol, methanol, toluene, xylene, N, N-dimethylformamide, acetonitrile. However, 
none of these could be used to isolate or solubilise successfully the desired porphyrin. 
c) Flash column chromatography using dichloromethane, 95: 5 dichloromethane 
methanol, 50: 50 40-60 petroleum ether : dichloromethane or 95: 5 40-60 petroleum ether 
: ethyl acetate as the eluants was performed on the crude sample. However, a great deal 
of product was adsorbed onto to the column. In addition none of the desired porphyrin 
could be adequately separated from the large number of by-products observed by TLC; 
many of which ran very closely to the desired porphyrin using each of the solvent systems 
above. Data agreed with the literature values given in brackets"' 
MS FAB+ve (NOBA matrix) C48H34Br4N4 M+ calculated as 986 (279Br, 281Br) 
m/z 991 [M + H]+ (481Br), 989 [M + H]+ (381Br, 79Br), 987 [M + H]* (28'Br, 279Br), 
985 [M + H]+ (8'Br, 379Br), 983 [M + H]+ (479Br), 909 [M - Br] + (3 $'Br), 907 [M - Br] 
(281Br79Br), 905 [M - Br]' (81Br, 279Br), 903 [M - Br]' (379Br) 
UV-Vis, chloroform, I. (% relative height of Soret band), nm; 
419 (100 %) [419.5 (100 %)], 515 (8.1 %) [515 (5.0 %)], 551 (5.0 %) [549 (2.2 %)], 
588 (4.4 %) [589 (1.7 %)], 645 (3.0 %) [646 (1.1 %)], 721 (2.3 %) 
Preparation of 5,10,15,20-tetrakis(3-chlorosulphonyl-4-methoxyphenyl)porphyrin (157) 
Ar 
S02C1 
ýNH N 
-Ar Ar = OMe %=N 
HN 
Ar 
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5,10,15,20-Tetrakis(4-methoxyphenyl)porphyrin (100 mg, 0.316 mmol) was stirred 
with chlorosulphonic acid (2 cm3) at 1000 C for 3 h. The mixture was cooled, ground ice 
(30 - 40 g, caution! ) was added and the green mixture diluted with water (50 cm). The 
desired product was extracted with chloroform (50 cm3 x 5). Any emulsions that formed 
were broken up using liberal amounts of acetonitrile. It is important not to use alcoholic 
solvents to break up emulsions so as not to convert the chlorosulphonyl groups on the 
desired product to sulphonyl esters. The organic extracts were combined and the solvent 
removed under reduced pressure to yield 126 mg (80 %) of the desired product as a purple 
solid. 
'H NMR (CDC13, RT, 300 MHz); 
8/ppm -2.492 (s, br, 2H, NH), 4.463 (s, 12H, OCH3), 7.863 (d, 4H, J=8.7 Hz, CH, 
C5 or C6, Ar), 8.534 (s, 8H, CH, ß-pyrrole), 9.007 (d, 4H, J=8.7 Hz, CH, C5 or C6, Ar), 
9.147 (s, 4H, CH, C2, Ar) 
MS FAB+ve (NOBA matrix) C48H34012N4S435C14 W calculated as 1126 
m/z 1135 [M + H]+ (4 "Cl), 1133 [M + H]' (3 37C1,35C1), 1131 [M + H]' (2 37C1,2 
350), 1129 [M + H]+ (37C1,3 35C1), 1127 [M + H]+ (4 35C1), 1033 [M - SO2C1]+ (3 37C1), 
1031 [M - SO2C1]+ (2 37C1,35C1), 1029 [M - SOZC1]+ (37C1,2 35C1), 1027 [M - SOZC1]+ (3 
35C1) 
UV-Vis, chloroform, ?.. (% relative height of Soret band), nm; 
422 (100 %), 518 (4.5 %), 554 (3.4 %), 596 (2.9 %), 650 (2.1 %) 
Rf (dichloromethane) 0.5 purple/pink spot 
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Preparation of 5,10,15,20-tetrakis(3-butylsulphonamide-4-methoxyphenyl)porphyrin (158) 
[Model reaction for capping of cyclic peptide onto 5,10,15,20-tetrakis(3-chlorosulphonyl-4- 
methoxyphenyl)poiphyrin] 
Ar 
Ar 
Ar 
S02Iýýý 
Ar Ar = OMe 
Freshly prepared 5,10,15,20-tetrakis(3-chlorosulphonyl-4-methoxyphenyl)porphyrin 
(156.7 mg, 0.139 mmol), butylamine (48.7 mg, 0.667 mmol), N, N-diisopropylethylamne 
(144 mg, 1.111 mmol) in NN-dimethylformamide (46.3 cm3) were stirred at room 
temperature under argon for 20 h. The solvent was removed under reduced pressure and 
residual solvent removed by forming an azeotrope with toluene (x 3). The toluene was 
removed under reduced pressure. The purple solid was dissolved in dichloromethane (150 
cm3) and washed with 1M HCl (50 cm3) and sat. brine (50 cm3). Flash column 
chromatography (gradient elution from 99: 1 dichloromethane : methanol to 95: 5 
dichloromethane : methanol) yielded 20 mg (11.2 %) of a purple solid. 
In order to obtain as sharp a 'H NMR as possible, three Ii NMR spectra were 
recorded using the conditions described below. The sharpest spectrum was obtained using 
CDCl3 as the solvent. 
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'H NMR (CDC13, RT, 300 MHz); 
S/ppm -2.51 (s, br, 2H, NH), 0.881 (m, 12H, CH. CHZCHZCH3), 1.2-1.8 (m, 16H, 
CH2CH2CH2CH3), 3.2 (m, br, 8H, CH2NHSO2), 4.381 (s, 12H, OCHS), 7.77 (d, br, 4H, 
CH, C5 or C6, Ar), 8.48 (s, br, 8H, CH, ß-pyrrole), 8.91 (d, br, 4H, CH, C5 or C6, Ar), 9.15 
(s, 4H, CH, C2, Ar) 
`H NMR (3: 1 d-TFA : CDC13,450 C, 300 MHz, from 6= -0.1 - 10.0); 
S/ppm 0.988 (t, 12H, J=7.3 Hz, CH2CH2CH2CH3), 1.3-1.6 (m, br, 16H, 
CH2CHZCH2CH3), 3.23 (m, br, 8H, CH2NHSO2), 4.373 (s, 12H, OCHS), 7.86 (m, br, 4H, 
CH, Ar), 8.73 (s, br, 8H, CH, ß-pyrrole), 8.94 (m, br, 4H, CH, Ar), 9.25 (m, br, 4H, CH, 
Ar) 
1H NMR (3: 1 d-TFA : CDC13, RT, 300 MHz, from S= -0.1 - 10.0); 
' S/ppm 0.981 (t, 12H, J=7.3 Hz, CH2CH2CH2CH3), 1.3-1.8 (m, br, 16H, 
CH2CH2CHZCH), 3.21 (m, br, 8H, CHZNHSO2), 4.367 (s, 12H, OCHS)07.86 (m, br, 4H, 
CH, Ar), 8.72 (s, br, 8H, CH, (3-pyrrole), 9.02 (m, br, 4H, CH, Ar), 9.31 (m, br, 4H, CH, 
Ar) 
MS FAB+ve (NOBA matrix) C64H74N$O12S4 M+ calculated as 1274.4 
m/z 1275 [M + H]+, 12201M - C4H8]+ 
MS FAB+ve (NOBA matrix) [M + H]+ accurate mass 
Calculated 1275.439 
Found 1275.439 
UV-Vis, chloroform, X. (% relative height of Soret band), run; 
420 (100 %), 521 (4.4 %), 556 (3.2 %), 589 (3.0 %), 646 (2.0 %) 
Rf 19: 1 (dichloromethane : methanol) 0.30 
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5.4.2 Preparation of cyclic peptides 
Preparation of cyclo-[tysyl-lysyl-glycyl-lysyl-lysyl-glycine-% (159) 
H2 
Palladium on activated carbon (wet degussa type, E101 NE/W) (5 mg) was preactivated 
with hydrogen in 2,2,2-trifluoroethanol (5 cm'). To this solution was added cyclo-[N-e- 
benzyloxycarbonyl-lysyl-N-e--benzyloxycarbonyl-lysyl-glycyl-N-e-benzyloxycarbonyl-lysyl- 
N-e-benzyloxycarbonyl-lysyl-glycine-] (100 mg, 0.086 mmol) and the mixture was stirred 
under an H2 atmosphere for 5 days. The mixture was filtered under suction through 
Kieselguhr and the solvent removed under reduced pressure from the filtrate. The residue 
was triturated with diethyl ether to yield 53.8 mg (100 %) of a hydroscopic white solid. 
The material was made as required for the next stage in the synthesis of the porphyrin 
capped cyclic peptide and used promptly. Data agreed with the literature values given in 
brackets [ ]' 18. 
'H NMR (CDC13 : trace CD3OD, RT, 400 MHz); [(d6-DMSO, RT, 300 MHz)] 
S/ppm 0.9-1.9 [1.2-1.9] (m, 24H, CH2CHZCH2CH2NH2), 2.585 [2.507] (t, 8H, 
CHZNH2, J=6.9 Hz), 3.578 [3.558] (d, 2H, J= 15.8 Hz [15.0], CH, Gly), 3.951 [3.867] 
(d, 2H, J= 15.8 Hz [15.0], CH, Gly), 4.051 (d, 1H, J=9.06 Hz, a-CH, Lys), 4.064 (d, 1H, 
J=8.94 Hz, a-CH, Lys), [4.032 (m, 2H, a-CH, Lys)], 4.204 (d, 1H, J=9.06 Hz, a-CH, 
Lys), 4.218 (d, 1H, J=8.94, a-CH, Lys), [4.174 (m, 2H, a-CH, Lys)] 
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MS FAB+ve (NOBA matrix) C2sH5406N, o M+ calculated as 626 
m/z 627 [M + H]' 
Rt 7: 7: 5: 1 (isopropanol : ethanol : water : ammonia) 0.2 (not UV active but stains with 
ninhydrin) 
Preparation of N- a-t-butoxycarbonyl-N E toluenesulphonyl-lysyl-N E toluenesulphonyl- 
lysyl-glycine 
Boc-Lys(Ts)-Lys(Ts)-Gly-OH 
N- a -t-Butoxycarbonyl-N-E-toluenesulphonyl-lysyl-N-E-toluenesulphonyl-lysyl- 
glycine-methyl-ester (500 mg, 0.664 mmol) was dissolved in 30 %1M potassium hydroxide 
solution in methanol (28 cm3) and the solution stirred at room temperature until the reaction 
had gone to completion as judged by TLC. The methanol was removed under reduced 
pressure and the remaining solution was acidified using 1M HCI to pH 3 (universal 
indicator paper), the solution diluted with water and the desired product extracted (x 5) with 
dichloromethane. The organic extracts were combined and the solvent removed under 
reduced pressure. The resultant solid was dried to yield 491 mg (100 %) of the free acid 
as a white solid. 
'H NMR (CDC13, RT, 270 MHz); 
S/ppm 1.2-2.0 (m, 12H, CH2CH2CH2CH2N), 1.423 (s, 9H, C(CH3)3), 2.430 (s, 6H, 
CH3, Ts), 2.9 (m, br, 4H, CH2NHTs), 4.184 (m, 2H, CH2, Gly), 4.13 6 (m, 1 H, a -CH, Lys), 
4.609 (m, 1H, a-CH, Lys), 5.782 (m, br, 1H, NH), 6.1 (m, br, 3H, NH), 7.346 (d, 4H, J 
= 8.0 Hz, CH, Ts), 7.593 (m, br, 1H, NH), 7.795 (d, 4H, J=8.0 Hz, CH, Ts) 
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13C NMR (CDC13, RT, 67.90 MHz); 
S/ppm 21.441 (CH3, Ts), 22.106,22.307 (CH2, Lys), 28.250 (CH3, Boc), 28.491, 
28.673 (CH2, Lys), 41.623,42.391,42.693 (CH2, Gly; CH2NHTs), 53.068,54.926 (CH, 
Lys), 80.203 (C, Boc), 129.638,126.979 (CH, Ts), 136.850,136.729,143.196 (C, Ts), 
156.108 (C=O, Boc), 172.285,172.949,173.272 (C=O) 
MS FAB+ve (NOBA matrix) C33H49N5O10S2 M* calculated as 739.3 
m/z 779 [M + K]*, 762 [M + Na]', 740 [M + H]+, 640 [M - Boc]* 
MS FAB+ve (NOBA matrix) [M + K]+ accurate mass 
Calculated 778.2558 
Found 778.2553 
MS FAB+ve (NOBA matrix) [M + Na]* accurate mass 
Calculated 762.2819 
Found 762.2825 
IR, v,,, x, cm' (nujol mull) 
3288.5,2925.5,2855.5,1659.2,1599.5,1526.7,1460.8,1377.9,1323.2,1250.0, 
1157.7,1093.9,861.1,815.8,722.4 
Rf 2: 1: 17 (methanol : acetic acid : chloroform) 0.4 
19: 1 (dichloromethane : methanol) 0.0 
mp (° C) 75-80 
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Preparation of cyclo-[N-c toluenesulphonyl-lysyl-N e-toluenesulphonyl-lysyl-glycyl-N c- 
toluenesulphonyl-lysyl-N-c toluenesulphonyl-lysyl-glycine-J 
TsHN IN n1S 
NHýýNH 
NH O 
O NH 
NH 
O 
iNH O 
TsHN NHTs 
N-a-t-Butoxycarbonyl-N-c-tosyl-lysyl-N-e-tosyl-lysyl-glycine (491 mg, 0.664 mmol), 
pentafluorophenol (244 mg, 1.33 mmol) and dicyclohexylcarbodiimide (274 mg, 1.33 mmol) 
were dissolved in dry (stored over 4A molecular sieves) ethyl acetate (30 cO) under argon. 
Previously, the solvent used was dry N, N-dimethylformamide. The mixture was stirred for 
24 h before more dicyclohexylcarbodiimide (274 mg) was added. The mixture was stirred 
for 48 h until shown to be complete by TLC. The mixture was filtered to remove 
precipitated dicyclohexylurea and the solvent removed under reduced pressure. Flash 
column chromatography (gradient elution from 4: 1 dichloromethane : ethyl acetate to 1: 1 
dichloromethane : ethyl acetate) followed by removal of the solvent under reduced pressure 
gave a white solid which was not characterised but was used immediately for the next stage 
in the procedure. 
N- a -t-B utoxycarbonyl-N-c-tosyl-lysyl-N-e-tosyl-lysyl-glycine-pentaflu orophenyl- 
ester (539 mg, 0.596 mmol) was dissolved in 1: 1 trifluoroacetic acid : dichloromethane (50 
cm3) and stirred at room temperature for approximately 1 h, when TLC showed the starting 
material to have been consumed. The solvent was removed under reduced pressure and any 
residual trifluoroacetic acid removed by forming an azeotrope three times with toluene. The 
toluene was removed under reduced pressure. The oily product was triturated twice with 
diethyl ether to form a brownish-white solid. This was not characterised but was used 
immediately. 
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Assuming 100 % deprotection, potassium carbonate (411 mg, 2.97 mmbl) or cacsium 
carbonate (968 mg, 2.97 mmol) and N, N-dimethylformamide (59.5 cm3,0.01 M) were 
added under argon and the reaction mixture stirred for 5 days. The solvent was removed 
under reduced pressure, ethyl acetate (50 cm3) was added and the mixture filtered. The 
solution was washed with water (50 cm' x 2) and sat. brine (50 co) and dried over MgSO4. 
The mixture was filtered and the solvent removed under reduced pressure. Flash column 
chromatography (95: 5 dichloromethane : methanol) yielded 111 mg (30 %) of a white solid. 
Data agreed with the literature values given in brackets [ ]121. 
'H NMR (CDC13, RT, 270 MHz); [(CDC13, RT, 300 MHz)] 
8/ppm 1.0-2.0 [1.06-1.82] (m, 24H, CHZCHZCH2CH2N), 2.368 [2.41] (s, 12H, CH3, 
Ts), 2.857 [2.86] (in, 8H, CHZNHTs), 4.271 [4.13](m, 4H, CH2, Gly), 4.40 [4.26] (m, 4H, 
a-CH, Lys), 5.02 [5.40] (d, br, 1H, NH), 6.24 (m, br, 1H, NH), 7.247 [7.30] (d, 8H, J= 
8.0 Hz, CH, Ts), 7.712 [7.71] (d, 8H, J=8.0 Hz, CH, Ts), 7.50 [7.51] (m, 1H, NH), 7.98 
(m, 1H, NH) 
MS FAB+ve (NOBA matrix) C56H78N10014S4 M+ calculated as 1242.5 
m/z 1243 [M + H]+ 
IR, u,,, a, r, cm' (nujol mull) 
2926.0,2855.2,2362.7,2343.7,1659.8,1520.2,1463.3,1377.9,1322.9,1158.0, 
1093.4,892.9,848.5,815.1,722.7 
Rf 2: 17: 1 (methanol : chloroform : acetic acid) 0.55 [0.551 
19: 1 (dichloromethane : methanol) 0.40 
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5.4.3 Attempted capping of a cyclic peptide onto a porphyrin 
Attempted synthesis of (150) by the reaction of 5,10,15,20-tetrakis(3- 
bromomethylphenyl)porphyrin and cyclo-[lysyl-tysyl-glycyl-lysyl-lysyl-glycine-J 
NX 
NX 
O NH 
p NH H 
NH 
NH O NH 
0 
X=H 
5,10,15,20-Tetrakis(3-bromomethylphenyl)porphyrin (8 mg, 0.008 mmol), cyclo- 
[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-] (5 mg, 0.008 mmol) and NN-diisopropylethylamine 
(8.3 mg, 0.062 mmol) in N, N-dimethylformamide (1.28 cm3) were stirred for 3 days under 
argon. The solvent was removed under reduced pressure and residual N, N- 
dimethylformamide removed by forming an azeotrope three times with toluene. The 
toluene was removed under reduced pressure. The crude product was analysed by FAB 
MS but failed to show evidence of the desired product (ie. no peak at m/z = 1289 due to [M 
+H]+. The sample was dissolved in 3-nitrobenzylalcohol and filtered to remove polymeric 
material, before analysis by FAB MS. However, again, no evidence of the desired product 
was obtained. 
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Attempted synthesis of (149) by the reaction of 5,10,15,20-tetrakis(3- 
bromomethylphenyl)porphyrin and cyclo-[1V c-tosyl-lysyl-N E-tosyl-lysyl-glycyl-N-e-tosyl- 
lysyl-N- e-tosyl-lysyl-glycine-] 
0 
NX 
0 
NH 
0 X=Ts 
5,10,15,20-Tetrakis(3-bromomethylporphyrin)porphyrin (1 mg, 0.001 mmol), cyclo- 
[N-E-tosyl-lysyl-N-(-tosyl-lysyl-glycyl-N-n-tosyl-lysyl-N-c-tosyl-lysyl-glycine-] (1.26 mg, 
0.001 mmol) and caesium carbonate (1.98 mg, 0.006 mmol) in N, N-dimethylformamide (1 
cm3) were stirred for 2 days under argon. The solvent was removed under reduced 
pressure and residual N, N-dimethylformamide removed by forming an azeotrope three times 
with toluene. The toluene was removed under reduced pressure. The crude product was 
analysed by FAB MS but no peak at m/z = 1905 due to [M + II]' and no recognisable 
fragment ions due to the desired product were observed. 
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Attempted synthesis of (151) by the reaction of 5,10,15,20-tetrakis(3-chlorosulphonyl-4- 
methoxyphenyl)porphyrin and cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-j 
nT, R- 
NX 
1 
NH-' 
O zzý 
NH 
0 NH 
0 
ýo 
OMe 
t 
n 
Three methods were used in the attempt to cap the above cyclic peptide with the 
above porphyrin. 
5,10,15,20-Tetrakis(3-chlorosulphonyl-4-methoxyphenyl)porphyrin (60 mg, 0.96 
mmol), cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-] (108 mg, 0.096 mmol) and N, N- 
diisopropylethylamine (99.1 mg, 0.767 mmol) in N, N-dimethylformamide (95.8 cO) were 
stirred together at room temperature for 5 days. The solvent was removed under reduced 
pressure and residual solvent removed by forming an azeotrope three times with toluene. 
The toluene was removed under reduced pressure. The crude product was analysed by 
FAB MS but no peak at m/z = 1609 due to [M + H]4 or any recognisable fragment ions of 
the desired product were observed. Flash column chromatography (90: 10 dichloromethane 
: methanol) resulted in three products being isolated none of which gave evidence by FAB 
MS of the desired product. None of these fractions could be adequately characterised by 
FAB MS. 
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5,10,15,20-Tetrakis(3-chlorosulphonyl-4-methoxyphenyl)porphyrin (60 mg, 0.96 
mmol), cyclo-[lysyl-lysyl-glycyl-Iysyl-lysyl-glycine-] (108 mg, 0.096 mmol) and N, N- 
diisopropylethylamine (99.1 mg, 0.767 mmol) in N, N-dimethylformamide (95.8 cm3) were 
stirred together at 50° C for 5 days. It was hoped that by increasing the temperature with 
respect to method A, the rate of the desired capping reaction would be increased over any 
side reactions such as the formation of polymeric material. The solvent was removed under 
reduced pressure. The reaction TLC (90: 10 dichloromethane : methanol) was identical to 
that for Method A with three products being present. An identical work up procedure to 
Method A failed to provide any evidence of the desired product. 
Cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-] (22 mg, 0.035 mmol) and N, N- 
diisopropylethylamine (36.3 mg, 0.281 mmol) in N, N-dimethylformamide (5 cm') were 
stirred together at room temperature under argon. 5,10,15,20-tetrakis(3-chlorosulphonyl- 
4-methoxyphenyl)porphyrin (39.6 mg, 0.035 mmol) in N, N-dimethylformamide (2 cm3) was 
added by syringe pump over 24 h. The mixture was stirred for another 48 h. The solvent 
was removed under reduced pressure with any residual solvent being removed by forming 
an azeotrope twice with toluene. The toluene was removed under reduced pressure and 
the solid washed twice with diethyl ether. No evidence was found in the FAB MS of the 
crude sample of the desired product. A sample of crude product was dissolved in 3- 
nitrobenzylalcohol and filtered in order to remove any polymeric material, but FAB MS 
failed to show any evidence of the desired compound in the filtrate. 
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5.4.4 Attempted porphyrin synthesis from a cyclic peptide tetraaldehyde 
Preparation of succinimidyl-4-formyl benzoate (163) 
CHO 
O 
O O-N 
0 
4-Carboxybenzaldehyde (1 g, 6.66 mmol), N-hydroxysuccinimide (843 mg, 7.32 
mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (1.4 g, 
7.30 mmol) in N, N-dimethylformamide (25 cm3) were stirred at room temperature under 
argon for 24 h. In order to ensure completion of the reaction, more N-hydroxysuccinimide 
(843 mg, 7.32 mmol) and EDC (1.4 g, 7.30 mmol) were added and the mixture stirred for 
a further 24 h. The solvent was removed under reduced pressure and residual solvent 
removed by forming an azeotrope twice with toluene - itself removed under reduced 
pressure. The resultant solid was dissolved in dichloromethane and washed with sat. 
sodium hydrogen carbonate solution (x 2), water and sat. brine. The solution was dried 
over MgSO4, filtered and the solvent removed under reduced pressure to produce a white 
solid. The solid was dried to yield 643 mg (39 %) of a white solid. 
'H NMR (CDC13, RT, 200 MHz); 
8/ppm 2.89 (s, 4H, CH2CH2), 7.96 (d, 2H, J=8.41 Hz, CH, Ar), 8.22 (d, 211, J= 
8.41 Hz, CH, Ar), 10.06 (s, 1 H, CHO) 
13C NMR (CDC13, RT, 50 MHz); 
" 8/ppm 25.573 (CH), 129.639,131.006 (C, Ar), 140.213,160.981 (CH, Ar), 169.066 
(C=O) 
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MS EI C, ZH9N05 M+ calculated as 247.0 
m/z 247 [M]+, 246 [M - H]+, 149 [M - C4H4OZN]*, 133 [M - C4H; O3N]* 
MS EI [M]+ accurate mass 
Calculated 247.0481 
Found 247.0465 
MS EI [M - H]* accurate mass 
Calculated 246.0403 
Found 246.0416 
IR, u,,, x, cm' (nujol mull); 
2924.9,2854.8,1776.2,1726.6,1703.4,1661.7,1464.9,1377.9,1203.7,1076.3, 
1001.8,746.0 
Rf 1: 1 (40-60 petroleum ether : ethyl acetate) 0.5 
19: 1 (dichloromethane : methanol) 0.8 
mp (° C) 145-147 
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Attempted preparation of cyclo-(N c (4-carboxybenzaldeh), de)-lysyl-N-e-(4- 
carboxybenzaldehyde)-lysyl-glycyl-N- e-(4-carboxybenzaldehyde)-l ysyl-N- c-(4- 
carboxybenzaldehyde)-lysyl-glycine-J 
HH 
Ru NNyR 
OOO 
O NH 
NH 
NH O 
ý>ýNH O 
OOO 
/NH4 
RýN 
LNR 
II 
HH 
R. CHO 
Cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-] (27.7 mg, 0.044 mmol) and succinimidyl- 
4-formyl benzoate (54.6 mg, 0.221 mmol) in chloroform (4 cm3) with a few drops of 
methanol to ensure solubility, were stirred under argon for 3 days. In alternative reactions, 
N, N-dirnethylformamide was used as the solvent. The solvent was removed under reduced 
pressure. `H NMR spectroscopy indicated the presence of the desired product alongside 
the starting material succinimidyl-4-formyl benzoate. 
Two attempts were made to effect the purification of the desired compound. 
The solid residue from the reaction was washed three times with diethylether 
following observations that succinimidyl-4-formyl benzoate is selectively soluble in 
diethylether over peptidic compounds. However, 'H NMR spectroscopy showed that the 
required product was not isolated. 
Method B 
Flash column chromatography (gradient elution from dichloromethane to 19: 1 
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dichloromethane : methanol) failed to isolate the desired product, but rather most of the 
desired product remained bound to the column. 
`H NMR (CDC13, RT, 200 MHz); 
8/ppm 1.0-1.7 (m, 24H, CH2CH2CH2CH2N), 1.7-1.9 (m, 8H, CHZN), 2.89 (s, 4H, 
CHZCH2, succinimidyl), 7.92 (d, 8H, J=6.7 Hz, CH, Ar), 7.98 (d, 2H, J=6.7 Hz, CH, 
Ar), 8.16 (d, 8H, J=6.7 Hz, CH, Ar), 8.24 (d, 2H, J=6.7 Hz, CH, Ar), 10.05 (s, 4H, 
CHO), 10.12 (s, 1H, CHO) 
The above spectrum is of a mixture of two compounds. Those assignments in italics are 
due to the desired cyclic peptide tetraaldehyde. Their integrations are H per H, 32 times 
smaller than the other assignments, which are due to the starting material succinimidyl-4- 
formyl benzoate. 
MS FAB+ve (NOBA matrix) C60H70O14Nio M+ calculated as 1154 
m/z 1155 [M + H]*, 133 [succinimidyl-4-formyl benzoate - C4H4O3N]+ 
Rf 9: 1 (dichloromethane : methanol) 0.3 (UV active and stains with 2,4- 
dinitrophenylhydrazine) 
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Attempted preparation of cyclo-[N E (3-carbotybenzaldelzyde)-lysyl-N c-(3- 
carboxybenzaldehyde)-lysyl-glycyl-N- e-(3-carboxybenzaldehyde)-lysyl-N- E-(3- 
carboxybenzaldehyde)-lysyl-glycine-1(160) 
HH 
R RyN Ny 
OO 
OO 
NH 
NH O 
O NH 
ö, 
NH O 
OO 
RAN 
LNAR 
HH 
Two attempts were made to prepare this compound. 
CHO 
R= 
Cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-] (26 mg, 0.042 mmol) and succinimidyl-3- 
formyl benzoate (50 mg, 0.202 mmol) in deuterated N, N-dimethylformamide (1 cm) were 
stirred under argon for 3 days. 'H NMR spectroscopy in the reaction solvent indicated the 
presence of the desired product together with starting material. The solvent was removed 
under reduced pressure and residual solvent was removed by forming an azeotrope twice 
with toluene - the toluene being removed under redcued pressure. An attempt was made 
to isolate the desired product by washing with toluene. However, 'H NMR spectroscopy 
showed this to be unsuccessful. 
Cyclo-[lysyl-lysyl-glycyl-lysyl-lysyl-glycine-1 (35.6 mg, 0.057 mmol), succinimidyl-3- 
formyl benzoate (67.4 mg, 0.0273 mmol) and N, N-diisopropylethylamine (36.75 mg, 0.284 
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mmol) in deuterated chloroform with a few drops of deuterated methanol (to aid solubility) 
(2 cm3) were stirred for 5 days under argon. The base was used in an attempt to drive the 
reaction to completion. 'H NMR and TLC (19: 1 dichloromethane : methanol) indicated 
the presence of the desired product as well as succinimidyl-3-formyl benzoate starting 
material. The solvent was removed under reduced pressure. An attempt was made to 
isolate the desired product by washing three times with toluene. It had been previously 
observed that succinimidyl-3-formyl benzoate was soluble in toluene and it was expected 
that the cyclic peptide tetraaldehyde, in common with many peptides, would be insoluble. 
Nevertheless, this was unsuccessful. Another attempt was made to isolate the desired 
product by washing three times with sodium hydrogen carbonate, stirring the mixture each 
time for 45 min. Theoretically, the ester bond of succinimidyl-3-formyl benzoate would be 
hydrolysed during this treatment to give 3-carboxybenzaldehyde and N-hydroxysuccinimide 
which could be removed by washing with water. The desired product should be untouched. 
The residue was washed with water and then dissolved in dichloromethane with trace 
methanol. TLC (19: 1 dichloromethane : methanol), however, indicated the loss of most of 
the desired product at Rf = 0.3 to baseline material. 'H NMR analysis indicated that this 
attempt to purify the desired product was unsuccessful and that the aldehyde peaks of the 
tetraaldehyde product (160) had been lost. 
'H NMR (CDC13, RT, 400 MHz); 
8/ppm 1.2-1.6 (m, 24H, CH2CH2CH2CHZ V), 1.6-1.9 (m, 8H, CH2N), 2.61 (s, 4H, 
CHZCH2, succinimidyl), 3.6 (s, HOD), 7.6-8.6 (m, 4H, Ar; 16H, Ar), 10.0 (s, 4H, CHO), 
10.1 (s, 1H, CHO) 
The above spectrum is of a mixture of two compounds. Those assignments in italics are 
due to the desired cyclic peptide tetraaldehyde. Their integrations are H per H, 1.3 times 
smaller than the other assignments, which are due to the starting material succinimidyl-3- 
formyl benzoate. 
Rf 9: 1 (dichloromethane : methanol) 0.3 (UV active and stains with 2,4- 
dinitrophenylhydrazine) 
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Attempted preparation of porphyrin capped cyclic peptide (152) from unpurified cyclo-[N- 
e-(3-carboxybenzaldehyde)-lysyl-N- c-(3-carboxybenzaldehyde)-lysyl-glycol-N- c-(3- 
carboxybenzaldehyde)-lysyl-N-c (3-carboxybenzaldehyde)-lysyl-glycine-] (160), pyrrole 
and propionic acid 
NX NX 
R 
NX NX 
0 
NH 
O H 
NH 
O NH 
O 
0 
0 
0 
To a solution of impure cyclo-[N-e-(3-carboxybenzaldehyde)-lysyl-N-e-(3- 
carboxybenzaldehyde)-lysyl-glycol-N-c-(3-carboxybenzaldehyde)-lysyl-N-e-(3- 
carboxybenzaldehyde)-lysyl-glycine-] (50 mg, 0.043 mmol), in propionic acid (5 cm3) was 
added freshly distilled pyrrole (12 mg, 0.18 mmol). The solution was heated to 141° C and 
refluxed for 30 min. The reaction mixture was allowed to cool before it was diluted with 
dichloromethane. A UV-Vis spectrum of the solution showed that no porphyrin had been 
formed and thus that the attempted synthesis of the desired compound was unsuccessful. 
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